General Information of Drug Transporter (DT)
DT ID	DTD0008 Transporter Info
Gene Name	SLCO1B1
Protein Name	Organic anion transporting polypeptide 1B1
Gene ID	10599
UniProt ID	Q9Y6L6
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs11045819
Site of GPD	chr12:21176879 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	A=0.0649/325 (Global)
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Rifampicin	Drug Info	Healthy Individuals	Correlated with the increased drug clearance in healthy individuals (compare with genotype CC)		[ 1]
Rifampin	N.A.	Amenorrhea	Genotype AC is associated with increased clearance of rifampin in healthy individuals as compared to genotype CC.		[ 1]
Fluvastatin	N.A.	Hypercholesterolemia	Patients with the AC genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin.		[ 2]
Hmg Coa Reductase Inhibitors	N.A.	Coronary Disease	Patients with the rs11045819 AC genotype may have an increased response to statins as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to statins.		[ 3]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Fluvastatin	Drug Info	Hypercholesterolemia	Correlated with the decreased LDL-C reduction in patients (compare with genotypes AA + AC)		[ 2]
Fluvastatin	N.A.	Statin-related Myopathy	Genotype CC is associated with decreased LDL-C reduction when treated with fluvastatin in people with Hypercholesterolemia as compared to genotypes AA + AC.		[ 2]
Hmg Coa Reductase Inhibitors	N.A.	Nephrotoxicity	Genotype CC is associated with decreased response to hmg coa reductase inhibitors as compared to genotypes AA + AC.		[ 3]
Rifampin	N.A.	Diabetes Mellitus, Type 2	Patients with the CC genotype may have decreased clearance of rifampin as compared to patients with the AC genotype. Other genetic and clinical factors may also influence rifampin clearance.		[ 1]
Fluvastatin	N.A.	Hypercholesterolemia	Genotype CC is associated with decreased LDL-C reduction when treated with fluvastatin in people with Hypercholesterolemia as compared to genotypes AA + AC.		[ 2]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Grazoprevir	N.A.	Neutropenia	Allele A is associated with increased exposure to grazoprevir in people with Hepatitis C, Chronic as compared to allele C.		[ 4]
Lopinavir	N.A.	Opioid-related Disorders	Allele A is not associated with trough concentration of lopinavir in people with HIV Infections as compared to allele C.		[ 5]
Elbasvir / Grazoprevir	N.A.	Sustained Virological Response (svr)	Allele A is not associated with increased sustained virological response (svr) when treated with elbasvir / grazoprevir in people with Hepatitis C, Chronic as compared to allele C.		[ 4]
Lopinavir	N.A.	Leukopenia	Allele A is not associated with trough concentration of lopinavir or ritonavir in men with HIV Infections as compared to allele C.		[ 6]
Ritonavir	N.A.	Leukopenia	Allele A is not associated with trough concentration of lopinavir or ritonavir in men with HIV Infections as compared to allele C.		[ 6]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Rifampin	N.A.	Diabetes Mellitus, Type 2	No patients with the AA genotype were available for analysis, but patients with the AC genotype may have increased clearance of rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rifampin clearance.		[ 1]
Fluvastatin	N.A.	Hypercholesterolemia	Patients with the AA genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's response to fluvastatin.		[ 2]
Hmg Coa Reductase Inhibitors	N.A.	Coronary Disease	Patients with the rs11045819 AA genotype may have an increased response to statins as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to statins.		[ 3]
Genetic Polymorphism	rs11045821
Site of GPD	chr12:21179489 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.0527/264 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug clearance in patients (compare with allele G)		[ 7]
Methotrexate	N.A.	Rhabdomyolysis	Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 7]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 7]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Pediatric patients with ALL and the AA genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.		[ 7]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Pediatric patients with ALL and the AG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.		[ 7]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Pediatric patients with ALL and the GG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.		[ 7]
Genetic Polymorphism	rs11045879
Site of GPD	chr12:21229685 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.2192/1098 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:         12 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug clearance in patients (compare with Allele T)		[ 7]
Methotrexate	N.A.	Muscular Diseases	Allele C is not associated with response to methotrexate in children with Lymphoma, Non-Hodgkin or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 9]
Methotrexate	N.A.	Statin-related Myopathy	Allele C is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 10]
Methotrexate	N.A.	Statin-related Myopathy	Allele C is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.		[ 11]
Methotrexate	N.A.	Mucositis	Allele C is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 12]
Methotrexate	N.A.	Discontinuation	Allele C is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 7]
Methotrexate	N.A.	Infectious Disease	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.		[ 13]
Methotrexate	N.A.	Neoplasms	Allele C is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 7]
Methotrexate	N.A.	Neoplasms	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.		[ 13]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele C is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 12]
Methotrexate	N.A.	Lymphoma	Allele C is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 12]
Methotrexate	N.A.	Osteosarcoma	Allele C is not associated with risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 12]
Allele T	Click to Show/Hide the Full List of Affected Drugs:         11 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased drug clearance in patients (compare with allele C); Correlated with the increased gastrointestinal toxicity in patients (compare with allele C)		[ 13], [ 14]
Mercaptopurine	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased gastrointestinal toxicity in patients (compare with allele C)		[ 13]
Methotrexate	N.A.	Mucositis	Allele T is associated with increased risk of mucositis when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 14]
Methotrexate	N.A.	Statin-related Myopathy	Allele T is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 14]
Mercaptopurine	N.A.	Statin-related Myopathy	Allele T is associated with increased GI toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 13]
Methotrexate	N.A.	Neoplasms	Allele T is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 14]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele T is associated with increased risk of mucositis when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 14]
Methotrexate	N.A.	Lymphoma	Allele T is associated with increased risk of mucositis when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 14]
Methotrexate	N.A.	Osteosarcoma	Allele T is associated with increased risk of mucositis when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 14]
Mercaptopurine	N.A.	Acute Lymphoblastic Leukemia	Allele T is associated with increased GI toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 13]
Mercaptopurine	N.A.	Gastrointestinal Toxicity	Allele T is associated with increased GI toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 13]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Methotrexate	Drug Info	Osteosarcoma	Correlated with the increased drug concentrations in patients (compare with Genotype TT)		[ 15]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Irrelevant to the drug concentrations in patients (compare with Genotype TT)		[ 9]
Methotrexate	N.A.	Statin-related Myopathy	Genotypes CC + CT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 9]
Methotrexate	N.A.	Discontinuation	Genotypes CC + CT is associated with increased exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 17]
Methotrexate	N.A.	Overall Survival	Genotypes CC + CT is associated with increased concentrations of methotrexate in people with Osteosarcoma as compared to genotype TT.		[ 15]
Methotrexate	N.A.	Neoplasms	Genotypes CC + CT is associated with increased concentrations of methotrexate in people with Osteosarcoma as compared to genotype TT.		[ 15]
Methotrexate	N.A.	Neoplasms	Genotypes CC + CT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 9]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:         12 Drugs in Total
Methotrexate	N.A.	Neutropenia	Genotype CC is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.		[ 17]
Methotrexate	N.A.	Mucositis	Genotype CC is not associated with likelihood of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.		[ 9]
Methotrexate	N.A.	Neoplasms	Genotype CC is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.		[ 17]
Methotrexate	N.A.	Neoplasms	Patients with the CC genotype and neoplasms who are treated with methotrexate may have a decreased clearance of methotrexate as compared to patients with the CT or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.		[ 7]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype CC is not associated with likelihood of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.		[ 9]
Methotrexate	N.A.	Lymphoma	Genotype CC is not associated with likelihood of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.		[ 9]
Methotrexate	N.A.	Osteosarcoma	Genotype CC is not associated with likelihood of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.		[ 9]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs11045879 CC genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.		[ 11]
Methotrexate	N.A.	Lymphoma	The current evidence base suggests that there is no significant association between the rs11045879 CC genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.		[ 11]
Methotrexate	N.A.	Osteosarcoma	The current evidence base suggests that there is no significant association between the rs11045879 CC genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.		[ 11]
Mercaptopurine	N.A.	Acute Lymphoblastic Leukemia	Patients with acute lymphoblastic leukemia (ALL) and the rs11045879 CC genotype may be at a decreased risk of experiencing toxicity when treated with mercaptopurine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of toxicity when treated with mercaptopurine.		[ 13]
Mercaptopurine	N.A.	Gastrointestinal Toxicity	Patients with acute lymphoblastic leukemia (ALL) and the rs11045879 CC genotype may be at a decreased risk of experiencing toxicity when treated with mercaptopurine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of toxicity when treated with mercaptopurine.		[ 13]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Methotrexate	N.A.	Neoplasms	Patients with the CT genotype and neoplasms who are treated with methotrexate may have increased clearance of methotrexate as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.		[ 7]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs11045879 CT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.		[ 11]
Methotrexate	N.A.	Lymphoma	The current evidence base suggests that there is no significant association between the rs11045879 CT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.		[ 11]
Methotrexate	N.A.	Osteosarcoma	The current evidence base suggests that there is no significant association between the rs11045879 CT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.		[ 11]
Mercaptopurine	N.A.	Acute Lymphoblastic Leukemia	Patients with acute lymphoblastic leukemia (ALL) and the rs11045879 CT genotype may be at an increased risk of experiencing toxicity when treated with mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with mercaptopurine.		[ 13]
Mercaptopurine	N.A.	Gastrointestinal Toxicity	Patients with acute lymphoblastic leukemia (ALL) and the rs11045879 CT genotype may be at an increased risk of experiencing toxicity when treated with mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with mercaptopurine.		[ 13]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Methotrexate	N.A.	Neoplasms	Patients with the TT genotype and neoplasms who are treated with methotrexate may have increased clearance of methotrexate as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.		[ 7]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs11045879 TT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.		[ 11]
Methotrexate	N.A.	Lymphoma	The current evidence base suggests that there is no significant association between the rs11045879 TT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.		[ 11]
Methotrexate	N.A.	Osteosarcoma	The current evidence base suggests that there is no significant association between the rs11045879 TT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.		[ 11]
Mercaptopurine	N.A.	Acute Lymphoblastic Leukemia	Patients with acute lymphoblastic leukemia (ALL) and the rs11045879 TT genotype may be at an increased risk of experiencing toxicity when treated with mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with mercaptopurine.		[ 13]
Mercaptopurine	N.A.	Gastrointestinal Toxicity	Patients with acute lymphoblastic leukemia (ALL) and the rs11045879 TT genotype may be at an increased risk of experiencing toxicity when treated with mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with mercaptopurine.		[ 13]
Genetic Polymorphism	rs113681054
Site of GPD	chr12:21250045 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.2188/1096 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Ticagrelor	N.A.	Statin-related Myopathy	Allele C is associated with increased concentrations of ticagrelor in people with Acute coronary syndrome as compared to allele T.		[ 18]
Ticagrelor	N.A.	Muscular Diseases	Allele C is not associated with increased exposure to ticagrelor in healthy individuals as compared to allele T.		[ 19]
Ticagrelor	N.A.	Acute Coronary Syndrome	Allele C is associated with increased concentrations of ticagrelor in people with Acute coronary syndrome as compared to allele T.		[ 18]
Ticagrelor	N.A.	Acute Coronary Syndrome	Correlated with the increased drug concentrations in patients (compare with Allele T)		[ 18]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Ticagrelor	N.A.	Muscular Diseases	Genotype CT is not associated with response to ticagrelor in healthy individuals as compared to genotypes CC + TT.		[ 19]
Ar-c124910xx	N.A.	Muscular Diseases	Genotype CT is associated with increased exposure to ar c124910xx in healthy individuals as compared to genotypes CC + TT.		[ 19]
Ticagrelor	N.A.	Acute Coronary Syndrome	Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.		[ 18]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Ticagrelor	N.A.	Acute Coronary Syndrome	Patients with the CC genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the CT and TT genotypes. Other factors may affect concentrations of ticagrelor.		[ 18]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Ticagrelor	N.A.	Acute Coronary Syndrome	Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CC and CT genotypes. Other factors may affect concentrations of ticagrelor.		[ 18]
Genetic Polymorphism	rs2306283
Site of GPD	chr12:21176804 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G / A>T
Minor Allele Frequency	A=0.3776/1891 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:         16 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug clearance in patients (compare with allele G)		[ 7]
Atazanavir	N.A.	Nephrolithiasis	Allele A is not associated with risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele G.		[ 21]
Ritonavir	N.A.	Nephrolithiasis	Allele A is not associated with risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele G.		[ 21]
Methotrexate	N.A.	Statin-related Myopathy	Allele A is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele G.		[ 10]
Hmg Coa Reductase Inhibitors	N.A.	Death	Allele A is not associated with risk of Death and Myocardial Infarction when treated with hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to allele G.		[ 23]
Hmg Coa Reductase Inhibitors	N.A.	Myocardial Infarction	Allele A is not associated with risk of Death and Myocardial Infarction when treated with hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to allele G.		[ 23]
Tacrolimus	N.A.	Overall Survival	Allele A is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.		[ 24]
Methotrexate	N.A.	Discontinuation	Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 7]
Simvastatin	N.A.	Diarrhea	Allele A is not associated with LDL-C response when treated with simvastatin in people with Coronary Disease as compared to allele G.		[ 25]
Rosuvastatin	N.A.	Toxic Liver Disease	Allele A is not associated with LDL-C response when treated with rosuvastatin in people with Coronary Disease as compared to allele G.		[ 25]
Bosentan	N.A.	Drug-induced Liver Injury	Allele A is not associated with increased risk of drug-induced liver injury when treated with bosentan in people with Hypertension, Pulmonary as compared to allele G.		[ 26]
Simvastatin	N.A.	Coronary Disease	Allele A is not associated with LDL-C response when treated with simvastatin in people with Coronary Disease as compared to allele G.		[ 25]
Simvastatin	N.A.	Dyslipidaemia	Allele A is not associated with LDL-C response when treated with simvastatin in people with Coronary Disease as compared to allele G.		[ 25]
Simvastatin	N.A.	Hypercholesterolemia	Allele A is not associated with LDL-C response when treated with simvastatin in people with Coronary Disease as compared to allele G.		[ 25]
Simvastatin	N.A.	Hyperlipidemias	Allele A is not associated with LDL-C response when treated with simvastatin in people with Coronary Disease as compared to allele G.		[ 25]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 7]
Allele G	Click to Show/Hide the Full List of Affected Drugs:         45 Drugs in Total
Atorvastatin	Drug Info	Coronary Artery Disease	Irrelevant to the likelihood of statin-related myopathy in patients (compare with allele A)		[ 25]
Rosuvastatin	Drug Info	Coronary Artery Disease	Irrelevant to the likelihood of statin-related myopathy in patients (compare with allele A)		[ 25]
Simvastatin	Drug Info	Coronary Artery Disease	Irrelevant to the likelihood of statin-related myopathy in patients (compare with allele A)		[ 25]
Mycophenolate Mofetil	N.A.	Muscular Diseases	Allele G is not associated with increased risk of adverse drug reactions when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele A.		[ 26]
Hmg Coa Reductase Inhibitors	N.A.	Abnormalities, Drug-induced	Allele G is associated with decreased risk of Abnormalities, Drug-Induced when treated with hmg coa reductase inhibitors in people with Diabetes Mellitus, Type 2 as compared to allele A.		[ 27]
Azathioprine	N.A.	Hemorrhage	Allele G is not associated with response to azathioprine or mycophenolic acid in people with lung transplantation as compared to allele A.		[ 28]
Mycophenolic Acid	N.A.	Hemorrhage	Allele G is not associated with response to azathioprine or mycophenolic acid in people with lung transplantation as compared to allele A.		[ 28]
Methotrexate	N.A.	Neutropenia	Allele G is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 9]
Atorvastatin	N.A.	Statin-related Myopathy	Allele G is not associated with likelihood of statin-related myopathy when treated with atorvastatin, rosuvastatin and simvastatin in people with Coronary Artery Disease as compared to allele A.		[ 25]
Rosuvastatin	N.A.	Statin-related Myopathy	Allele G is not associated with likelihood of statin-related myopathy when treated with atorvastatin, rosuvastatin and simvastatin in people with Coronary Artery Disease as compared to allele A.		[ 25]
Simvastatin	N.A.	Statin-related Myopathy	Allele G is not associated with likelihood of statin-related myopathy when treated with atorvastatin, rosuvastatin and simvastatin in people with Coronary Artery Disease as compared to allele A.		[ 25]
Grazoprevir	N.A.	Statin-related Myopathy	Allele G is not associated with increased exposure to grazoprevir in people with Hepatitis C, Chronic as compared to allele A.		[ 4]
Methotrexate	N.A.	Drug Toxicity	Allele G is not associated with increased likelihood of Drug Toxicity when treated with methotrexate in children with Acute lymphoblastic leukemia as compared to allele A.		[ 31]
Letermovir	N.A.	Neutropenia	Allele G is not associated with exposure to letermovir as compared to allele A.		[ 32]
Atorvastatin	N.A.	Diarrhea	Allele G is not associated with decreased response to atorvastatin, fluvastatin, lovastatin, pravastatin or simvastatin in people with Dyslipidaemia as compared to genotype AA.		[ 33]
Fluvastatin	N.A.	Diarrhea	Allele G is not associated with decreased response to atorvastatin, fluvastatin, lovastatin, pravastatin or simvastatin in people with Dyslipidaemia as compared to genotype AA.		[ 33]
Lovastatin	N.A.	Diarrhea	Allele G is not associated with decreased response to atorvastatin, fluvastatin, lovastatin, pravastatin or simvastatin in people with Dyslipidaemia as compared to genotype AA.		[ 33]
Pravastatin	N.A.	Diarrhea	Allele G is not associated with decreased response to atorvastatin, fluvastatin, lovastatin, pravastatin or simvastatin in people with Dyslipidaemia as compared to genotype AA.		[ 33]
Simvastatin	N.A.	Diarrhea	Allele G is not associated with decreased response to atorvastatin, fluvastatin, lovastatin, pravastatin or simvastatin in people with Dyslipidaemia as compared to genotype AA.		[ 33]
Pravastatin	N.A.	Toxic Liver Disease	Allele G is associated with decreased clearance of pravastatin in healthy individuals as compared to allele A.		[ 34]
Methotrexate	N.A.	Toxic Liver Disease	Allele G is associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 35]
Pravastatin	N.A.	Infectious Disease	Allele G is associated with decreased plasma AUC of pravastatin.		[ 36]
Mycophenolate Mofetil	N.A.	Diarrhea	Allele G is not associated with increased risk of Diarrhea when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele A.		[ 37]
Opioids	N.A.	Opioid-related Disorders	Allele G is not associated with risk of Opioid-Related Disorders when exposed to opioids as compared to allele A.		[ 38]
Rosuvastatin	N.A.	Opioid-related Disorders	Allele G is not associated with exposure to rosuvastatin in healthy individuals as compared to allele A.		[ 39]
Lopinavir	N.A.	Peripheral Nervous System Diseases	Allele G is not associated with exposure to lopinavir or ritonavir in children with HIV Infections as compared to allele A.		[ 40]
Ritonavir	N.A.	Peripheral Nervous System Diseases	Allele G is not associated with exposure to lopinavir or ritonavir in children with HIV Infections as compared to allele A.		[ 40]
Mycophenolate Mofetil	N.A.	Leukopenia	Allele G is not associated with increased risk of Leukopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele A.		[ 37]
Lopinavir	N.A.	Leukopenia	Allele G is not associated with trough concentration of lopinavir or ritonavir in men with HIV Infections as compared to allele A.		[ 6]
Ritonavir	N.A.	Leukopenia	Allele G is not associated with trough concentration of lopinavir or ritonavir in men with HIV Infections as compared to allele A.		[ 6]
Atorvastatin	N.A.	Amenorrhea	Allele G is associated with decreased plasma concentrations of atorvastatin as compared to allele A.		[ 42]
Rosuvastatin	N.A.	Muscular Diseases	Allele G is not associated with increased risk of Muscular Diseases when treated with rosuvastatin in people with Hyperlipoproteinemia Type II as compared to allele A.		[ 43]
Atorvastatin	N.A.	Hypercholesterolemia	Allele G is not associated with decreased response to atorvastatin, fluvastatin, lovastatin, pravastatin or simvastatin in people with Dyslipidaemia as compared to genotype AA.		[ 33]
Pravastatin	N.A.	Dyslipidaemia	Allele G is not associated with decreased response to atorvastatin, fluvastatin, lovastatin, pravastatin or simvastatin in people with Dyslipidaemia as compared to genotype AA.		[ 33]
Simvastatin	N.A.	Coronary Disease	Allele G is not associated with decreased response to atorvastatin, fluvastatin, lovastatin, pravastatin or simvastatin in people with Dyslipidaemia as compared to genotype AA.		[ 33]
Simvastatin	N.A.	Dyslipidaemia	Allele G is not associated with decreased response to atorvastatin, fluvastatin, lovastatin, pravastatin or simvastatin in people with Dyslipidaemia as compared to genotype AA.		[ 33]
Simvastatin	N.A.	Hypercholesterolemia	Allele G is not associated with decreased response to atorvastatin, fluvastatin, lovastatin, pravastatin or simvastatin in people with Dyslipidaemia as compared to genotype AA.		[ 33]
Simvastatin	N.A.	Hyperlipidemias	Allele G is not associated with decreased response to atorvastatin, fluvastatin, lovastatin, pravastatin or simvastatin in people with Dyslipidaemia as compared to genotype AA.		[ 33]
Hmg Coa Reductase Inhibitors	N.A.	Coronary Artery Disease	Allele G is associated with decreased risk of Abnormalities, Drug-Induced when treated with hmg coa reductase inhibitors in people with Diabetes Mellitus, Type 2 as compared to allele A.		[ 27]
Hmg Coa Reductase Inhibitors	N.A.	Diabetes Mellitus	Allele G is associated with decreased risk of Abnormalities, Drug-Induced when treated with hmg coa reductase inhibitors in people with Diabetes Mellitus, Type 2 as compared to allele A.		[ 27]
Hmg Coa Reductase Inhibitors	N.A.	Hypercholesterolemia	Allele G is associated with decreased risk of Abnormalities, Drug-Induced when treated with hmg coa reductase inhibitors in people with Diabetes Mellitus, Type 2 as compared to allele A.		[ 27]
Hmg Coa Reductase Inhibitors	N.A.	Coronary Artery Disease	Allele G is not associated with likelihood of statin-related myopathy when treated with atorvastatin, rosuvastatin and simvastatin in people with Coronary Artery Disease as compared to allele A.		[ 25]
Hmg Coa Reductase Inhibitors	N.A.	Diabetes Mellitus	Allele G is not associated with likelihood of statin-related myopathy when treated with atorvastatin, rosuvastatin and simvastatin in people with Coronary Artery Disease as compared to allele A.		[ 25]
Hmg Coa Reductase Inhibitors	N.A.	Hypercholesterolemia	Allele G is not associated with likelihood of statin-related myopathy when treated with atorvastatin, rosuvastatin and simvastatin in people with Coronary Artery Disease as compared to allele A.		[ 25]
Hmg coa reductase inhibitors	N.A.	Diabetes Mellitus	Correlated with the decreased drug-Induced abnormalities risk in patients (compare with Allele A)		[ 27]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:         41 Drugs in Total
Mycophenolic acid	Drug Info	Lung Transplantation	Correlated with the decreased drug concentrations in patients (compare with genotypes AG + GG)		[ 41]
Atorvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug response in patients (compare with genotypes AG + GG)		[ 42]
Pravastatin	Drug Info	Hypercholesterolemia	Irrelevant to the drug response in patients (compare with genotype GG)		[ 43]
Rocuronium	Drug Info	Muscle Relaxant	Correlated with the decreased drug response in patients (compare with genotypes AG + GG)		[ 44]
Atorvastatin	N.A.	Muscular Diseases	Genotype AA is associated with increased clinical benefit to atorvastatin in people with Coronary Artery Disease as compared to genotypes AG + GG.		[ 45]
Rosuvastatin	N.A.	Drug-induced Liver Injury	Genotype AA is not associated with plasma concentrations of rosuvastatin when treated with rosuvastatin in people with Hypercholesterolemia as compared to genotype GG.		[ 46]
Pravastatin	N.A.	Statin-related Myopathy	Genotype AA is not associated with response to pravastatin as compared to genotype GG.		[ 43]
Simvastatin	N.A.	Nephrotoxicity	Genotype AA is associated with increased response to simvastatin as compared to genotype GG.		[ 3]
Atorvastatin	N.A.	Discontinuation	Genotype AA is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes AG + GG.		[ 42]
Rocuronium	N.A.	Cough	Genotype AA is associated with decreased response to rocuronium as compared to genotypes AG + GG.		[ 44]
Fluvastatin	N.A.	Peripheral Nervous System Diseases	Genotype AA is not associated with response to fluvastatin as compared to genotypes AG + GG.		[ 48]
Enalapril	N.A.	Cough	Genotype AA is associated with increased likelihood of Cough when treated with enalapril in people with Hypertension as compared to genotypes AG + GG.		[ 49]
Mycophenolic Acid	N.A.	Leukopenia	Genotype AA is associated with decreased concentrations of mycophenolic acid in people with lung transplantation as compared to genotypes AG + GG.		[ 41]
Hmg Coa Reductase Inhibitors	N.A.	Elevated Circulating Creatine Kinase Concentration	Genotype AA is associated with increased likelihood of Elevated circulating creatine kinase concentration when treated with hmg coa reductase inhibitors as compared to genotype AG.		[ 50]
Sorafenib	N.A.	Diarrhea	Patients with the AA genotype may have increased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to sorafenib.		[ 51]
Pitavastatin	N.A.	Acute Lymphoblastic Leukemia	Patients with the AA genotype may have decreased pitavastatin plasma concentrations as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.		[ 52]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the AA genotype and metastatic colorectal cancer may have 1) increased rapid response to treatment containing irinotecan, 2) longer progression free survival, and 3) greater irinotecan-related time to treatment failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.		[ 53]
Repaglinide	N.A.	Hypercholesterolemia	Patients with the AA genotype may have higher plasma concentrations of repaglinide in people with no health problems compared to GG genotype. Other genetic and clinical factors may also influence a patient's response.		[ 54]
Mycophenolic Acid	N.A.	Kidney Transplantation	Genotype AA is associated with decreased concentrations of mycophenolic acid in people with lung transplantation as compared to genotypes AG + GG.		[ 41]
Mycophenolic Acid	N.A.	Kidney Transplantation	Kidney transplant patients with the AA genotype may have reduced clearance rates of mycophenolic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.		[ 55]
Pravastatin	N.A.	Muscular Diseases	Patients with the rs2306283 AA genotype may have increased clearance of pravastatin as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence pravastatin clearance. This annotation only covers the pharmacokinetic relationship between rs2306283 and pravastatin and does not include evidence about clinical outcomes.		[ 32]
Atorvastatin	N.A.	Hypercholesterolemia	Genotype AA is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes AG + GG.		[ 42]
Atorvastatin	N.A.	Hypercholesterolemia	The current evidence base suggests that there is no significant association between the rs2306283 AA genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.		[ 57]
Hmg Coa Reductase Inhibitors	N.A.	Hypercholesterolemia	Patients with the rs2306283 AA genotype may have a decreased response to statins as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to statins.		[ 3]
Pravastatin	N.A.	Dyslipidaemia	Genotype AA is not associated with response to pravastatin as compared to genotype GG.		[ 43]
Pravastatin	N.A.	Dyslipidaemia	The current evidence base suggests that there is no significant association between the rs2306283 AA genotype and response to pravastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.		[ 31]
Simvastatin	N.A.	Coronary Disease	Genotype AA is associated with increased response to simvastatin as compared to genotype GG.		[ 3]
Simvastatin	N.A.	Dyslipidaemia	Genotype AA is associated with increased response to simvastatin as compared to genotype GG.		[ 3]
Simvastatin	N.A.	Hypercholesterolemia	Genotype AA is associated with increased response to simvastatin as compared to genotype GG.		[ 3]
Simvastatin	N.A.	Hyperlipidemias	Genotype AA is associated with increased response to simvastatin as compared to genotype GG.		[ 3]
Simvastatin	N.A.	Coronary Disease	The current evidence base suggests that there is no significant association between the rs2306283 AA genotype and response to simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.		[ 59]
Simvastatin	N.A.	Dyslipidaemia	The current evidence base suggests that there is no significant association between the rs2306283 AA genotype and response to simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.		[ 59]
Simvastatin	N.A.	Hypercholesterolemia	The current evidence base suggests that there is no significant association between the rs2306283 AA genotype and response to simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.		[ 59]
Simvastatin	N.A.	Hyperlipidemias	The current evidence base suggests that there is no significant association between the rs2306283 AA genotype and response to simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.		[ 59]
Hmg Coa Reductase Inhibitors	N.A.	Coronary Artery Disease	Genotype AA is associated with increased likelihood of Elevated circulating creatine kinase concentration when treated with hmg coa reductase inhibitors as compared to genotype AG.		[ 50]
Hmg Coa Reductase Inhibitors	N.A.	Diabetes Mellitus	Genotype AA is associated with increased likelihood of Elevated circulating creatine kinase concentration when treated with hmg coa reductase inhibitors as compared to genotype AG.		[ 50]
Hmg Coa Reductase Inhibitors	N.A.	Hypercholesterolemia	Genotype AA is associated with increased likelihood of Elevated circulating creatine kinase concentration when treated with hmg coa reductase inhibitors as compared to genotype AG.		[ 50]
Rifampin	N.A.	Hypercholesterolemia	Patients with the AA genotype may have increased clearance of rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rifampin clearance.		[ 1]
Irinotecan	N.A.	Neoplasms	Patients with the AA genotype and solid tumors may experience deceased risk of neutropenia compared to patients with the GG genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy.		[ 61]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs2306283 AA genotype may have increased exposure to methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2306283 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 7]
Hmg coa reductase inhibitors	N.A.	Coronary Artery Disease	Correlated with the increased creatine kinase in patients (compare with genotype AG)		[ 50]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:         53 Drugs in Total
Rifampicin	Drug Info	Healthy Individuals	Correlated with the decreased drug clearance in healthy individuals (compare with genotypes AA + AG)		[ 1]
Repaglinide	Drug Info	Healthy Individuals	Correlated with the decreased the total area under the plasma concentration-time curve (AUC) of drug and Cmax in healthy individuals (compare with genotype AA)		[ 53]
Irinotecan	Drug Info	Neoplasm	Correlated with the increased neutropenia risk in patients (compare with genotype AA)		[ 60]
Atorvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased reduction in LDL in patients (compare with genotypes AA + AG); Irrelevant to the increased drug response in patients (compare with genotypes AA + AG)		[ 61], [ 62]
Simvastatin	Drug Info	Hypercholesterolemia	Irrelevant to the increased drug response in patients (compare with genotypes AA + AG)		[ 61]
Irinotecan	Drug Info	Non-Small-Cell Lung Carcinoma	Irrelevant to the neutropenia in patients (compare with genotypes AA + AG)		[ 63]
Rosuvastatin	N.A.	Statin-related Myopathy	Genotype GG is associated with increased concentrations of rosuvastatin in healthy individuals as compared to genotype AA.		[ 64]
Atorvastatin	N.A.	Drug-induced Liver Injury	Genotype GG is not associated with increased response to atorvastatin or simvastatin in people with Hyperlipidemias as compared to genotypes AA + AG.		[ 61]
Simvastatin	N.A.	Drug-induced Liver Injury	Genotype GG is not associated with increased response to atorvastatin or simvastatin in people with Hyperlipidemias as compared to genotypes AA + AG.		[ 61]
Atorvastatin	N.A.	Muscular Diseases	Genotype GG is associated with increased reduction in LDL when treated with atorvastatin in people with Hypercholesterolemia as compared to genotypes AA + AG.		[ 62]
Edoxaban	N.A.	Hemorrhage	Genotype GG is associated with decreased likelihood of Hemorrhage when treated with edoxaban as compared to genotypes AA + AG.		[ 65]
Irinotecan	N.A.	Neutropenia	Genotype GG is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype AA.		[ 60]
Irinotecan	N.A.	Diarrhea	Genotype GG is not associated with Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.		[ 63]
Irinotecan	N.A.	Neutropenia	Genotype GG is not associated with Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.		[ 63]
Repaglinide	N.A.	Myocardial Infarction	Genotype GG is associated with decreased repaglinide plasma concentration (AUC) and Cmax when exposed to repaglinide in healthy individuals as compared to genotype AA.		[ 53]
Hmg Coa Reductase Inhibitors	N.A.	Nephrotoxicity	Genotype GG is associated with increased response to hmg coa reductase inhibitors as compared to genotype AA.		[ 3]
Simvastatin	N.A.	Nephrotoxicity	Genotype GG is associated with increased response to simvastatin as compared to genotype AA.		[ 3]
Pravastatin	N.A.	Mucositis	Genotype GG is associated with decreased response to pravastatin as compared to genotype AA.		[ 3]
Atorvastatin	N.A.	Neutropenia	Genotype GG is not associated with response to atorvastatin as compared to genotype AA.		[ 3]
Atorvastatin	N.A.	Muscular Diseases	Genotype GG is associated with decreased clinical benefit to atorvastatin in people with Hyperlipidemias as compared to genotype AA.		[ 67]
Atazanavir	N.A.	Statin-related Myopathy	Genotype GG (assigned as deficiency phenotype) is not associated with concentrations of atazanavir in people with HIV Infections as compared to genotypes AA + AG.		[ 68]
Rifampin	N.A.	Amenorrhea	Genotype GG is associated with decreased clearance of rifampin in healthy individuals as compared to genotypes AA + AG.		[ 1]
Sorafenib	N.A.	Diarrhea	Patients with the GG genotype may have decreased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to sorafenib.		[ 50]
Pitavastatin	N.A.	Acute Lymphoblastic Leukemia	Patients with the GG genotype may have increased pitavastatin plasma concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.		[ 51]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the GG genotype and metastatic colorectal cancer may have 1) decreased rapid response to treatment containing irinotecan, 2) shorter progression free survival, and 3) lower irinotecan-related time to treatment failure as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.		[ 52]
Mycophenolic Acid	N.A.	Kidney Transplantation	Kidney transplant patients with the GG genotype may have more rapid clearance rates of mycophenolic acid as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.		[ 54]
Pravastatin	N.A.	Muscular Diseases	Patients with the rs2306283 GG genotype may have decreased clearance of pravastatin as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence pravastatin clearance. This annotation only covers the pharmacokinetic relationship between rs2306283 and pravastatin and does not include evidence about clinical outcomes.		[ 32]
Atorvastatin	N.A.	Hypercholesterolemia	Genotype GG is not associated with response to atorvastatin as compared to genotype AA.		[ 3]
Atorvastatin	N.A.	Hypercholesterolemia	Genotype GG is associated with increased reduction in LDL when treated with atorvastatin in people with Hypercholesterolemia as compared to genotypes AA + AG.		[ 62]
Atorvastatin	N.A.	Hypercholesterolemia	Genotype GG is not associated with increased response to atorvastatin or simvastatin in people with Hyperlipidemias as compared to genotypes AA + AG.		[ 61]
Atorvastatin	N.A.	Hypercholesterolemia	The current evidence base suggests that there is no significant association between the rs2306283 GG genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.		[ 55]
Pravastatin	N.A.	Dyslipidaemia	Genotype GG is associated with decreased response to pravastatin as compared to genotype AA.		[ 3]
Pravastatin	N.A.	Dyslipidaemia	The current evidence base suggests that there is no significant association between the rs2306283 GG genotype and response to pravastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.		[ 31]
Simvastatin	N.A.	Coronary Disease	Genotype GG is associated with increased response to simvastatin as compared to genotype AA.		[ 3]
Simvastatin	N.A.	Dyslipidaemia	Genotype GG is associated with increased response to simvastatin as compared to genotype AA.		[ 3]
Simvastatin	N.A.	Hypercholesterolemia	Genotype GG is associated with increased response to simvastatin as compared to genotype AA.		[ 3]
Simvastatin	N.A.	Hyperlipidemias	Genotype GG is associated with increased response to simvastatin as compared to genotype AA.		[ 3]
Simvastatin	N.A.	Coronary Disease	Genotype GG is not associated with increased response to atorvastatin or simvastatin in people with Hyperlipidemias as compared to genotypes AA + AG.		[ 61]
Simvastatin	N.A.	Dyslipidaemia	Genotype GG is not associated with increased response to atorvastatin or simvastatin in people with Hyperlipidemias as compared to genotypes AA + AG.		[ 61]
Simvastatin	N.A.	Hypercholesterolemia	Genotype GG is not associated with increased response to atorvastatin or simvastatin in people with Hyperlipidemias as compared to genotypes AA + AG.		[ 61]
Simvastatin	N.A.	Hyperlipidemias	Genotype GG is not associated with increased response to atorvastatin or simvastatin in people with Hyperlipidemias as compared to genotypes AA + AG.		[ 61]
Simvastatin	N.A.	Coronary Disease	The current evidence base suggests that there is no significant association between the rs2306283 GG genotype and response to simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.		[ 56]
Simvastatin	N.A.	Dyslipidaemia	The current evidence base suggests that there is no significant association between the rs2306283 GG genotype and response to simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.		[ 56]
Simvastatin	N.A.	Hypercholesterolemia	The current evidence base suggests that there is no significant association between the rs2306283 GG genotype and response to simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.		[ 56]
Simvastatin	N.A.	Hyperlipidemias	The current evidence base suggests that there is no significant association between the rs2306283 GG genotype and response to simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.		[ 56]
Hmg Coa Reductase Inhibitors	N.A.	Coronary Artery Disease	Patients with the GG genotype who are treated with statins (hmg coa reductase inhibitors) may have decreased creatine kinase levels, and may have a lower risk of adverse events in response to treatment as compared to patients with the AA or AG genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment.		[ 49]
Hmg Coa Reductase Inhibitors	N.A.	Diabetes Mellitus	Patients with the GG genotype who are treated with statins (hmg coa reductase inhibitors) may have decreased creatine kinase levels, and may have a lower risk of adverse events in response to treatment as compared to patients with the AA or AG genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment.		[ 49]
Hmg Coa Reductase Inhibitors	N.A.	Hypercholesterolemia	Patients with the GG genotype who are treated with statins (hmg coa reductase inhibitors) may have decreased creatine kinase levels, and may have a lower risk of adverse events in response to treatment as compared to patients with the AA or AG genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment.		[ 49]
Irinotecan	N.A.	Neoplasms	Genotype GG is not associated with Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.		[ 63]
Irinotecan	N.A.	Neoplasms	Genotype GG is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype AA.		[ 60]
Irinotecan	N.A.	Neoplasms	Patients with the GG genotype and solid tumors may experience increased risk of neutropenia compared to patients with the AA genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy.		[ 57]
Rocuronium	N.A.	Essential Hypertension	Patients with the GG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium.		[ 44]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs2306283 GG genotype may have decreased exposure to methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2306283 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 7]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:         22 Drugs in Total
Mycophenolic acid	Drug Info	Kidney Transplantation	Correlated with the decreased drug clearance in patients (compare with genotype GG)		[ 54]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased drug clearance in patients (compare with genotype GG)		[ 67]
Irinotecan	Drug Info	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with genotype GG)		[ 52]
Fluorouracil	Drug Info	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with genotype GG)		[ 52]
Leucovorin	Drug Info	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with genotype GG)		[ 52]
Capecitabine	Drug Info	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with genotype GG)		[ 52]
Ar-c124910xx	N.A.	Neutropenia	Genotypes AA + AG is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype GG.		[ 69]
Ticagrelor	N.A.	Neutropenia	Genotypes AA + AG is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype GG.		[ 69]
Methotrexate	N.A.	Muscular Diseases	Genotypes AA + AG are associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 67]
Lopinavir	N.A.	Drug Toxicity	Genotypes AA + AG is not associated with concentrations of lopinavir in people with HIV Infections as compared to genotype GG.		[ 70]
Atorvastatin	N.A.	Drug Toxicity	Genotypes AA + AG are not associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to genotype GG.		[ 71]
Capecitabine	N.A.	Rhabdomyolysis	Genotypes AA + AG are associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotype GG.		[ 52]
Fluorouracil	N.A.	Rhabdomyolysis	Genotypes AA + AG are associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotype GG.		[ 52]
Irinotecan	N.A.	Rhabdomyolysis	Genotypes AA + AG are associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotype GG.		[ 52]
Leucovorin	N.A.	Rhabdomyolysis	Genotypes AA + AG are associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotype GG.		[ 52]
Mycophenolic Acid	N.A.	Overall Survival	Genotypes AA + AG are not associated with exposure to mycophenolic acid in people with Kidney Transplantation as compared to genotype GG.		[ 72]
Mycophenolic Acid	N.A.	Leukopenia	Genotypes AA + AG is associated with decreased clearance of mycophenolic acid in people with Kidney Transplantation as compared to genotype GG.		[ 54]
Methotrexate	N.A.	Nausea	Genotypes AA + AG are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 73]
Irinotecan	N.A.	Colorectal Neoplasms	Genotypes AA + AG are associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotype GG.		[ 52]
Mycophenolic Acid	N.A.	Kidney Transplantation	Genotypes AA + AG is associated with decreased clearance of mycophenolic acid in people with Kidney Transplantation as compared to genotype GG.		[ 54]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes AA + AG are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 73]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes AA + AG are associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 67]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:         53 Drugs in Total
Sorafenib	Drug Info	Diarrhea	Correlated with the decreased likelihood of diarrhea in patients (compare with genotype AA)		[ 50]
Atorvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug response in patients (compare with genotype AA); Irrelevant to the increased myalgia unspecified risk in patients (compare with genotype AA)		[ 73], [ 74]
Pitavastatin calcium	Drug Info	Healthy Individuals	Correlated with the increased the total area under the plasma concentration-time curve (AUC) of drug and Cmax in healthy individuals (compare with genotype AA)		[ 51]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Irrelevant to the drug concentrations in patients (compare with genotype AA)		[ 9]
Irinotecan	Drug Info	Neoplasm	Irrelevant to the severity of neutropenia in patients (compare with genotype AA)		[ 57]
Simvastatin Acid	N.A.	Hypoventilation	Genotypes AG + GG is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype AA.		[ 78]
Methotrexate	N.A.	Statin-related Myopathy	Genotypes AG + GG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 9]
Atorvastatin	N.A.	Drug Toxicity	Genotypes AG + GG are not associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotype AA.		[ 55]
Simvastatin	N.A.	Drug Toxicity	Genotypes AG + GG are not associated with response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.		[ 80]
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Genotypes AG + GG are not associated with likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to genotype AA.		[ 81]
Irinotecan	N.A.	Neutropenia	Genotypes AG + GG are not associated with severity of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype AA.		[ 57]
Sorafenib	N.A.	Hyperbilirubinemia	Genotypes AG + GG are associated with increased likelihood of Hyperbilirubinemia when treated with sorafenib as compared to genotype AA.		[ 50]
Sorafenib	N.A.	Diarrhea	Genotypes AG + GG are associated with decreased likelihood of Diarrhea when treated with sorafenib as compared to genotype AA.		[ 50]
Atorvastatin	N.A.	Myalgia	Genotypes AG + GG are not associated with increased risk of Myalgia unspecified when treated with atorvastatin in people with Hypercholesterolemia as compared to genotype AA.		[ 73]
Atorvastatin	N.A.	Discontinuation	Genotypes AG + GG are not associated with decreased response to atorvastatin or simvastatin as compared to genotype AA.		[ 82]
Simvastatin	N.A.	Discontinuation	Genotypes AG + GG are not associated with decreased response to atorvastatin or simvastatin as compared to genotype AA.		[ 82]
Pitavastatin	N.A.	Discontinuation	Genotypes AG + GG are not associated with response to pitavastatin in people with Hyperlipidemias as compared to genotype AA.		[ 83]
Methotrexate	N.A.	Drug Toxicity	Genotypes AG + GG is associated with increased likelihood of Drug Toxicity, gastrointestinal toxicity or Toxic liver disease when treated with methotrexate in children with Juvenile Rheumatoid Arthritis as compared to genotype AA.		[ 84]
Methotrexate	N.A.	Gastrointestinal Toxicity	Genotypes AG + GG is associated with increased likelihood of Drug Toxicity, gastrointestinal toxicity or Toxic liver disease when treated with methotrexate in children with Juvenile Rheumatoid Arthritis as compared to genotype AA.		[ 84]
Methotrexate	N.A.	Toxic Liver Disease	Genotypes AG + GG is associated with increased likelihood of Drug Toxicity, gastrointestinal toxicity or Toxic liver disease when treated with methotrexate in children with Juvenile Rheumatoid Arthritis as compared to genotype AA.		[ 84]
Atorvastatin	N.A.	Toxic Liver Disease	Genotypes AG + GG is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotype AA.		[ 74]
Atorvastatin	N.A.	Toxic Liver Disease	Genotypes AG + GG are not associated with increased concentrations of atorvastatin in healthy individuals as compared to genotype AA.		[ 85]
Methotrexate	N.A.	Nephrotoxicity	Genotypes AG + GG are associated with increased risk of nephrotoxicity when treated with methotrexate in people with Neoplasms as compared to genotype AA.		[ 86]
Tamoxifen	N.A.	Overall Survival	Genotypes AG + GG are not associated with decreased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to genotype AA.		[ 87]
Pravastatin	N.A.	Overall Survival	Genotypes AG + GG are not associated with decreased response to pravastatin as compared to genotype AA.		[ 88]
Rosuvastatin	N.A.	Overall Survival	Genotypes AG + GG are not associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype AA.		[ 89]
Simvastatin	N.A.	Cough	Genotypes AG + GG are not associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.		[ 56]
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Genotypes AG + GG are not associated with increased risk of statin-related myopathy when treated with hmg coa reductase inhibitors as compared to genotype AA.		[ 91]
Enalapril	N.A.	Cough	Genotypes AG + GG are not associated with increased likelihood of Cough when treated with enalapril in people with Essential hypertension as compared to genotype AA.		[ 92]
Methotrexate	N.A.	Mucositis	Genotypes AG + GG is not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 9]
Pitavastatin	N.A.	Elevated Circulating Creatine Kinase Concentration	Genotypes AG + GG are associated with increased pitavastatin plasma concentrations (AUC) and Cmax when exposed to pitavastatin in healthy individuals as compared to genotype AA.		[ 51]
Atorvastatin	N.A.	Statin-related Myopathy	Genotypes AG + GG are not associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype AA.		[ 93]
Atorvastatin	N.A.	Hypercholesterolemia	Genotypes AG + GG are not associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotype AA.		[ 55]
Atorvastatin	N.A.	Hypercholesterolemia	Genotypes AG + GG are not associated with decreased response to atorvastatin or simvastatin as compared to genotype AA.		[ 82]
Atorvastatin	N.A.	Hypercholesterolemia	Genotypes AG + GG is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotype AA.		[ 74]
Pravastatin	N.A.	Dyslipidaemia	Genotypes AG + GG are not associated with decreased response to pravastatin as compared to genotype AA.		[ 88]
Simvastatin	N.A.	Coronary Disease	Genotypes AG + GG are not associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.		[ 56]
Simvastatin	N.A.	Dyslipidaemia	Genotypes AG + GG are not associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.		[ 56]
Simvastatin	N.A.	Hypercholesterolemia	Genotypes AG + GG are not associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.		[ 56]
Simvastatin	N.A.	Hyperlipidemias	Genotypes AG + GG are not associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.		[ 56]
Simvastatin	N.A.	Coronary Disease	Genotypes AG + GG are not associated with response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.		[ 80]
Simvastatin	N.A.	Dyslipidaemia	Genotypes AG + GG are not associated with response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.		[ 80]
Simvastatin	N.A.	Hypercholesterolemia	Genotypes AG + GG are not associated with response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.		[ 80]
Simvastatin	N.A.	Hyperlipidemias	Genotypes AG + GG are not associated with response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.		[ 80]
Simvastatin	N.A.	Coronary Disease	Genotypes AG + GG are not associated with decreased response to atorvastatin or simvastatin as compared to genotype AA.		[ 82]
Simvastatin	N.A.	Dyslipidaemia	Genotypes AG + GG are not associated with decreased response to atorvastatin or simvastatin as compared to genotype AA.		[ 82]
Simvastatin	N.A.	Hypercholesterolemia	Genotypes AG + GG are not associated with decreased response to atorvastatin or simvastatin as compared to genotype AA.		[ 82]
Simvastatin	N.A.	Hyperlipidemias	Genotypes AG + GG are not associated with decreased response to atorvastatin or simvastatin as compared to genotype AA.		[ 82]
Hmg Coa Reductase Inhibitors	N.A.	Coronary Artery Disease	Genotypes AG + GG are not associated with increased risk of Myalgia unspecified when treated with atorvastatin in people with Hypercholesterolemia as compared to genotype AA.		[ 73]
Hmg Coa Reductase Inhibitors	N.A.	Diabetes Mellitus	Genotypes AG + GG are not associated with increased risk of Myalgia unspecified when treated with atorvastatin in people with Hypercholesterolemia as compared to genotype AA.		[ 73]
Hmg Coa Reductase Inhibitors	N.A.	Hypercholesterolemia	Genotypes AG + GG are not associated with increased risk of Myalgia unspecified when treated with atorvastatin in people with Hypercholesterolemia as compared to genotype AA.		[ 73]
Irinotecan	N.A.	Neoplasms	Genotypes AG + GG are not associated with severity of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype AA.		[ 57]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes AG + GG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 9]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:         22 Drugs in Total
Irinotecan	N.A.	Drug Toxicity	Genotype AG is associated with decreased likelihood of Drug Toxicity when treated with irinotecan in people with Colorectal Neoplasms.		[ 88]
Mycophenolic Acid	N.A.	Overall Survival	Genotype AG is not associated with exposure to mycophenolic acid in people with Kidney Transplantation as compared to genotype GG.		[ 70]
Sorafenib	N.A.	Diarrhea	Patients with the AG genotype may have decreased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to sorafenib.		[ 50]
Pitavastatin	N.A.	Acute Lymphoblastic Leukemia	Patients with the AG genotype may have increased pitavastatin plasma concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.		[ 51]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the AG genotype and metastatic colorectal cancer may have 1) increased rapid response to treatment containing irinotecan, 2) longer progression free survival, and 3) greater irinotecan-related time to treatment failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.		[ 52]
Repaglinide	N.A.	Hypercholesterolemia	While the GG genotype is associated with reduced plasma concentrations of repaglinide, no results are shown for the GA genotype.		[ 53]
Mycophenolic Acid	N.A.	Kidney Transplantation	Kidney transplant patients with the AG genotype may have reduced clearance rates of mycophenolic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.		[ 54]
Pravastatin	N.A.	Muscular Diseases	Patients with the rs2306283 AG genotype may have increased clearance of pravastatin as compared to patients with the GG genotype but decreased clearance as compared to the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence pravastatin clearance. This annotation only covers the pharmacokinetic relationship between rs2306283 and pravastatin and does not include evidence about clinical outcomes.		[ 32]
Atorvastatin	N.A.	Hypercholesterolemia	The current evidence base suggests that there is no significant association between the rs2306283 AG genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.		[ 55]
Hmg Coa Reductase Inhibitors	N.A.	Hypercholesterolemia	There is currently no available evidence regarding the association between the rs2306283 AG genotype and response to statins. However, patients with the rs2306283 AA genotype may have a decreased response to statins as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to statins.		[ 3]
Pravastatin	N.A.	Dyslipidaemia	The current evidence base suggests that there is no significant association between the rs2306283 AG genotype and response to pravastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.		[ 31]
Simvastatin	N.A.	Coronary Disease	The current evidence base suggests that there is no significant association between the rs2306283 AG genotype and response to simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.		[ 56]
Simvastatin	N.A.	Dyslipidaemia	The current evidence base suggests that there is no significant association between the rs2306283 AG genotype and response to simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.		[ 56]
Simvastatin	N.A.	Hypercholesterolemia	The current evidence base suggests that there is no significant association between the rs2306283 AG genotype and response to simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.		[ 56]
Simvastatin	N.A.	Hyperlipidemias	The current evidence base suggests that there is no significant association between the rs2306283 AG genotype and response to simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to simvastatin.		[ 56]
Hmg Coa Reductase Inhibitors	N.A.	Coronary Artery Disease	Patients with the AG genotype who are treated with statins (hmg coa reductase inhibitors) may have increased creatine kinase levels, and an increased risk of adverse events in response to treatment as compared to patients with the GG genotype, but a lower creatine kinase levels and lower risk of intolerance as compared to the AA genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment.		[ 49]
Hmg Coa Reductase Inhibitors	N.A.	Diabetes Mellitus	Patients with the AG genotype who are treated with statins (hmg coa reductase inhibitors) may have increased creatine kinase levels, and an increased risk of adverse events in response to treatment as compared to patients with the GG genotype, but a lower creatine kinase levels and lower risk of intolerance as compared to the AA genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment.		[ 49]
Hmg Coa Reductase Inhibitors	N.A.	Hypercholesterolemia	Patients with the AG genotype who are treated with statins (hmg coa reductase inhibitors) may have increased creatine kinase levels, and an increased risk of adverse events in response to treatment as compared to patients with the GG genotype, but a lower creatine kinase levels and lower risk of intolerance as compared to the AA genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment.		[ 49]
Rifampin	N.A.	Hypercholesterolemia	Patients with the AG genotype may have increased clearance of rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rifampin clearance.		[ 1]
Irinotecan	N.A.	Neoplasms	Patients with the AG genotype and solid tumors may experience increased risk of neutropenia compared to patients with the AA genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy.		[ 57]
Rocuronium	N.A.	Essential Hypertension	Patients with the AG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium.		[ 44]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs2306283 AG genotype may have increased exposure to methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2306283 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.		[ 7]
Genetic Polymorphism	rs2900478
Site of GPD	chr12:21215863 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A
Minor Allele Frequency	A=0.0895/448 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Hmg Coa Reductase Inhibitors	N.A.	Drug-induced Liver Injury	Allele A is associated with decreased response to hmg coa reductase inhibitors as compared to allele T.		[ 89]
Hmg coa reductase inhibitors	N.A.	Coronary Artery Disease	Correlated with the decreased drug response in patients (compare with Allele T)		[ 89]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Hmg Coa Reductase Inhibitors	N.A.	Acute Lymphoblastic Leukemia	Patients with the AA genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the AT or TT genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.		[ 89]
Genotype AT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Hmg Coa Reductase Inhibitors	N.A.	Acute Lymphoblastic Leukemia	Patients with the AT genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the TT genotypes and an increased response to hmg coa reductase inhibitors as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.		[ 89]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Hmg Coa Reductase Inhibitors	N.A.	Acute Lymphoblastic Leukemia	Patients with the TT genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the AT or AA genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.		[ 89]
Genetic Polymorphism	rs4149015
Site of GPD	chr12:21130388 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	A=0.0547/274 (Global)
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Pravastatin	Drug Info	Hypercholesterolemia	Correlated with the decreased drug response (compare with genotype GG)		[ 90]
Pravastatin	Drug Info	Healthy Individuals	Correlated with the increased drug AUC0-12 in healthy individuals (compare with genotype GG)		[ 91]
Pravastatin	N.A.	Discontinuation	Genotype AG is associated with decreased response to pravastatin as compared to genotype GG.		[ 90]
Moxifloxacin	N.A.	Statin-related Myopathy	Genotype AG is associated with increased exposure to moxifloxacin in people with Drug Resistance and Tuberculosis as compared to genotype GG.		[ 92]
Pravastatin	N.A.	Statin-related Myopathy	Genotype AG is associated with increased metabolism of pravastatin in children with Hyperlipoproteinemia Type II as compared to genotype GG.		[ 93]
Pravastatin	N.A.	Infectious Disease	Genotype AG is associated with increased AUC0-12 when exposed to pravastatin in healthy individuals as compared to genotype GG.		[ 91]
Irinotecan	N.A.	Non-small Cell Lung Carcinoma	Patients with the AG genotype and non-small cell lung cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.		[ 61]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Irinotecan	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the increased neutropenia in patients (compare with genotype GG); Irrelevant to the diarrhea in patients (compare with genotype GG)		[ 61]
Irinotecan	N.A.	Neutropenia	Genotypes AA + AG are associated with increased Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.		[ 61]
Irinotecan	N.A.	Diarrhea	Genotypes AA + AG are not associated with Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.		[ 61]
Irinotecan	N.A.	Non-small Cell Lung Carcinoma	Genotypes AA + AG are associated with increased Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.		[ 61]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Mycophenolate Mofetil	N.A.	Muscular Diseases	Allele A is associated with increased risk of adverse drug reactions when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele G.		[ 26]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Irinotecan	N.A.	Non-small Cell Lung Carcinoma	Patients with the AA genotype and non-small cell lung cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.		[ 61]
Pravastatin	N.A.	Nephrotoxicity	Patients carrying the AA genotype may have decreased pravastatin plasma AUC compared with patients carrying the GG genotype. This annotation only covers the pharmacokinetic relationship between rs4149015 and pravastatin and does not include evidence about clinical outcomes.		[ 93]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Irinotecan	N.A.	Non-small Cell Lung Carcinoma	Patients with the GG genotype and non-small cell lung cancer may have a decreased risk of neutropenia when treated with irinotecan as compared to patients with the AG or GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.		[ 61]
Pravastatin	N.A.	Nephrotoxicity	Patients carrying the GG genotype may have increased pravastatin plasma AUC compared to patients carrying the AA or AG genotype. This annotation only covers the pharmacokinetic relationship between rs4149015 and pravastatin and does not include evidence about clinical outcomes.		[ 93]
Genetic Polymorphism	rs4149032
Site of GPD	chr12:21164857 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.4643/2325 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Rifampicin	Drug Info	Tuberculosis	Correlated with the decreased drug exposure in patients (compare with allele C)		[ 94]
Ethambutol	N.A.	Statin-related Myopathy	Allele T is associated with decreased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to allele C.		[ 94]
Isoniazid	N.A.	Statin-related Myopathy	Allele T is associated with decreased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to allele C.		[ 94]
Pyrazinamide	N.A.	Statin-related Myopathy	Allele T is associated with decreased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to allele C.		[ 94]
Rifampin	N.A.	Statin-related Myopathy	Allele T is associated with decreased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to allele C.		[ 94]
Lopinavir	N.A.	Opioid-related Disorders	Allele T is not associated with trough concentration of lopinavir in people with HIV Infections as compared to allele C.		[ 5]
Rifampin	N.A.	Tuberculosis	Allele T is associated with decreased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to allele C.		[ 94]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Rifampin	N.A.	Hypoventilation	Genotype TT is associated with increased concentrations of rifampin in people with Tuberculosis as compared to genotypes CC + CT.		[ 95]
Letermovir	N.A.	Neutropenia	Genotype TT is associated with decreased exposure to letermovir as compared to genotypes CC + CT.		[ 30]
Rifampin	N.A.	Tuberculosis	Tuberculosis patients with the TT genotype may have decreased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's exposure to rifampicin.		[ 94]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Ar-c124910xx	N.A.	Neutropenia	Genotypes CT + TT is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype CC.		[ 67]
Ticagrelor	N.A.	Neutropenia	Genotypes CT + TT is not associated with decreased concentrations of AR-C124910XX or ticagrelor in healthy individuals as compared to genotype CC.		[ 67]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Isoniazid	N.A.	Drug-induced Liver Injury	Genotype CC is associated with decreased exposure to isoniazid in people with HIV Infections and Tuberculosis as compared to genotypes CT + TT.		[ 96]
Rifampin	N.A.	Tuberculosis	Tuberculosis patients with the CC genotype may have increased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with the TT or TC genotypes. Other genetic and clinical factors may influence also a patient's exposure to rifampicin.		[ 94]
Letermovir	N.A.	Gastrointestinal Toxicity	Patients with the CC genotype may have an increased AUC of letermovir as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.		[ 30]
Genotype TC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rifampin	N.A.	Tuberculosis	Tuberculosis patients with the TC genotype may have decreased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's exposure to rifampicin.		[ 94]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Letermovir	N.A.	Gastrointestinal Toxicity	Patients with the CT genotype may have an increased AUC of letermovir as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.		[ 30]
Genetic Polymorphism	rs4149056
Site of GPD	chr12:21178615 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.0877/439 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:       143 Drugs in Total
Fluvastatin	Drug Info	Muscular Diseases	Correlated with the all statin-induced myopathy and severe myopathy in patients (compare with Allele T)		[ 97]
Simvastatin	Drug Info	Muscular Diseases	Correlated with the all statin-induced myopathy and severe myopathy in patients (compare with Allele T)		[ 97]
Atorvastatin	Drug Info	Muscular Diseases	Correlated with the all statin-induced myopathy and severe myopathy in patients (compare with Allele T); Correlated with the increased drug plasma concentrations in patients (compare with Allele T)		[ 39], [ 97]
Rosuvastatin	Drug Info	Muscular Diseases	Correlated with the all statin-induced myopathy and severe myopathy in patients (compare with Allele T); Correlated with the increased drug plasma concentrations in patients (compare with Allele T)		[ 39], [ 97]
Pravastatin	Drug Info	Muscular Diseases	Correlated with the all statin-induced myopathy and severe myopathy in patients (compare with Allele T); Correlated with the increased the total area under the plasma concentration-time curve (AUC) of drug and Cmax in patients (compare with Allele T)		[ 97], [ 99]
Mycophenolate mofetil	Drug Info	Kidney Transplantation	Correlated with the decreased adverse drug reactions risk in patients (compare with Allele T)		[ 26]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug clearance in patients (compare with Allele T)		[ 7]
Pravastatin	Drug Info	Healthy Individuals	Correlated with the decreased drug metabolism in healthy individuals (compare with Allele T); Correlated with the increased the total area under the plasma concentration-time curve (AUC) of drug in healthy individuals (compare with Allele T)		[ 34], [ 102]
Atorvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased composite adverse events risk in patients (compare with Allele T)		[ 104]
Pravastatin	Drug Info	Hypercholesterolemia	Correlated with the increased composite adverse events risk in patients (compare with Allele T)		[ 104]
Simvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased composite adverse events risk in patients (compare with Allele T)		[ 104]
Rosuvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug plasma concentrations in patients (compare with Allele T)		[ 39]
Rosuvastatin	Drug Info	Coronary Artery Disease	Correlated with the increased likelihood of statin-related myopathy in patients (compare with Allele T)		[ 25]
Cytarabine	Drug Info	Acute Myeloid Leukemia	Correlated with the increased likelihood of toxic liver disease in patients (compare with Allele T)		[ 106]
Nateglinide	Drug Info	Diabetes	Irrelevant to the drug pharmacokinetics (compare with Genotype TT)		[ 107]
Atorvastatin	Drug Info	Hyperlipidemias	Irrelevant to the muscular diseases risk in patients (compare with Allele T)		[ 108]
Rosiglitazone	Drug Info	Diabetes Mellitus	Correlated with the increased drug response in patients (compare with Allele T)		[ 109]
Fludarabine	Drug Info	Acute Myeloid Leukemia	Correlated with the increased likelihood of toxic liver disease in patients (compare with Allele T)		[ 106]
Gemtuzumab ozogamicin	Drug Info	Acute Myeloid Leukemia	Correlated with the increased likelihood of toxic liver disease in patients (compare with Allele T)		[ 106]
Idarubicin	Drug Info	Acute Myeloid Leukemia	Correlated with the increased likelihood of toxic liver disease in patients (compare with Allele T)		[ 106]
Methotrexate	N.A.	Mucositis	Allele C is associated with decreased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 14]
Simvastatin	N.A.	Muscular Diseases	Allele C is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Coronary Artery Disease as compared to allele T.		[ 111]
Methotrexate	N.A.	Muscular Diseases	Allele C is not associated with response to methotrexate in children with Lymphoma, Non-Hodgkin or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 8]
Mycophenolate Mofetil	N.A.	Muscular Diseases	Allele C is associated with decreased risk of adverse drug reactions when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.		[ 26]
Atorvastatin	N.A.	Muscular Diseases	Allele C is not associated with risk of Muscular Diseases when treated with atorvastatin in people with Hyperlipidemias as compared to allele T.		[ 108]
Atorvastatin	N.A.	Muscular Diseases	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 113]
Fluvastatin	N.A.	Muscular Diseases	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 113]
Hmg Coa Reductase Inhibitors	N.A.	Muscular Diseases	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 113]
Pitavastatin	N.A.	Muscular Diseases	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 113]
Pravastatin	N.A.	Muscular Diseases	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 113]
Rosuvastatin	N.A.	Muscular Diseases	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 113]
Simvastatin	N.A.	Muscular Diseases	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 113]
Hmg Coa Reductase Inhibitors	N.A.	Abnormalities, Drug-induced	Allele C is associated with increased risk of Abnormalities, Drug-Induced when treated with hmg coa reductase inhibitors in people with Diabetes Mellitus, Type 2 as compared to allele T.		[ 27]
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Allele C is associated with increased likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors as compared to allele T.		[ 115]
Atorvastatin	N.A.	Myalgia	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 97]
Fluvastatin	N.A.	Myalgia	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 97]
Hmg Coa Reductase Inhibitors	N.A.	Myalgia	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 97]
Pravastatin	N.A.	Myalgia	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 97]
Rosuvastatin	N.A.	Myalgia	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 97]
Simvastatin	N.A.	Myalgia	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 97]
Nateglinide	N.A.	Hemorrhage	Allele C is not associated with PK of nateglinide as compared to genotype TT.		[ 107]
Pravastatin	N.A.	Hemorrhage	Allele C is associated with decreased metabolism of pravastatin in healthy individuals as compared to allele T.		[ 102]
Rosuvastatin	N.A.	Statin-related Myopathy	Allele C is associated with increased likelihood of statin-related myopathy when treated with rosuvastatin in people with Coronary Artery Disease as compared to allele T.		[ 25]
Atorvastatin	N.A.	Statin-related Myopathy	Allele C is not associated with likelihood of statin-related myopathy when treated with atorvastatin or simvastatin in people with Coronary Artery Disease as compared to allele T.		[ 25]
Simvastatin	N.A.	Statin-related Myopathy	Allele C is not associated with likelihood of statin-related myopathy when treated with atorvastatin or simvastatin in people with Coronary Artery Disease as compared to allele T.		[ 25]
Lopinavir	N.A.	Hypercholesterolemia	Allele C is not associated with concentrations of lopinavir in people with HIV Infections.		[ 68]
Atorvastatin	N.A.	Drug Toxicity	Allele C is associated with increased exposure to atorvastatin as compared to allele T.		[ 117]
Pitavastatin	N.A.	Statin-related Myopathy	Allele C is associated with increased exposure to pitavastatin and pitavastatin lactone in healthy individuals as compared to allele T.		[ 118]
Pitavastatin Lactone	N.A.	Statin-related Myopathy	Allele C is associated with increased exposure to pitavastatin and pitavastatin lactone in healthy individuals as compared to allele T.		[ 118]
Pravastatin	N.A.	Rhabdomyolysis	Allele C is associated with increased exposure to pravastatin in healthy individuals as compared to allele T.		[ 118]
Methotrexate	N.A.	Statin-related Myopathy	Allele C is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele T.		[ 10]
Rifampin	N.A.	Statin-related Myopathy	Allele C is not associated with exposure to rifampin in men as compared to allele T.		[ 120]
Grazoprevir	N.A.	Neutropenia	Allele C is associated with increased exposure to grazoprevir in people with Hepatitis C, Chronic as compared to allele T.		[ 4]
Methotrexate	N.A.	Drug-induced Liver Injury	Allele C is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 122]
Simvastatin Acid	N.A.	Drug-induced Liver Injury	Allele C is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.		[ 123]
Simvastatin	N.A.	Diarrhea	Allele C is associated with decreased response to simvastatin as compared to genotype TT.		[ 124]
Simvastatin	N.A.	Discontinuation	Allele C is associated with increased concentrations of simvastatin and simvastatin acid in people with Hypercholesterolemia as compared to allele T.		[ 125]
Simvastatin Acid	N.A.	Discontinuation	Allele C is associated with increased concentrations of simvastatin and simvastatin acid in people with Hypercholesterolemia as compared to allele T.		[ 125]
Hmg Coa Reductase Inhibitors	N.A.	Death	Allele C is not associated with risk of Death and Myocardial Infarction when treated with hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to allele T.		[ 21]
Hmg Coa Reductase Inhibitors	N.A.	Myocardial Infarction	Allele C is not associated with risk of Death and Myocardial Infarction when treated with hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to allele T.		[ 21]
Simvastatin	N.A.	Muscular Diseases	Allele C is not associated with increased concentrations of simvastatin in healthy individuals as compared to genotype TT.		[ 127]
Pravastatin	N.A.	Muscular Diseases	Allele C is associated with decreased clearance of pravastatin in healthy individuals as compared to allele T.		[ 32]
Methotrexate	N.A.	Toxic Liver Disease	Allele C is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 71]
Hmg Coa Reductase Inhibitors	N.A.	Muscular Diseases	Allele C is associated with increased risk of Muscular Diseases when treated with hmg coa reductase inhibitors as compared to allele T.		[ 130]
Hmg Coa Reductase Inhibitors	N.A.	Thrombocytopenia	Allele C is associated with decreased response to hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to allele T.		[ 21]
Methotrexate	N.A.	Discontinuation	Allele C is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 7]
Atorvastatin	N.A.	Statin-related Myopathy	Allele C is not associated with risk of statin-related myopathy due to atorvastatin as compared to allele T.		[ 131]
Rosiglitazone	N.A.	Statin-related Myopathy	Allele C is associated with increased response to rosiglitazone in people with Diabetes Mellitus as compared to allele T.		[ 109]
Erythromycin	N.A.	Statin-related Myopathy	Allele C is associated with decreased erythromycin metabolism when treated with erythromycin in people with Neoplasms as compared to allele T.		[ 132]
Methotrexate	N.A.	Infectious Disease	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.		[ 12]
Atorvastatin	N.A.	Muscular Diseases	Allele C is associated with increased risk of Muscular Diseases when treated with atorvastatin.		[ 117]
2-hydroxyatorvastatin	N.A.	Muscular Diseases	Allele C is associated with increased exposure to 2-hydroxyatorvastatin, 2-hydroxyatorvastatin lactone, 4-hydroxyatorvastatin, 4-hydroxyatorvastatin lactone, atorvastatin and atorvastatin lactone in healthy individuals as compared to allele T.		[ 134]
2-hydroxyatorvastatin Lactone	N.A.	Muscular Diseases	Allele C is associated with increased exposure to 2-hydroxyatorvastatin, 2-hydroxyatorvastatin lactone, 4-hydroxyatorvastatin, 4-hydroxyatorvastatin lactone, atorvastatin and atorvastatin lactone in healthy individuals as compared to allele T.		[ 134]
4-hydroxyatorvastatin	N.A.	Muscular Diseases	Allele C is associated with increased exposure to 2-hydroxyatorvastatin, 2-hydroxyatorvastatin lactone, 4-hydroxyatorvastatin, 4-hydroxyatorvastatin lactone, atorvastatin and atorvastatin lactone in healthy individuals as compared to allele T.		[ 134]
4-hydroxyatorvastatin Lactone	N.A.	Muscular Diseases	Allele C is associated with increased exposure to 2-hydroxyatorvastatin, 2-hydroxyatorvastatin lactone, 4-hydroxyatorvastatin, 4-hydroxyatorvastatin lactone, atorvastatin and atorvastatin lactone in healthy individuals as compared to allele T.		[ 134]
Atorvastatin	N.A.	Muscular Diseases	Allele C is associated with increased exposure to 2-hydroxyatorvastatin, 2-hydroxyatorvastatin lactone, 4-hydroxyatorvastatin, 4-hydroxyatorvastatin lactone, atorvastatin and atorvastatin lactone in healthy individuals as compared to allele T.		[ 134]
Atorvastatin Lactone	N.A.	Muscular Diseases	Allele C is associated with increased exposure to 2-hydroxyatorvastatin, 2-hydroxyatorvastatin lactone, 4-hydroxyatorvastatin, 4-hydroxyatorvastatin lactone, atorvastatin and atorvastatin lactone in healthy individuals as compared to allele T.		[ 134]
Bosentan	N.A.	Drug-induced Liver Injury	Allele C is not associated with increased risk of drug-induced liver injury when treated with bosentan in people with Hypertension, Pulmonary as compared to allele T.		[ 24]
Pravastatin	N.A.	Drug-induced Liver Injury	Allele C is not associated with the lipid-lowering efficacy of pravastatin when exposed to pravastatin in healthy individuals.		[ 99]
Amprenavir	N.A.	Overall Survival	Allele C is associated with decreased trough concentration of amprenavir in people with HIV Infections as compared to allele T.		[ 136]
Saquinavir	N.A.	Overall Survival	Allele C is not associated with trough concentration of saquinavir in people with HIV Infections as compared to allele T.		[ 136]
Lopinavir	N.A.	Opioid-related Disorders	Allele C is associated with increased trough concentration of lopinavir in people with HIV Infections as compared to allele T.		[ 5]
Elbasvir / Grazoprevir	N.A.	Sustained Virological Response (svr)	Allele C is not associated with increased sustained virological response (svr) when treated with elbasvir / grazoprevir in people with Hepatitis C, Chronic as compared to allele T.		[ 4]
Ritonavir	N.A.	Nephrotoxicity	Allele C is not associated with clearance of ritonavir in children with HIV Infections as compared to allele T.		[ 38]
Lopinavir	N.A.	Peripheral Nervous System Diseases	Allele C is not associated with response to lopinavir or ritonavir in children with HIV Infections as compared to allele T.		[ 38]
Cytarabine	N.A.	Toxic Liver Disease	Allele C is associated with increased likelihood of Toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele T.		[ 106]
Fludarabine	N.A.	Toxic Liver Disease	Allele C is associated with increased likelihood of Toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele T.		[ 106]
Gemtuzumab Ozogamicin	N.A.	Toxic Liver Disease	Allele C is associated with increased likelihood of Toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele T.		[ 106]
Idarubicin	N.A.	Toxic Liver Disease	Allele C is associated with increased likelihood of Toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele T.		[ 106]
Mycophenolic Acid	N.A.	Leukopenia	Allele C is not associated with metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele T.		[ 54]
Ritonavir	N.A.	Leukopenia	Allele C is not associated with trough concentration of ritonavir in men with HIV Infections as compared to allele T.		[ 6]
Methotrexate	N.A.	Drug Toxicity	Allele C is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele T.		[ 141]
Methotrexate	N.A.	Nausea	Allele C is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele T.		[ 141]
Mercaptopurine	N.A.	Leukopenia	Allele C is not associated with increased likelihood of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 142]
Pravastatin	N.A.	Amenorrhea	Allele C is associated with increased pravastatin plasma concentrations (AUC) when exposed to pravastatin in healthy individuals as compared to allele T.		[ 34]
Atorvastatin	N.A.	Amenorrhea	Allele C is associated with increased plasma concentrations of atorvastatin as compared to allele T.		[ 39]
Rosuvastatin	N.A.	Amenorrhea	Allele C is associated with increased plasma concentrations of rosuvastatin as compared to allele T.		[ 39]
Atorvastatin	N.A.	Statin-related Myopathy	Allele C is associated with increased dose-adjusted trough concentrations of atorvastatin in children with Hypercholesterolemia as compared to allele T.		[ 143]
Fluvastatin	N.A.	Statin-related Myopathy	Allele C is associated with increased concentrations of fluvastatin in healthy individuals as compared to allele T.		[ 144]
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Allele C is associated with increased risk of Muscular Diseases when treated with hmg coa reductase inhibitors as compared to allele T.		[ 130]
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Allele C is associated with increased risk of Abnormalities, Drug-Induced when treated with hmg coa reductase inhibitors in people with Diabetes Mellitus, Type 2 as compared to allele T.		[ 27]
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 97]
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 113]
Lopinavir	N.A.	HIV Infectious Disease	Allele C is associated with increased trough concentration of lopinavir in people with HIV Infections as compared to allele T.		[ 136]
Lopinavir	N.A.	HIV Infectious Disease	Allele C is not associated with concentrations of lopinavir in people with HIV Infections.		[ 68]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Allele C is associated with increased likelihood of Toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele T.		[ 106]
Fludarabine	N.A.	Leukemia, Myeloid, Acute	Allele C is associated with increased likelihood of Toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele T.		[ 106]
Gemtuzumab Ozogamicin	N.A.	Leukemia, Myeloid, Acute	Allele C is associated with increased likelihood of Toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele T.		[ 106]
Idarubicin	N.A.	Leukemia, Myeloid, Acute	Allele C is associated with increased likelihood of Toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele T.		[ 106]
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Allele C is associated with decreased risk of adverse drug reactions when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.		[ 26]
Rosiglitazone	N.A.	Diabetes Mellitus, Type 2	Allele C is associated with increased response to rosiglitazone in people with Diabetes Mellitus as compared to allele T.		[ 109]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele C is not associated with response to methotrexate in children with Lymphoma, Non-Hodgkin or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 8]
Rosuvastatin	N.A.	Hypercholesterolemia	Allele C is associated with increased plasma concentrations of rosuvastatin as compared to allele T.		[ 39]
Simvastatin	N.A.	Hypercholesterolemia	Allele C is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.		[ 123]
Simvastatin	N.A.	Statin-related Myopathy	Allele C is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Coronary Artery Disease as compared to allele T.		[ 111]
Simvastatin	N.A.	Statin-related Myopathy	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 97]
Simvastatin	N.A.	Statin-related Myopathy	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 113]
Rosuvastatin	N.A.	Statin-related Myopathy	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 97]
Rosuvastatin	N.A.	Statin-related Myopathy	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 113]
Atorvastatin	N.A.	Statin-related Myopathy	Allele C is associated with increased risk of Muscular Diseases when treated with atorvastatin.		[ 117]
Atorvastatin	N.A.	Statin-related Myopathy	Allele C is not associated with risk of Muscular Diseases when treated with atorvastatin in people with Hyperlipidemias as compared to allele T.		[ 108]
Atorvastatin	N.A.	Statin-related Myopathy	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 97]
Atorvastatin	N.A.	Statin-related Myopathy	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 113]
Pravastatin	N.A.	Statin-related Myopathy	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 97]
Pravastatin	N.A.	Statin-related Myopathy	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 113]
Fluvastatin	N.A.	Statin-related Myopathy	Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 97]
Fluvastatin	N.A.	Statin-related Myopathy	Allele C is not associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to allele T.		[ 113]
Hmg Coa Reductase Inhibitors	N.A.	Cardiovascular Disease	Allele C is associated with decreased response to hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to allele T.		[ 21]
Hmg Coa Reductase Inhibitors	N.A.	Hyperlipidemias	Allele C is associated with decreased response to hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to allele T.		[ 21]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele C is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 7]
Methotrexate	N.A.	Osteosarcoma	Allele C is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 7]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele C is associated with decreased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 14]
Methotrexate	N.A.	Osteosarcoma	Allele C is associated with decreased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 14]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele C is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 122]
Methotrexate	N.A.	Osteosarcoma	Allele C is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 122]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele C is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 71]
Methotrexate	N.A.	Osteosarcoma	Allele C is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 71]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.		[ 12]
Methotrexate	N.A.	Osteosarcoma	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.		[ 12]
Amprenavir	N.A.	HIV Infectious Disease	Allele C is associated with decreased trough concentration of amprenavir in people with HIV Infections as compared to allele T.		[ 136]
Hmg coa reductase inhibitors	N.A.	Muscular Diseases	Correlated with the all statin-induced myopathy and severe myopathy in patients (compare with Allele T)		[ 97]
Simvastatin acid	N.A.	Hypercholesterolemia	Correlated with the increased drug concentrations (compare with Genotype TT); Correlated with the increased drug concentrations in patients (compare with Allele T)		[ 123], [ 125]
Hmg coa reductase inhibitors	N.A.	Diabetes Mellitus	Correlated with the increased drug-Induced abnormalities risk in patients (compare with Allele T)		[ 27]
Allele T	Click to Show/Hide the Full List of Affected Drugs:         21 Drugs in Total
Rosuvastatin	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with allele C)		[ 37]
Mycophenolate mofetil	Drug Info	Kidney Transplantation	Irrelevant to the increased diarrhea risk in patients (compare with allele C); Irrelevant to the increased leukopenia risk in patients (compare with allele C)		[ 35]
Rosuvastatin	Drug Info	Coronary Disease	Irrelevant to the LDL-C response in patients (compare with allele C)		[ 23]
Simvastatin	Drug Info	Coronary Disease	Irrelevant to the LDL-C response in patients (compare with allele C)		[ 23]
Atazanavir	N.A.	Nephrolithiasis	Allele T is not associated with risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele C.		[ 20]
Ritonavir	N.A.	Nephrolithiasis	Allele T is not associated with risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele C.		[ 20]
Ticagrelor	N.A.	Statin-related Myopathy	Allele T is associated with decreased concentrations of ticagrelor in people with Acute coronary syndrome as compared to allele C.		[ 18]
Tacrolimus	N.A.	Overall Survival	Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C.		[ 22]
Pioglitazone	N.A.	Statin-related Myopathy	Allele T is not associated with response to pioglitazone in people with Diabetes Mellitus as compared to allele C.		[ 104]
Hmg Coa Reductase Inhibitors	N.A.	Muscular Diseases	Allele T is not associated with increased likelihood of Muscular Diseases when treated with hmg coa reductase inhibitors in people with familial hypercholesterolemia as compared to allele C.		[ 132]
Simvastatin	N.A.	Infectious Disease	Allele T is not associated with LDL-C response when treated with simvastatin in people with Coronary Disease as compared to allele C.		[ 23]
Mycophenolate Mofetil	N.A.	Diarrhea	Allele T is not associated with increased risk of Diarrhea when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.		[ 35]
Rosuvastatin	N.A.	Muscular Diseases	Allele T is not associated with LDL-C response when treated with rosuvastatin in people with Coronary Disease as compared to allele C.		[ 23]
Opioids	N.A.	Opioid-related Disorders	Allele T is not associated with risk of Opioid-Related Disorders when exposed to opioids as compared to allele C.		[ 36]
Rosuvastatin	N.A.	Opioid-related Disorders	Allele T is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele C.		[ 37]
Mycophenolate Mofetil	N.A.	Leukopenia	Allele T is not associated with increased risk of Leukopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.		[ 35]
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Allele T is not associated with increased likelihood of Muscular Diseases when treated with hmg coa reductase inhibitors in people with familial hypercholesterolemia as compared to allele C.		[ 132]
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Allele T is not associated with increased risk of Diarrhea when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.		[ 35]
Rosuvastatin	N.A.	Hypercholesterolemia	Allele T is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele C.		[ 37]
Ticagrelor	N.A.	Acute Coronary Syndrome	Allele T is associated with decreased concentrations of ticagrelor in people with Acute coronary syndrome as compared to allele C.		[ 18]
Ticagrelor	N.A.	Acute Coronary Syndrome	Correlated with the decreased drug concentrations in patients (compare with allele C)		[ 18]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:       110 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug response in patients (compare with Genotypes CT + TT)		[ 9]
Rosuvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug AUC in patients (p=0.002) and Cmax in patients (p=0.003) (compare with Genotype TT)		[ 127]
Pravastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug mean peak concentration in plasma and area under the plasma concentration in patients (compare with Genotypes CT + TT); Irrelevant to the drug response in patients (compare with Genotype TT)		[ 43], [ 129]
Lopinavir	Drug Info	HIV Infection	Correlated with the increased drug median plasma Cmin and C2-6 (compare with Genotypes CT + TT)		[ 130]
Simvastatin	Drug Info	Healthy Individuals	Correlated with the increased drug plasma concentrations in healthy individuals (compare with Genotypes CT + TT)		[ 131]
Simvastatin	Drug Info	Myocardial Infarction	Correlated with the increased likelihood of muscular diseases in patients (compare with Genotype TT)		[ 132]
Simvastatin	Drug Info	Muscular Diseases	Correlated with the increased muscular diseases risk in patients (compare with genotype Ct); Irrelevant to the increased drug dose decrease or switch to another cholesterol-lowering drug risk in patients (compare with Genotype TT)		[ 132], [ 133]
Cerivastatin	Drug Info	Muscular Diseases	Correlated with the increased rhabdomyolysis risk in patients (compare with Genotype TT)		[ 134]
Cerivastatin	Drug Info	Rhabdomyolysis	Correlated with the increased rhabdomyolysis risk in patients (compare with Genotype TT)		[ 134]
Repaglinide	Drug Info	Diabetes Mellitus	Correlated with the increased the total area under the plasma concentration-time curve (AUC) of drug (compare with Genotypes CT + TT)		[ 102]
Atorvastatin	Drug Info	Healthy Individuals	Correlated with the increased the total area under the plasma concentration-time curve (AUC) of drug in healthy individuals (compare with Genotype TT)		[ 127]
Fluvastatin	Drug Info	Muscular Diseases	Irrelevant to the increased mean peak concentration in plasma and area under the plasma concentration in patients (compare with Genotypes CT + TT)		[ 129]
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Genotype CC is associated with increased risk of statin-related myopathy when treated with hmg coa reductase inhibitors as compared to genotype TT.		[ 136]
Atorvastatin	N.A.	Statin-related Myopathy	Genotype CC is not associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.		[ 136]
Rosuvastatin	N.A.	Statin-related Myopathy	Genotype CC is associated with increased concentrations of rosuvastatin in healthy individuals as compared to genotypes CT + TT.		[ 62]
Atorvastatin	N.A.	Statin-related Myopathy	Genotype CC is not associated with the short-term effects of statins on cholesterol homeostasis when exposed to atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin.		[ 138]
Fluvastatin	N.A.	Statin-related Myopathy	Genotype CC is not associated with the short-term effects of statins on cholesterol homeostasis when exposed to atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin.		[ 138]
Pravastatin	N.A.	Statin-related Myopathy	Genotype CC is not associated with the short-term effects of statins on cholesterol homeostasis when exposed to atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin.		[ 138]
Rosuvastatin	N.A.	Statin-related Myopathy	Genotype CC is not associated with the short-term effects of statins on cholesterol homeostasis when exposed to atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin.		[ 138]
Simvastatin	N.A.	Statin-related Myopathy	Genotype CC is not associated with the short-term effects of statins on cholesterol homeostasis when exposed to atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin.		[ 138]
Atorvastatin	N.A.	Drug-induced Liver Injury	Genotype CC is not associated with increased response to atorvastatin or simvastatin in people with Hyperlipidemias as compared to genotypes CT + TT.		[ 59]
Simvastatin	N.A.	Drug-induced Liver Injury	Genotype CC is not associated with increased response to atorvastatin or simvastatin in people with Hyperlipidemias as compared to genotypes CT + TT.		[ 59]
Simvastatin	N.A.	Statin-related Myopathy	Genotype CC is associated with increased risk of statin-related myopathy when treated with simvastatin as compared to genotype TT.		[ 136]
Lovastatin	N.A.	Statin-related Myopathy	Genotype CC is associated with increased risk of statin-related myopathy when treated with lovastatin as compared to genotype TT.		[ 136]
Lopinavir	N.A.	Hemorrhage	Genotype CC is associated with increased median plasma lopinavir Cmin and C2-6 when treated with lopinavir as compared to genotypes CT + TT.		[ 130]
Methotrexate	N.A.	Hemorrhage	Genotype CC is associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.		[ 9]
Simvastatin	N.A.	Discontinuation	Genotype CC is associated with increased risk of discontinuation when treated with simvastatin as compared to genotype TT.		[ 140]
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Genotype CC is associated with increased likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors as compared to genotypes CT + TT.		[ 141]
Repaglinide	N.A.	Neutropenia	Genotype CC is associated with increased mean plasma AUC of repaglinide as compared to genotypes CT + TT.		[ 102]
Hmg Coa Reductase Inhibitors	N.A.	Discontinuation	Genotype CC is associated with increased likelihood of discontinuation when treated with hmg coa reductase inhibitors in people with Acute coronary syndrome and Myocardial Infarction as compared to genotype TT.		[ 142]
Simvastatin	N.A.	Fever	Genotype CC is associated with increased risk of dose decrease or switch to another cholesterol-lowering drug when treated with simvastatin as compared to genotype TT.		[ 133]
Pravastatin	N.A.	Fever	Genotype CC is not associated with response to pravastatin as compared to genotype TT.		[ 43]
Simvastatin	N.A.	Muscular Diseases	Genotype CC is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Myocardial Infarction as compared to genotype TT.		[ 132]
Axitinib	N.A.	Overall Survival	Genotype CC is not associated with metabolism of axitinib in healthy individuals as compared to genotypes CT + TT.		[ 143]
Cerivastatin	N.A.	Rhabdomyolysis	Genotype CC is associated with increased risk of Rhabdomyolysis when treated with cerivastatin as compared to genotype TT.		[ 134]
Simvastatin Acid	N.A.	Cough	Genotype CC is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.		[ 144]
Fluvastatin	N.A.	Amenorrhea	Genotype CC is not associated with increased mean peak concentration in plasma and area under the plasma concentration when exposed to fluvastatin in men as compared to genotypes CT + TT.		[ 129]
Pravastatin	N.A.	Amenorrhea	Genotype CC is associated with increased mean peak concentration in plasma and area under the plasma concentration when exposed to pravastatin in men as compared to genotypes CT + TT.		[ 129]
Hmg Coa Reductase Inhibitors	N.A.	Elevated Circulating Creatine Kinase Concentration	Genotype CC is associated with increased likelihood of Elevated circulating creatine kinase concentration when exposed to hmg coa reductase inhibitors as compared to genotypes CT + TT.		[ 49]
Atorvastatin	N.A.	Elevated Circulating Creatine Kinase Concentration	Genotype CC is associated with increased AUC when exposed to atorvastatin in healthy individuals as compared to genotype TT.		[ 127]
Rosuvastatin	N.A.	Elevated Circulating Creatine Kinase Concentration	Genotype CC is associated with increased AUC (p=0.002) and Cmax (p=0.003) when exposed to rosuvastatin in healthy individuals as compared to genotype TT.		[ 127]
Simvastatin Acid	N.A.	Statin-related Myopathy	Genotype CC is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotypes CT + TT.		[ 131]
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Genotype CC is associated with increased likelihood of discontinuation when treated with hmg coa reductase inhibitors in people with Acute coronary syndrome and Myocardial Infarction as compared to genotype TT.		[ 142]
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Patients with the rs4149056 CC genotype may have an increased risk of developing myopathy when treated with statins as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of statin-induced myopathy.		[ 116]
Lovastatin Acid	N.A.	Statin-related Myopathy	Patients with the CC genotype may have increased concentrations of lovastatin acid as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of lovastatin acid. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid and does not include evidence about clinical outcomes.		[ 147]
Lopinavir	N.A.	HIV Infectious Disease	Genotype CC is associated with increased median plasma lopinavir Cmin and C2-6 when treated with lopinavir as compared to genotypes CT + TT.		[ 130]
Rosuvastatin	N.A.	HIV Infectious Disease	The current evidence base suggests that there is no association between the rs4149056 CC genotype and the LDL-lowering response to rosuvastatin. Some studies report an association, however the majority of the studies documented no association. Other genetic and clinical factors may also influence response to rosuvastatin.		[ 148]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Patients with the CC genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.gemtuzumab ozogamicin and idarubicin.		[ 101]
Fludarabine	N.A.	Leukemia, Myeloid, Acute	Patients with the CC genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.gemtuzumab ozogamicin and idarubicin.		[ 101]
Gemtuzumab Ozogamicin	N.A.	Leukemia, Myeloid, Acute	Patients with the CC genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.gemtuzumab ozogamicin and idarubicin.		[ 101]
Idarubicin	N.A.	Leukemia, Myeloid, Acute	Patients with the CC genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.gemtuzumab ozogamicin and idarubicin.		[ 101]
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Patients with the CC genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have a decreased risk of adverse drug reaction as compared to patients with the TT genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.		[ 35]
Rosiglitazone	N.A.	Diabetes Mellitus, Type 2	Patients with the CC genotype may have increased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to rosiglitazone.		[ 104]
Sorafenib	N.A.	Thrombocytopenia	Patients with the CC genotype may have decreased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to sorafenib.		[ 50]
Irinotecan	N.A.	Neoplasms	Patients with the CC genotype and cancer may have an increased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the TT genotype. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea.		[ 57]
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the CC genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.		[ 154]
Docetaxel	N.A.	Breast Neoplasms	Patients with the CC genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.		[ 154]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the CC genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.		[ 154]
Epirubicin	N.A.	Breast Neoplasms	Patients with the CC genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.		[ 154]
Fluorouracil	N.A.	Breast Neoplasms	Patients with the CC genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.		[ 154]
Glucarpidase	N.A.	Nephrotoxicity	Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs4149056 CC genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.		[ 155]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype CC is associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.		[ 9]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with precursor cell lymphoblastic leukemia-lymphoma and the rs4149056 CC genotype may have a decreased response to methotrexate as compared to patients with the CT and TT genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence response to methotrexate.		[ 8]
Mercaptopurine	N.A.	Acute Lymphoblastic Leukemia	Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 157]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 157]
Rosuvastatin	N.A.	Hypercholesterolemia	Genotype CC is associated with increased AUC (p=0.002) and Cmax (p=0.003) when exposed to rosuvastatin in healthy individuals as compared to genotype TT.		[ 127]
Rosuvastatin	N.A.	Hypercholesterolemia	Genotype CC is associated with increased concentrations of rosuvastatin in healthy individuals as compared to genotypes CT + TT.		[ 62]
Rosuvastatin	N.A.	Hypercholesterolemia	Patients with the rs4149056 CC genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and does not include evidence about clinical outcomes.		[ 158]
Pravastatin	N.A.	Hypercholesterolemia	Patients with the rs4149056 CC genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pravastatin and does not include evidence about clinical outcomes.		[ 159]
Simvastatin	N.A.	Hypercholesterolemia	Genotype CC is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotypes CT + TT.		[ 131]
Simvastatin	N.A.	Hypercholesterolemia	Genotype CC is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.		[ 144]
Simvastatin	N.A.	Hypercholesterolemia	Patients with the rs4149056 CC genotype may have increased serum concentrations of simvastatin acid as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs4149056 and simvastatin acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid.		[ 114]
Simvastatin Acid	N.A.	Hypercholesterolemia	Patients with the rs4149056 CC genotype may have increased serum concentrations of simvastatin acid as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs4149056 and simvastatin acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid.		[ 114]
Simvastatin	N.A.	Statin-related Myopathy	Genotype CC is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Myocardial Infarction as compared to genotype TT.		[ 132]
Simvastatin	N.A.	Statin-related Myopathy	Genotype CC is associated with increased risk of dose decrease or switch to another cholesterol-lowering drug when treated with simvastatin as compared to genotype TT.		[ 133]
Simvastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 CC genotype may have a higher risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity to simvastatin.		[ 105]
Rosuvastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 CC genotype may have increased risk of statin-related myopathy or myalgia when treated with rosuvastatin as compared to patients with genotype TT. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk to rosuvastatin.		[ 162]
Atorvastatin	N.A.	Statin-related Myopathy	Patients with the CC genotype may have increased exposure to atorvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to atorvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and atorvastatin and does not include evidence about clinical outcomes.		[ 108]
Atorvastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 CC genotype may have an increased risk of myopathy when treated with atorvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing myopathy when treated with atorvastatin.		[ 117]
Pravastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 CC genotype may have an increased risk of developing myopathy when treated with pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of experiencing pravastatin-induced myopathy.		[ 97]
Lovastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 CC genotype may have increased concentration of lovastatin acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of lovastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid or lovastatin and does not include evidence about clinical outcomes.		[ 147]
Pitavastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 CC genotype may have increased concentrations of pitavastatin when treated with pitavastatin as compared to patients with TT genotype. Other genetic and clinical factors may also influence the metabolism of pitavastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pitavastatin and does not include evidence about clinical outcomes.		[ 166]
Fluvastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 CC genotype may have an increased risk of developing myopathy when treated with fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of developing fluvastatin-induced myopathy.		[ 97]
SN-38	N.A.	Non-small Cell Lung Carcinoma	Patients with the CC genotype and non-small cell lung cancer may have receive an increased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38.		[ 61]
Hmg Coa Reductase Inhibitors	N.A.	Cardiovascular Disease	Patients with the rs4149056 CC genotype may have a decreased response to statins as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to statins.		[ 168]
Hmg Coa Reductase Inhibitors	N.A.	Hyperlipidemias	Patients with the rs4149056 CC genotype may have a decreased response to statins as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to statins.		[ 168]
Pravastatin	N.A.	Hyperlipidemias	Patients with the rs4149056 CC genotype who are treated with pravastatin may have a smaller reduction in LDL and total cholesterol as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.		[ 31]
Simvastatin	N.A.	Hyperlipidemias	Patients with the rs4149056 CC genotype may have a decreased response to simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. The effect size may be small. Other genetic and clinical factors may also influence response to simvastatin.		[ 56]
Atorvastatin	N.A.	Dyslipidaemia	Genotype CC is associated with increased cholesterol synthesis rate when exposed to atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin as compared to genotype TT.		[ 138]
Atorvastatin	N.A.	Familial Hypercholesterolemia	Genotype CC is associated with increased cholesterol synthesis rate when exposed to atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin as compared to genotype TT.		[ 138]
Atorvastatin	N.A.	Hypercholesterolemia	Genotype CC is associated with increased cholesterol synthesis rate when exposed to atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin as compared to genotype TT.		[ 138]
Atorvastatin	N.A.	Hyperlipidemias	Genotype CC is associated with increased cholesterol synthesis rate when exposed to atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin as compared to genotype TT.		[ 138]
Atorvastatin	N.A.	Dyslipidaemia	Genotype CC is not associated with increased response to atorvastatin or simvastatin in people with Hyperlipidemias as compared to genotypes CT + TT.		[ 59]
Atorvastatin	N.A.	Familial Hypercholesterolemia	Genotype CC is not associated with increased response to atorvastatin or simvastatin in people with Hyperlipidemias as compared to genotypes CT + TT.		[ 59]
Atorvastatin	N.A.	Hypercholesterolemia	Genotype CC is not associated with increased response to atorvastatin or simvastatin in people with Hyperlipidemias as compared to genotypes CT + TT.		[ 59]
Atorvastatin	N.A.	Hyperlipidemias	Genotype CC is not associated with increased response to atorvastatin or simvastatin in people with Hyperlipidemias as compared to genotypes CT + TT.		[ 59]
Atorvastatin	N.A.	Dyslipidaemia	The current evidence base suggests that there is no significant association between the rs4149056 CC genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.		[ 55]
Atorvastatin	N.A.	Familial Hypercholesterolemia	The current evidence base suggests that there is no significant association between the rs4149056 CC genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.		[ 55]
Atorvastatin	N.A.	Hypercholesterolemia	The current evidence base suggests that there is no significant association between the rs4149056 CC genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.		[ 55]
Atorvastatin	N.A.	Hyperlipidemias	The current evidence base suggests that there is no significant association between the rs4149056 CC genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.		[ 55]
Ticagrelor	N.A.	Acute Coronary Syndrome	Patients with the CC genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the CT and TT genotypes. Other factors may affect concentrations of ticagrelor.		[ 18]
Atorvastatin	N.A.	Acute Coronary Syndrome	Patients with the CC genotype may have decreased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.		[ 110]
Rifampin	N.A.	Acute Coronary Syndrome	Patients with the CC genotype may have decreased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.		[ 110]
Enalapril	N.A.	Essential Hypertension	Patients with the CC genotype and essential hypertension may have an increased likelihood of cough when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.		[ 86]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Pediatric patients with the rs4149056 CC genotype and cancers may have decreased clearance of methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149056 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of methotrexate.		[ 7]
Methotrexate	N.A.	Osteosarcoma	Pediatric patients with the rs4149056 CC genotype and cancers may have decreased clearance of methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149056 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of methotrexate.		[ 7]
Letermovir	N.A.	Gastrointestinal Toxicity	Patients with the CC genotype may have an increased AUC of letermovir as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.		[ 30]
Amprenavir	N.A.	HIV Infectious Disease	Patients with HIV infections and the CC genotype may have decreased trough concentrations of amprenavir as compared to patients with the TT genotype. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of amprenavir in patients.		[ 120]
Hmg coa reductase inhibitors	N.A.	Muscular Diseases	Correlated with the increased creatine kinase in patients (compare with Genotypes CT + TT); Correlated with the increased drug dose decrease or switch to another cholesterol-lowering drug risk in patients (compare with Genotype TT)		[ 49], [ 133]
Simvastatin acid	N.A.	Healthy Individuals	Correlated with the increased drug concentrations in healthy individuals (compare with Genotype TT)		[ 144]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:         99 Drugs in Total
Simvastatin	Drug Info	Muscular Diseases	Correlated with the decreased drug clearance in patients (compare with Genotype TT); Correlated with the increased muscular diseases risk in patients (compare with Genotype TT)		[ 130], [ 151]
Pravastatin	Drug Info	Coronary Stenosis	Correlated with the decreased drug response in patients (compare with Genotype TT)		[ 152]
Pravastatin	Drug Info	Muscular Diseases	Correlated with the decreased drug response in patients (compare with Genotype TT); Correlated with the increased drug AUC0-12 in patients (compare with Genotype TT); Correlated with the increased drug metabolism in patients (compare with Genotype TT)		[ 91], [ 93], [ 152]
Pravastatin	Drug Info	Transplantation	Correlated with the drug response in patients (compare with Genotype TT)		[ 93]
Pravastatin	Drug Info	Healthy Individuals	Correlated with the increased drug AUC and Cmax in healthy individuals (compare with Genotype TT); Correlated with the increased drug AUC0-12 in healthy individuals (compare with Genotype TT)		[ 91], [ 155]
Repaglinide	Drug Info	Healthy Individuals	Correlated with the increased drug concentrations in healthy individuals (compare with Genotype TT)		[ 156]
Atorvastatin	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with Genotype TT)		[ 157]
Rosuvastatin	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with Genotype TT)		[ 157]
Pravastatin	Drug Info	Hyperlipoproteinemia	Irrelevant to the increased drug metabolism in patients (compare with Genotype TT)		[ 93]
Irinotecan	Drug Info	Neoplasm	Irrelevant to the severity of neutropenia in patients (compare with Genotype TT)		[ 57]
Atorvastatin	N.A.	Statin-related Myopathy	Genotype CT is associated with increased severity of statin-related myopathy when treated with atorvastatin, carvedilol, diltiazem, dulaglutide, ezetimibe, fluoxetine, furosemide, lansoprazole, levothyroxine, lorazepam and warfarin.		[ 159]
Carvedilol	N.A.	Statin-related Myopathy	Genotype CT is associated with increased severity of statin-related myopathy when treated with atorvastatin, carvedilol, diltiazem, dulaglutide, ezetimibe, fluoxetine, furosemide, lansoprazole, levothyroxine, lorazepam and warfarin.		[ 159]
Diltiazem	N.A.	Statin-related Myopathy	Genotype CT is associated with increased severity of statin-related myopathy when treated with atorvastatin, carvedilol, diltiazem, dulaglutide, ezetimibe, fluoxetine, furosemide, lansoprazole, levothyroxine, lorazepam and warfarin.		[ 159]
Dulaglutide	N.A.	Statin-related Myopathy	Genotype CT is associated with increased severity of statin-related myopathy when treated with atorvastatin, carvedilol, diltiazem, dulaglutide, ezetimibe, fluoxetine, furosemide, lansoprazole, levothyroxine, lorazepam and warfarin.		[ 159]
Ezetimibe	N.A.	Statin-related Myopathy	Genotype CT is associated with increased severity of statin-related myopathy when treated with atorvastatin, carvedilol, diltiazem, dulaglutide, ezetimibe, fluoxetine, furosemide, lansoprazole, levothyroxine, lorazepam and warfarin.		[ 159]
Fluoxetine	N.A.	Statin-related Myopathy	Genotype CT is associated with increased severity of statin-related myopathy when treated with atorvastatin, carvedilol, diltiazem, dulaglutide, ezetimibe, fluoxetine, furosemide, lansoprazole, levothyroxine, lorazepam and warfarin.		[ 159]
Furosemide	N.A.	Statin-related Myopathy	Genotype CT is associated with increased severity of statin-related myopathy when treated with atorvastatin, carvedilol, diltiazem, dulaglutide, ezetimibe, fluoxetine, furosemide, lansoprazole, levothyroxine, lorazepam and warfarin.		[ 159]
Lansoprazole	N.A.	Statin-related Myopathy	Genotype CT is associated with increased severity of statin-related myopathy when treated with atorvastatin, carvedilol, diltiazem, dulaglutide, ezetimibe, fluoxetine, furosemide, lansoprazole, levothyroxine, lorazepam and warfarin.		[ 159]
Levothyroxine	N.A.	Statin-related Myopathy	Genotype CT is associated with increased severity of statin-related myopathy when treated with atorvastatin, carvedilol, diltiazem, dulaglutide, ezetimibe, fluoxetine, furosemide, lansoprazole, levothyroxine, lorazepam and warfarin.		[ 159]
Lorazepam	N.A.	Statin-related Myopathy	Genotype CT is associated with increased severity of statin-related myopathy when treated with atorvastatin, carvedilol, diltiazem, dulaglutide, ezetimibe, fluoxetine, furosemide, lansoprazole, levothyroxine, lorazepam and warfarin.		[ 159]
Warfarin	N.A.	Statin-related Myopathy	Genotype CT is associated with increased severity of statin-related myopathy when treated with atorvastatin, carvedilol, diltiazem, dulaglutide, ezetimibe, fluoxetine, furosemide, lansoprazole, levothyroxine, lorazepam and warfarin.		[ 159]
Repaglinide	N.A.	Muscular Diseases	Genotype CT is associated with increased concentrations of repaglinide in healthy individuals as compared to genotype TT.		[ 156]
Conjugated Estrogens	N.A.	Muscular Diseases	Genotype CT is not associated with response to conjugated estrogens in women with Menopause as compared to genotype TT.		[ 160]
Irinotecan	N.A.	Neutropenia	Genotype CT is not associated with severity of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype TT.		[ 57]
Simvastatin Acid	N.A.	Drug-induced Liver Injury	Genotype CT is associated with increased exposure to simvastatin acid as compared to genotype TT.		[ 161]
Atorvastatin	N.A.	Drug-induced Liver Injury	Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotype TT.		[ 157]
Simvastatin	N.A.	Drug-induced Liver Injury	Genotype CT is not associated with increased exposure to simvastatin as compared to genotype TT.		[ 161]
Rosuvastatin	N.A.	Drug-induced Liver Injury	Genotype CT is associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.		[ 157]
Atorvastatin	N.A.	Drug-induced Liver Injury	Genotype CT is associated with increased exposure to atorvastatin as compared to genotype TT.		[ 162]
Simvastatin Acid	N.A.	Statin-related Myopathy	Genotype CT is associated with increased exposure to simvastatin acid in healthy individuals as compared to genotype TT.		[ 157]
Pravastatin	N.A.	Statin-related Myopathy	Genotype CT is associated with increased AUC0-12 when exposed to pravastatin in healthy individuals as compared to genotype TT.		[ 91]
Simvastatin Acid	N.A.	Muscular Diseases	Genotype CT is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.		[ 163]
Rifampin	N.A.	Nephrotoxicity	Genotype CT is associated with increased concentrations of rifampin in people with Tuberculosis as compared to genotype TT.		[ 164]
Atazanavir	N.A.	Statin-related Myopathy	Genotype CT (assigned as deficiency phenotype) is not associated with concentrations of atazanavir in people with HIV Infections as compared to genotype TT.		[ 65]
Pravastatin	N.A.	Statin-related Myopathy	Genotype CT is not associated with increased metabolism of pravastatin in children with Hyperlipoproteinemia Type II as compared to genotype TT.		[ 93]
Pravastatin	N.A.	Infectious Disease	Genotype CT is associated with decreased response to pravastatin in people with Coronary Stenosis as compared to genotype TT.		[ 152]
Lopinavir	N.A.	Peripheral Nervous System Diseases	Genotype CT is associated with increased exposure to lopinavir in children with HIV Infections as compared to genotype TT.		[ 38]
Simvastatin Acid	N.A.	Nausea	Genotype CT is associated with decreased clearance of simvastatin acid as compared to genotype TT.		[ 151]
Pravastatin	N.A.	Elevated Circulating Creatine Kinase Concentration	Genotype CT is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to genotype TT.		[ 155]
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Patients with the rs4149056 CT genotype may have an increased risk of developing myopathy when treated with statins as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of statin-induced myopathy.		[ 116]
Lovastatin Acid	N.A.	Statin-related Myopathy	Patients with the CT genotype may have increased concentrations of lovastatin acid as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of lovastatin acid. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid and does not include evidence about clinical outcomes.		[ 140]
Lopinavir	N.A.	HIV Infectious Disease	Genotype CT is associated with increased exposure to lopinavir in children with HIV Infections as compared to genotype TT.		[ 38]
Lopinavir	N.A.	HIV Infectious Disease	Patients with HIV and the CT genotype may have decreased plasma levels of lopinavir as compared to patients with the CC genotype, but increased plasma levels as compared to patients with the TT genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence lopinavir concentrations in a patients. This annotation only covers the pharmacokinetic relationship between rs4149056 and lopinavir and does not include evidence about clinical outcomes.		[ 128]
Rosuvastatin	N.A.	HIV Infectious Disease	The current evidence base suggests that there is no association between the rs4149056 CT genotype and the LDL-lowering response to rosuvastatin. Some studies report an association, however the majority of the studies documented no association. Other genetic and clinical factors may also influence response to rosuvastatin.		[ 141]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Patients with the CT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of toxic liver disease as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.		[ 101]
Fludarabine	N.A.	Leukemia, Myeloid, Acute	Patients with the CT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of toxic liver disease as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.		[ 101]
Gemtuzumab Ozogamicin	N.A.	Leukemia, Myeloid, Acute	Patients with the CT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of toxic liver disease as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.		[ 101]
Idarubicin	N.A.	Leukemia, Myeloid, Acute	Patients with the CT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of toxic liver disease as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.		[ 101]
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of adverse drug reaction as compared to patients with the CC genotype and may have a decreased risk of adverse drug reaction as compared to patients with the TT genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.		[ 35]
Rosiglitazone	N.A.	Diabetes Mellitus, Type 2	Patients with the CT genotype may have increased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to rosiglitazone.		[ 104]
Sorafenib	N.A.	Thrombocytopenia	Patients with the CT genotype may have increased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.		[ 50]
Irinotecan	N.A.	Neoplasms	Genotype CT is not associated with severity of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype TT.		[ 57]
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the CT genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.		[ 142]
Docetaxel	N.A.	Breast Neoplasms	Patients with the CT genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.		[ 142]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the CT genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.		[ 142]
Epirubicin	N.A.	Breast Neoplasms	Patients with the CT genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.		[ 142]
Fluorouracil	N.A.	Breast Neoplasms	Patients with the CT genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.		[ 142]
Cerivastatin	N.A.	Rhabdomyolysis	Patients with the CT genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.		[ 132]
Glucarpidase	N.A.	Nephrotoxicity	Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs4149056 CT genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.		[ 143]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with precursor cell lymphoblastic leukemia-lymphoma and the rs4149056 CT genotype may have an increased response to methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence response to methotrexate.		[ 8]
Mercaptopurine	N.A.	Acute Lymphoblastic Leukemia	Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 144]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 144]
Rosuvastatin	N.A.	Hypercholesterolemia	Genotype CT is associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.		[ 157]
Rosuvastatin	N.A.	Hypercholesterolemia	Patients with the rs4149056 CT genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and does not include evidence about clinical outcomes.		[ 145]
Pravastatin	N.A.	Hypercholesterolemia	Patients with the rs4149056 CT genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pravastatin and does not include evidence about clinical outcomes.		[ 146]
Simvastatin	N.A.	Hypercholesterolemia	Genotype CT is associated with decreased clearance of simvastatin acid as compared to genotype TT.		[ 151]
Simvastatin	N.A.	Hypercholesterolemia	Genotype CT is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.		[ 163]
Simvastatin	N.A.	Hypercholesterolemia	Genotype CT is associated with increased exposure to simvastatin acid in healthy individuals as compared to genotype TT.		[ 157]
Simvastatin	N.A.	Hypercholesterolemia	Patients with the rs4149056 CT genotype may have increased serum concentrations of simvastatin acid as compared to patients with the TT genotype, but decreased concentrations as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs4149056 and simvastatin acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid.		[ 114]
Simvastatin Acid	N.A.	Hypercholesterolemia	Patients with the rs4149056 CT genotype may have increased serum concentrations of simvastatin acid as compared to patients with the TT genotype, but decreased concentrations as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs4149056 and simvastatin acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid.		[ 114]
Simvastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 CT genotype may have a higher risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity to simvastatin.		[ 105]
Rosuvastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 CT genotype may have increased risk of statin-related myopathy or myalgia when treated with rosuvastatin as compared to patients with genotype TT. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk to rosuvastatin.		[ 147]
Fluvastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 CT genotype may have increased concentrations of fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fluvastatin concentrations. This annotation only covers the pharmacokinetic relationship between rs4149056 and fluvastatin and does not include evidence about clinical outcomes.		[ 127]
Atorvastatin	N.A.	Statin-related Myopathy	Patients with the CT genotype may have increased exposure to atorvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to atorvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and atorvastatin and does not include evidence about clinical outcomes.		[ 108]
Atorvastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 CT genotype may have an increased risk of myopathy when treated with atorvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing myopathy when treated with atorvastatin.		[ 117]
Pravastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 CT genotype may have an increased risk of developing myopathy when treated with pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of experiencing pravastatin-induced myopathy.		[ 97]
Lovastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 CT genotype may have increased concentration of lovastatin acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of lovastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid or lovastatin and does not include evidence about clinical outcomes.		[ 140]
Pitavastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 CT genotype may have increased concentrations of pitavastatin when treated with pitavastatin as compared to patients with TT genotype. Other genetic and clinical factors may also influence the metabolism of pitavastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pitavastatin and does not include evidence about clinical outcomes.		[ 148]
Fluvastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 CT genotype may have an increased risk of developing myopathy when treated with fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of developing fluvastatin-induced myopathy.		[ 97]
Lovastatin	N.A.	Statin-related Myopathy	TPatients with the rs4149056 CT genotype may have an increased risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity to lovastatin.		[ 133]
SN-38	N.A.	Non-small Cell Lung Carcinoma	Patients with the CT genotype and non-small cell lung cancer may receive an increased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38.		[ 61]
Hmg Coa Reductase Inhibitors	N.A.	Cardiovascular Disease	Patients with the rs4149056 CT genotype may have a decreased response to statins as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to statins.		[ 149]
Hmg Coa Reductase Inhibitors	N.A.	Hyperlipidemias	Patients with the rs4149056 CT genotype may have a decreased response to statins as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to statins.		[ 149]
Pravastatin	N.A.	Hyperlipidemias	Patients with the rs4149056 CT genotype who are treated with pravastatin may have a smaller reduction in LDL and total cholesterol as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.		[ 31]
Simvastatin	N.A.	Hyperlipidemias	Patients with the rs4149056 CT genotype may have a decreased response to simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. The effect size may be small. Other genetic and clinical factors may also influence response to simvastatin.		[ 56]
Atorvastatin	N.A.	Dyslipidaemia	The current evidence base suggests that there is no significant association between the rs4149056 CT genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.		[ 55]
Atorvastatin	N.A.	Familial Hypercholesterolemia	The current evidence base suggests that there is no significant association between the rs4149056 CT genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.		[ 55]
Atorvastatin	N.A.	Hypercholesterolemia	The current evidence base suggests that there is no significant association between the rs4149056 CT genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.		[ 55]
Atorvastatin	N.A.	Hyperlipidemias	The current evidence base suggests that there is no significant association between the rs4149056 CT genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.		[ 55]
Ticagrelor	N.A.	Acute Coronary Syndrome	Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.		[ 18]
Atorvastatin	N.A.	Acute Coronary Syndrome	Patients with the CT genotype may have decreased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.		[ 110]
Rifampin	N.A.	Acute Coronary Syndrome	Patients with the CT genotype may have decreased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.		[ 110]
Enalapril	N.A.	Essential Hypertension	Patients with the CT genotype and essential hypertension may have an increased likelihood of cough when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.		[ 86]
Repaglinide	N.A.	Essential Hypertension	Patients with the CT genotype may have decreased exposure of repaglinide and decreased response to repaglinide as compared to patients with the CC genotype and increased exposure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a exposure of and response to repaglinide.		[ 102]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Pediatric patients with the rs4149056 CT genotype and cancers may have decreased clearance of methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149056 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of methotrexate.		[ 7]
Methotrexate	N.A.	Osteosarcoma	Pediatric patients with the rs4149056 CT genotype and cancers may have decreased clearance of methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149056 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of methotrexate.		[ 7]
Letermovir	N.A.	Gastrointestinal Toxicity	Patients with the CT genotype may have an increased AUC of letermovir as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.		[ 30]
Amprenavir	N.A.	HIV Infectious Disease	Patients with HIV infections and the CT genotype may have decreased trough concentrations of amprenavir as compared to patients with the TT genotype. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of amprenavir in patients.		[ 120]
Simvastatin acid	N.A.	Hypercholesterolemia	Correlated with the increased drug exposure in patients (compare with Genotype TT)		[ 161]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:       105 Drugs in Total
Atorvastatin	Drug Info	Coronary Artery Disease	Correlated with the a nearly tripled increased percentage of drug AUC (0 - 48) values in patients (compare with genotype CC)		[ 110]
Rifampicin	Drug Info	Tuberculosis	Correlated with the a nearly tripled increased percentage of drug AUC (0 - 48) values in patients (compare with genotype CC)		[ 110]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug concentrations in patients (compare with genotypes CC + CT)		[ 162]
Rosuvastatin	Drug Info	Hypercholesterolemia	Correlated with the decreased drug plasma concentrations in patients (compare with genotypes CC + CT); Irrelevant to the percentage change in LDL-cholesterol levels in patients (compare with Genotypes CT + TT)		[ 46]
Mycophenolate mofetil	Drug Info	Kidney Transplantation	Correlated with the increased adverse drug reaction risk in patients (compare with genotype CC)		[ 26]
Fluorouracil	Drug Info	Breast Neoplasm	Correlated with the increased alcoholism risk in patients (compare with genotype GG)		[ 142]
Epirubicin	Drug Info	Breast Neoplasm	Correlated with the increased alcoholism risk in patients (compare with genotype GG)		[ 142]
Docetaxel	Drug Info	Breast Neoplasm	Correlated with the increased alcoholism risk in patients (compare with genotype GG)		[ 142]
Doxorubicin	Drug Info	Breast Neoplasm	Correlated with the increased alcoholism risk in patients (compare with genotype GG)		[ 142]
Cyclophosphamide	Drug Info	Breast Neoplasm	Correlated with the increased alcoholism risk in patients (compare with genotype GG)		[ 142]
Fluvastatin	Drug Info	Muscular Diseases	Correlated with the increased drug response as in patients (compare with genotypes CC + CT)		[ 43]
Goserelin	Drug Info	Breast Neoplasm	Correlated with the increased alcoholism risk in patients (compare with genotype GG)		[ 142]
Conjugated Estrogens	N.A.	Mucositis	Genotype TT is associated with decreased concentrations of conjugated estrogens in women with Menopause as compared to genotypes CC + CT.		[ 156]
Atazanavir	N.A.	Statin-related Myopathy	Genotype TT is not associated with clearance of atazanavir in healthy individuals as compared to genotypes CC + CT.		[ 168]
Repaglinide	N.A.	Muscular Diseases	Genotype TT is associated with exposure to repaglinide in healthy individuals.		[ 153]
Mycophenolate Mofetil	N.A.	Muscular Diseases	Genotype TT is associated with increased risk of adverse drug reaction when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype CC.		[ 26]
Glucose	N.A.	Muscular Diseases	Genotype TT is associated with concentrations of glucose in healthy individuals.		[ 153]
Atazanavir	N.A.	Muscular Diseases	Genotype TT is associated with dose of atazanavir in people with HIV Infections.		[ 170]
Methotrexate	N.A.	Neutropenia	Genotype TT is associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 162]
Rosuvastatin	N.A.	Drug-induced Liver Injury	Genotype TT is not associated with percentage change in LDL-cholesterol levels when treated with rosuvastatin in people with Hypercholesterolemia as compared to genotypes CT + TT.		[ 46]
Lovastatin	N.A.	Muscular Diseases	Genotype TT is not associated with increased concentrations of lovastatin in healthy individuals as compared to genotypes CC + CT.		[ 140]
Fluvastatin	N.A.	Myocardial Infarction	Genotype TT is associated with increased response to fluvastatin as compared to genotypes CC + CT.		[ 43]
Methotrexate	N.A.	Toxic Liver Disease	Genotype TT is associated with increased exposure to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 172]
Methotrexate	N.A.	Nephrotoxicity	Genotype TT is associated with decreased risk of nephrotoxicity when treated with methotrexate in people with Neoplasms as compared to genotypes CC + CT.		[ 81]
Atorvastatin	N.A.	Nephrotoxicity	Genotype TT is associated with decreased response to atorvastatin as compared to genotypes CC + CT.		[ 3]
Atorvastatin	N.A.	Discontinuation	Genotype TT is associated with increased likelihood of discontinuation when treated with atorvastatin or simvastatin as compared to genotypes CC + CT.		[ 175]
Simvastatin	N.A.	Discontinuation	Genotype TT is associated with increased likelihood of discontinuation when treated with atorvastatin or simvastatin as compared to genotypes CC + CT.		[ 175]
Simvastatin	N.A.	Cough	Genotype TT is associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.		[ 56]
Methotrexate	N.A.	Infectious Disease	Genotype TT is associated with increased severity of Infection when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 177]
Mycophenolic Acid	N.A.	Overall Survival	Genotype TT is not associated with exposure to mycophenolic acid in people with Kidney Transplantation as compared to genotype CT.		[ 70]
Hmg Coa Reductase Inhibitors	N.A.	Nausea	Genotype TT is associated with increased response to hmg coa reductase inhibitors as compared to genotypes CC + CT.		[ 3]
Simvastatin	N.A.	Nausea	Genotype TT is associated with increased response to simvastatin as compared to genotype CT.		[ 3]
Pravastatin	N.A.	Nausea	Genotype TT is associated with increased response to pravastatin as compared to genotype CC.		[ 3]
Cyclophosphamide	N.A.	Amenorrhea	Genotype TT is associated with increased risk of Amenorrhea when treated with cyclophosphamide, docetaxel, doxorubicin, epirubicin, fluorouracil or goserelin in women with Breast Neoplasms as compared to genotype CT.		[ 142]
Docetaxel	N.A.	Amenorrhea	Genotype TT is associated with increased risk of Amenorrhea when treated with cyclophosphamide, docetaxel, doxorubicin, epirubicin, fluorouracil or goserelin in women with Breast Neoplasms as compared to genotype CT.		[ 142]
Doxorubicin	N.A.	Amenorrhea	Genotype TT is associated with increased risk of Amenorrhea when treated with cyclophosphamide, docetaxel, doxorubicin, epirubicin, fluorouracil or goserelin in women with Breast Neoplasms as compared to genotype CT.		[ 142]
Epirubicin	N.A.	Amenorrhea	Genotype TT is associated with increased risk of Amenorrhea when treated with cyclophosphamide, docetaxel, doxorubicin, epirubicin, fluorouracil or goserelin in women with Breast Neoplasms as compared to genotype CT.		[ 142]
Fluorouracil	N.A.	Amenorrhea	Genotype TT is associated with increased risk of Amenorrhea when treated with cyclophosphamide, docetaxel, doxorubicin, epirubicin, fluorouracil or goserelin in women with Breast Neoplasms as compared to genotype CT.		[ 142]
Goserelin	N.A.	Amenorrhea	Genotype TT is associated with increased risk of Amenorrhea when treated with cyclophosphamide, docetaxel, doxorubicin, epirubicin, fluorouracil or goserelin in women with Breast Neoplasms as compared to genotype CT.		[ 142]
Ticagrelor	N.A.	Muscular Diseases	Genotype TT is not associated with response to ticagrelor in healthy individuals as compared to genotypes CC + CT.		[ 19]
Atorvastatin	N.A.	Muscular Diseases	Genotype TT is not associated with increased likelihood of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Diabetes Mellitus, Hyperlipidemias, Hypertension or Obesity as compared to genotypes CC + CT.		[ 147]
Rosuvastatin	N.A.	Muscular Diseases	Genotype TT is not associated with increased likelihood of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Diabetes Mellitus, Hyperlipidemias, Hypertension or Obesity as compared to genotypes CC + CT.		[ 147]
Atorvastatin	N.A.	Muscular Diseases	Genotype TT is associated with a nearly tripled increased percentage of atorvastatin AUC(0 - 48) values after a single oral dose of rifampicin when exposed to atorvastatin and rifampin as compared to genotype CC.		[ 110]
Rifampin	N.A.	Muscular Diseases	Genotype TT is associated with a nearly tripled increased percentage of atorvastatin AUC(0 - 48) values after a single oral dose of rifampicin when exposed to atorvastatin and rifampin as compared to genotype CC.		[ 110]
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Patients with the rs4149056 TT genotype may have a decreased risk of developing myopathy when treated with statins as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of statin-induced myopathy.		[ 116]
Lovastatin Acid	N.A.	Statin-related Myopathy	Patients with the TT genotype may have decreased concentrations of lovastatin acid as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect metabolism of lovastatin acid. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid and does not include evidence about clinical outcomes.		[ 140]
Lopinavir	N.A.	HIV Infectious Disease	Patients with HIV and the TT genotype may have decreased plasma levels of lopinavir as compared to patients with the CC genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence lopinavir concentrations in a patients. This annotation only covers the pharmacokinetic relationship between rs4149056 and lopinavir and does not include evidence about clinical outcomes.		[ 128]
Rosuvastatin	N.A.	HIV Infectious Disease	The current evidence base suggests that there is no association between the rs4149056 TT genotype and the LDL-lowering response to rosuvastatin. Some studies report an association, however the majority of the studies documented no association. Other genetic and clinical factors may also influence response to rosuvastatin.		[ 141]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Patients with the TT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.		[ 101]
Fludarabine	N.A.	Leukemia, Myeloid, Acute	Patients with the TT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.		[ 101]
Gemtuzumab Ozogamicin	N.A.	Leukemia, Myeloid, Acute	Patients with the TT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.		[ 101]
Idarubicin	N.A.	Leukemia, Myeloid, Acute	Patients with the TT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.		[ 101]
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Genotype TT is associated with increased risk of adverse drug reaction when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype CC.		[ 26]
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Patients with the TT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of adverse drug reaction as compared to patients with the CC genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.		[ 35]
Rosiglitazone	N.A.	Diabetes Mellitus, Type 2	Patients with the TT genotype may have decreased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to rosiglitazone.		[ 104]
Sorafenib	N.A.	Thrombocytopenia	Patients with the TT genotype may have increased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.		[ 50]
Irinotecan	N.A.	Neoplasms	Patients with the TT genotype and cancer may have a decreased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the CC or CT genotype. However, a different study of similar size found no association between the TT genotype and neutropenia. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea.		[ 57]
Cyclophosphamide	N.A.	Breast Neoplasms	Genotype TT is associated with increased risk of Amenorrhea when treated with cyclophosphamide, docetaxel, doxorubicin, epirubicin, fluorouracil or goserelin in women with Breast Neoplasms as compared to genotype CT.		[ 142]
Docetaxel	N.A.	Breast Neoplasms	Genotype TT is associated with increased risk of Amenorrhea when treated with cyclophosphamide, docetaxel, doxorubicin, epirubicin, fluorouracil or goserelin in women with Breast Neoplasms as compared to genotype CT.		[ 142]
Doxorubicin	N.A.	Breast Neoplasms	Genotype TT is associated with increased risk of Amenorrhea when treated with cyclophosphamide, docetaxel, doxorubicin, epirubicin, fluorouracil or goserelin in women with Breast Neoplasms as compared to genotype CT.		[ 142]
Epirubicin	N.A.	Breast Neoplasms	Genotype TT is associated with increased risk of Amenorrhea when treated with cyclophosphamide, docetaxel, doxorubicin, epirubicin, fluorouracil or goserelin in women with Breast Neoplasms as compared to genotype CT.		[ 142]
Fluorouracil	N.A.	Breast Neoplasms	Genotype TT is associated with increased risk of Amenorrhea when treated with cyclophosphamide, docetaxel, doxorubicin, epirubicin, fluorouracil or goserelin in women with Breast Neoplasms as compared to genotype CT.		[ 142]
Cerivastatin	N.A.	Rhabdomyolysis	Patients with the TT genotype may have a lower risk of cerivastatin-related rhabdomyolysis as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.		[ 132]
Glucarpidase	N.A.	Nephrotoxicity	Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs4149056 TT genotype may be less likely to require glucarpidase treatment as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment.		[ 143]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with precursor cell lymphoblastic leukemia-lymphoma and the rs4149056 TT genotype may have an increased response to methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence response to methotrexate.		[ 8]
Mercaptopurine	N.A.	Acute Lymphoblastic Leukemia	Patients with the TT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need an increased dose of mercaptopurine, or methotrexate, as compared to children with the CC or CT genotypes. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 144]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the TT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need an increased dose of mercaptopurine, or methotrexate, as compared to children with the CC or CT genotypes. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 144]
Rosuvastatin	N.A.	Hypercholesterolemia	Genotype TT is associated with decreased plasma concentrations of rosuvastatin when treated with rosuvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.		[ 46]
Rosuvastatin	N.A.	Hypercholesterolemia	Patients with the rs4149056 TT genotype may have lower plasma concentrations of rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and does not include evidence about clinical outcomes.		[ 145]
Pravastatin	N.A.	Hypercholesterolemia	Patients with the rs4149056 TT genotype may have decreased plasma concentrations of pravastatin as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pravastatin and does not include evidence about clinical outcomes.		[ 146]
Simvastatin	N.A.	Hypercholesterolemia	Patients with the rs4149056 TT genotype may have decreased serum concentrations of simvastatin acid as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs4149056 and simvastatin acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid.		[ 114]
Simvastatin Acid	N.A.	Hypercholesterolemia	Patients with the rs4149056 TT genotype may have decreased serum concentrations of simvastatin acid as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs4149056 and simvastatin acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid.		[ 114]
Simvastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 TT genotype may have a lower risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity to simvastatin.		[ 105]
Rosuvastatin	N.A.	Statin-related Myopathy	Genotype TT is not associated with increased likelihood of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Diabetes Mellitus, Hyperlipidemias, Hypertension or Obesity as compared to genotypes CC + CT.		[ 147]
Fluvastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 TT genotype may have decreased concentrations of fluvastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fluvastatin concentrations. This annotation only covers the pharmacokinetic relationship between rs4149056 and fluvastatin and does not include evidence about clinical outcomes.		[ 127]
Atorvastatin	N.A.	Statin-related Myopathy	Patients with the TT genotype may have decreased exposure to atorvastatin as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's exposure to atorvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and atorvastatin and does not include evidence about clinical outcomes.		[ 108]
Atorvastatin	N.A.	Statin-related Myopathy	Genotype TT is not associated with increased likelihood of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Diabetes Mellitus, Hyperlipidemias, Hypertension or Obesity as compared to genotypes CC + CT.		[ 147]
Atorvastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 TT genotype may have a decreased risk of myopathy when treated with atorvastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing myopathy when treated with atorvastatin.		[ 117]
Pravastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 TT genotype may have a decreased risk of developing myopathy when treated with pravastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of experiencing pravastatin-induced myopathy.		[ 97]
Pitavastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 TT genotype may have decreased concentrations of pitavastatin when treated with pitavastatin as compared to patients with CC or CT genotype. Other genetic and clinical factors may also influence the metabolism of pitavastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pitavastatin and does not include evidence about clinical outcomes.		[ 148]
Fluvastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 TT genotype may have a decreased risk of developing myopathy when treated with fluvastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of developing fluvastatin-induced myopathy.		[ 97]
Lovastatin	N.A.	Statin-related Myopathy	Patients with the rs4149056 TT genotype may have a decreased risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity to lovastatin.		[ 133]
SN-38	N.A.	Non-small Cell Lung Carcinoma	Patients with the TT genotype and non-small cell lung cancer may have a decreased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the CC or CT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38.		[ 61]
Hmg Coa Reductase Inhibitors	N.A.	Cardiovascular Disease	Genotype TT is associated with increased response to hmg coa reductase inhibitors as compared to genotypes CC + CT.		[ 3]
Hmg Coa Reductase Inhibitors	N.A.	Hyperlipidemias	Genotype TT is associated with increased response to hmg coa reductase inhibitors as compared to genotypes CC + CT.		[ 3]
Hmg Coa Reductase Inhibitors	N.A.	Cardiovascular Disease	Patients with the rs4149056 TT genotype may have an increased response to statins as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to statins.		[ 149]
Hmg Coa Reductase Inhibitors	N.A.	Hyperlipidemias	Patients with the rs4149056 TT genotype may have an increased response to statins as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to statins.		[ 149]
Pravastatin	N.A.	Hyperlipidemias	Patients with the rs4149056 TT genotype who are treated with pravastatin may have a larger reduction in LDL and total cholesterol as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.		[ 31]
Atorvastatin	N.A.	Dyslipidaemia	Genotype TT is associated with decreased response to atorvastatin as compared to genotypes CC + CT.		[ 3]
Atorvastatin	N.A.	Familial Hypercholesterolemia	Genotype TT is associated with decreased response to atorvastatin as compared to genotypes CC + CT.		[ 3]
Atorvastatin	N.A.	Hypercholesterolemia	Genotype TT is associated with decreased response to atorvastatin as compared to genotypes CC + CT.		[ 3]
Atorvastatin	N.A.	Hyperlipidemias	Genotype TT is associated with decreased response to atorvastatin as compared to genotypes CC + CT.		[ 3]
Atorvastatin	N.A.	Dyslipidaemia	The current evidence base suggests that there is no significant association between the rs4149056 TT genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.		[ 55]
Atorvastatin	N.A.	Familial Hypercholesterolemia	The current evidence base suggests that there is no significant association between the rs4149056 TT genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.		[ 55]
Atorvastatin	N.A.	Hypercholesterolemia	The current evidence base suggests that there is no significant association between the rs4149056 TT genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.		[ 55]
Atorvastatin	N.A.	Hyperlipidemias	The current evidence base suggests that there is no significant association between the rs4149056 TT genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin.		[ 55]
Ticagrelor	N.A.	Acute Coronary Syndrome	Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CC and CT genotypes. Other factors may affect concentrations of ticagrelor.		[ 18]
Enalapril	N.A.	Essential Hypertension	Patients with the TT genotype and essential hypertension may have a decreased likelihood of cough when treated with enalapril as compared to patients with the CC and CT genotypes. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.		[ 86]
Repaglinide	N.A.	Essential Hypertension	Patients with the TT genotype may have decreased exposure of repaglinide and decreased response to repaglinide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a exposure of and response to repaglinide.		[ 102]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype TT is associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 162]
Methotrexate	N.A.	Osteosarcoma	Genotype TT is associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 162]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Pediatric patients with the rs4149056 TT genotype and cancers may have increased clearance of methotrexate as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149056 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of methotrexate.		[ 7]
Methotrexate	N.A.	Osteosarcoma	Pediatric patients with the rs4149056 TT genotype and cancers may have increased clearance of methotrexate as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149056 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of methotrexate.		[ 7]
Letermovir	N.A.	Gastrointestinal Toxicity	Patients with the TT genotype may have a decreased AUC of letermovir as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's exposure to letermovir.		[ 30]
Amprenavir	N.A.	HIV Infectious Disease	Patients with HIV infections and the TT genotype may have increased trough concentrations of amprenavir as compared to patients with the CC or CT genotypes. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of amprenavir in patients.		[ 120]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:       171 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug clearance in patients (compare with Genotype TT); Correlated with the decreased drug dose in patients (compare with Genotype TT)		[ 66], [ 144]
Mercaptopurine	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug dose in patients (compare with Genotype TT)		[ 144]
Atorvastatin	Drug Info	Obesity	Correlated with the decreased drug oral clearance in patients (compare with Genotype TT)		[ 169]
Atorvastatin	Drug Info	Muscular Diseases	Correlated with the increased drug dose decrease or switch to another cholesterol-lowering drug risk in patients (compare with Genotype TT); Correlated with the increased likelihood of drug toxicity, muscular diseases, rhabdomyolysis and toxic liver disease in patients (compare with Genotype TT); Irrelevant to the increased drug dose decrease or switch to another cholesterol-lowering drug risk in patients (compare with Genotype TT)		[ 131], [ 171]
Sn-38	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the increased drug dose in patients (compare with Genotype TT)		[ 61]
Enalapril	Drug Info	Essential Hypertension	Correlated with the increased likelihood of cough in patients (compare with Genotype TT)		[ 86]
Simvastatin	Drug Info	Hyperlipidemias	Correlated with the increased muscular diseases risk in patients (compare with Genotype TT)		[ 103]
Irinotecan	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the increased neutropenia risk in patients (compare with Genotype TT)		[ 61]
Irinotecan	Drug Info	Neoplasm	Irrelevant to the diarrhea in patients (compare with Genotype TT)		[ 61]
Atorvastatin	Drug Info	Hypercholesterolemia	Irrelevant to the increased myalgia unspecified risk in patients (compare with Genotype TT)		[ 72]
Rosuvastatin	Drug Info	Muscular Diseases	Irrelevant to the increased myalgia unspecified risk in patients (compare with Genotype TT)		[ 176]
Simvastatin Acid	N.A.	Hypoventilation	Genotypes CC + CT is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype TT.		[ 74]
Atorvastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT is associated with increased likelihood of statin-related myopathy when treated with atorvastatin in people with Cardiovascular Disease, Diabetes Mellitus, Acute coronary syndrome or Dyslipidaemia as compared to genotype TT.		[ 178]
Rosuvastatin	N.A.	Mucositis	Genotypes CC + CT are associated with increased exposure to rosuvastatin in people with Diabetes Mellitus and Hypercholesterolemia as compared to genotype TT.		[ 179]
Methotrexate	N.A.	Toxic Liver Disease	Genotypes CC + CT is associated with increased likelihood of Toxic liver disease when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotype TT.		[ 180]
Irinotecan	N.A.	Neutropenia	Genotypes CC + CT are associated with increased risk of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.		[ 61]
Hmg Coa Reductase Inhibitors	N.A.	Neutropenia	Genotypes CC + CT is associated with decreased clinical benefit to hmg coa reductase inhibitors in people with HIV Infections as compared to genotype TT.		[ 181]
SN-38	N.A.	Statin-related Myopathy	Genotypes CC + CT are associated with increased dose of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.		[ 61]
Mercaptopurine	N.A.	Muscular Diseases	Genotypes CC + CT is associated with decreased dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 144]
Methotrexate	N.A.	Muscular Diseases	Genotypes CC + CT is associated with decreased dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 144]
Simvastatin	N.A.	Muscular Diseases	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with simvastatin in people with Hyperlipidemias as compared to genotype TT.		[ 103]
Methotrexate	N.A.	Muscular Diseases	Genotypes CC + CT are associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 66]
Atorvastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT are associated with decreased oral clearance of atorvastatin when exposed to atorvastatin in people with Obesity as compared to genotype TT.		[ 169]
Rosuvastatin	N.A.	Myalgia	Genotypes CC + CT is not associated with increased risk of Myalgia unspecified when treated with rosuvastatin as compared to genotype TT.		[ 176]
Edoxaban	N.A.	Hemorrhage	Genotypes CC + CT is associated with increased likelihood of Hemorrhage when treated with edoxaban as compared to genotype TT.		[ 63]
Atorvastatin	N.A.	Discontinuation	Genotypes CC + CT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype TT.		[ 135]
Fluvastatin	N.A.	Discontinuation	Genotypes CC + CT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype TT.		[ 135]
Rosuvastatin	N.A.	Discontinuation	Genotypes CC + CT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype TT.		[ 135]
Pravastatin	N.A.	Discontinuation	Genotypes CC + CT is associated with increased risk of discontinuation when treated with pravastatin as compared to genotype TT.		[ 135]
Rosuvastatin	N.A.	Hypercholesterolemia	Genotypes CC + CT are associated with response to rosuvastatin as compared to genotype TT.		[ 184]
Atorvastatin	N.A.	Drug Toxicity	Genotypes CC + CT are associated with increased concentrations of atorvastatin in healthy individuals as compared to genotype TT.		[ 185]
Atorvastatin	N.A.	Drug Toxicity	Genotypes CC + CT are associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to genotype TT.		[ 69]
Atorvastatin	N.A.	Drug Toxicity	Genotypes CC + CT are not associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotype TT.		[ 55]
Rosuvastatin	N.A.	Drug Toxicity	Genotypes CC + CT are associated with increased concentrations of rosuvastatin as compared to genotype TT.		[ 145]
Simvastatin	N.A.	Drug Toxicity	Genotypes CC + CT are not associated with response to simvastatin in people with Hypercholesterolemia as compared to genotype TT.		[ 75]
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with hmg coa reductase inhibitors as compared to genotype TT.		[ 85]
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Genotypes CC + CT are not associated with likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to genotype TT.		[ 76]
Hmg Coa Reductase Inhibitors	N.A.	Rhabdomyolysis	Genotypes CC + CT are associated with increased likelihood of Rhabdomyolysis when treated with hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to genotype TT.		[ 76]
Atorvastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT are associated with increased likelihood of statin-related myopathy when treated with atorvastatin or simvastatin as compared to genotype TT.		[ 192]
Simvastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT are associated with increased likelihood of statin-related myopathy when treated with atorvastatin or simvastatin as compared to genotype TT.		[ 192]
Letermovir	N.A.	Neutropenia	Genotypes CC + CT are associated with increased exposure to letermovir as compared to genotype TT.		[ 30]
Atazanavir / Ritonavir	N.A.	Mucositis	Genotypes CC + CT is associated with increased concentrations of atazanavir / ritonavir in people with HIV Infections as compared to genotype TT.		[ 194]
Atorvastatin	N.A.	Myalgia	Genotypes CC + CT are not associated with increased risk of Myalgia unspecified when treated with atorvastatin in people with Hypercholesterolemia as compared to genotype TT.		[ 72]
Simvastatin	N.A.	Drug-induced Liver Injury	Genotypes CC + CT is associated with decreased response to simvastatin in people with Dyslipidaemia as compared to genotype TT.		[ 31]
Simvastatin	N.A.	Muscular Diseases	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with simvastatin as compared to genotype TT.		[ 130]
Lovastatin Acid	N.A.	Muscular Diseases	Genotypes CC + CT is associated with increased concentrations of lovastatin acid in healthy individuals as compared to genotype TT.		[ 140]
Irinotecan	N.A.	Diarrhea	Genotypes CC + CT are not associated with Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.		[ 61]
Atorvastatin	N.A.	Diarrhea	Genotypes CC + CT is not associated with decreased response to atorvastatin in people with Dyslipidaemia as compared to genotype TT.		[ 31]
Pravastatin	N.A.	Diarrhea	Genotypes CC + CT is associated with decreased response to pravastatin in people with Dyslipidaemia as compared to genotype TT.		[ 31]
Hmg Coa Reductase Inhibitors	N.A.	Discontinuation	Genotypes CC + CT are not associated with decreased response to hmg coa reductase inhibitors as compared to genotype TT.		[ 149]
Simvastatin	N.A.	Discontinuation	Genotypes CC + CT are associated with decreased response to simvastatin as compared to genotype TT.		[ 149]
Simvastatin	N.A.	Discontinuation	Genotypes CC + CT are associated with decreased response to simvastatin.		[ 199]
Rosuvastatin	N.A.	Discontinuation	Genotypes CC + CT are not associated with decreased response to rosuvastatin as compared to genotype TT.		[ 141]
Atorvastatin	N.A.	Discontinuation	Genotypes CC + CT are not associated with decreased response to atorvastatin or simvastatin as compared to genotype TT.		[ 77]
Simvastatin	N.A.	Discontinuation	Genotypes CC + CT are not associated with decreased response to atorvastatin or simvastatin as compared to genotype TT.		[ 77]
Simvastatin	N.A.	Discontinuation	Genotypes CC + CT are not associated with decreased response to simvastatin as compared to genotype TT.		[ 141]
Atorvastatin	N.A.	Discontinuation	Genotypes CC + CT are associated with decreased response to atorvastatin, hmg coa reductase inhibitors, pravastatin or simvastatin in people with Hyperlipidemias as compared to genotype TT.		[ 202]
Hmg Coa Reductase Inhibitors	N.A.	Discontinuation	Genotypes CC + CT are associated with decreased response to atorvastatin, hmg coa reductase inhibitors, pravastatin or simvastatin in people with Hyperlipidemias as compared to genotype TT.		[ 202]
Pravastatin	N.A.	Discontinuation	Genotypes CC + CT are associated with decreased response to atorvastatin, hmg coa reductase inhibitors, pravastatin or simvastatin in people with Hyperlipidemias as compared to genotype TT.		[ 202]
Simvastatin	N.A.	Discontinuation	Genotypes CC + CT are associated with decreased response to atorvastatin, hmg coa reductase inhibitors, pravastatin or simvastatin in people with Hyperlipidemias as compared to genotype TT.		[ 202]
Pitavastatin	N.A.	Discontinuation	Genotypes CC + CT are not associated with response to pitavastatin in people with Hyperlipidemias as compared to genotype TT.		[ 78]
Atorvastatin	N.A.	Toxic Liver Disease	Genotypes CC + CT are associated with increased concentrations of atorvastatin as compared to genotype TT.		[ 204]
Atorvastatin	N.A.	Toxic Liver Disease	Genotypes CC + CT are not associated with increased risk of dose decrease or switch to another cholesterol-lowering drug in users with a starting dose of more than 20 mg when treated with atorvastatin as compared to genotype TT.		[ 131]
Atorvastatin	N.A.	Toxic Liver Disease	Genotypes CC + CT is not associated with response to atorvastatin in people with Hypercholesterolemia as compared to genotype TT.		[ 73]
Ritonavir	N.A.	Toxic Liver Disease	Genotypes CC + CT is associated with increased concentrations of ritonavir in people with HIV Infections as compared to genotype TT.		[ 206]
Nateglinide	N.A.	Nephrotoxicity	Genotypes CC + CT are associated with decreased metabolism of nateglinide in healthy individuals as compared to genotype TT.		[ 207]
Methotrexate	N.A.	Mucositis	Genotypes CC + CT is associated with increased likelihood of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 16]
Methotrexate	N.A.	Neutropenia	Genotypes CC + CT is associated with increased likelihood of Neutropenia when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 164]
Methotrexate	N.A.	Thrombocytopenia	Genotypes CC + CT is associated with increased likelihood of Thrombocytopenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 16]
Tamoxifen	N.A.	Overall Survival	Genotypes CC + CT are associated with decreased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to genotype TT.		[ 82]
Pravastatin	N.A.	Overall Survival	Genotypes CC + CT are associated with decreased response to pravastatin as compared to genotype TT.		[ 83]
Methotrexate	N.A.	Overall Survival	Genotypes CC + CT is associated with increased concentrations of methotrexate in people with Osteosarcoma as compared to genotype TT.		[ 15]
Rosuvastatin	N.A.	Overall Survival	Genotypes CC + CT are associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.		[ 84]
Simvastatin Acid	N.A.	Rhabdomyolysis	Genotypes CC + CT are associated with increased concentrations of simvastatin acid in children as compared to genotype TT.		[ 214]
Capecitabine	N.A.	Rhabdomyolysis	Genotypes CC + CT are not associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotype TT.		[ 52]
Fluorouracil	N.A.	Rhabdomyolysis	Genotypes CC + CT are not associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotype TT.		[ 52]
Irinotecan	N.A.	Rhabdomyolysis	Genotypes CC + CT are not associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotype TT.		[ 52]
Leucovorin	N.A.	Rhabdomyolysis	Genotypes CC + CT are not associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotype TT.		[ 52]
Enalapril	N.A.	Cough	Genotypes CC + CT are associated with increased likelihood of Cough when treated with enalapril in people with Essential hypertension as compared to genotype TT.		[ 86]
Atorvastatin	N.A.	Cough	Genotypes CC + CT is not associated with decreased response to atorvastatin in children with familial hypercholesterolemia as compared to genotype TT.		[ 216]
Atorvastatin	N.A.	Cough	Genotypes CC + CT is associated with decreased response to atorvastatin as compared to genotype TT.		[ 87]
Rosuvastatin	N.A.	Cough	Genotypes CC + CT are associated with increased concentrations of rosuvastatin in children with Hypercholesterolemia as compared to genotype TT.		[ 218]
Cerivastatin	N.A.	Muscular Diseases	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with cerivastatin, hmg coa reductase inhibitors, rosuvastatin or simvastatin as compared to genotype TT.		[ 219]
Hmg Coa Reductase Inhibitors	N.A.	Muscular Diseases	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with cerivastatin, hmg coa reductase inhibitors, rosuvastatin or simvastatin as compared to genotype TT.		[ 219]
Rosuvastatin	N.A.	Muscular Diseases	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with cerivastatin, hmg coa reductase inhibitors, rosuvastatin or simvastatin as compared to genotype TT.		[ 219]
Simvastatin	N.A.	Muscular Diseases	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with cerivastatin, hmg coa reductase inhibitors, rosuvastatin or simvastatin as compared to genotype TT.		[ 219]
Atorvastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.		[ 85]
Simvastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with simvastatin as compared to genotype TT.		[ 85]
Rosuvastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT are associated with decreased response to rosuvastatin as compared to genotype TT.		[ 220]
Atorvastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT are not associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.		[ 221]
Pravastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT are associated with increased concentrations of pravastatin in children with Hypercholesterolemia as compared to genotype TT.		[ 146]
Atorvastatin	N.A.	Drug Toxicity	Genotypes CC + CT is associated with increased likelihood of Drug Toxicity, Muscular Diseases, Rhabdomyolysis and Toxic liver disease when treated with atorvastatin as compared to genotype TT.		[ 171]
Atorvastatin	N.A.	Muscular Diseases	Genotypes CC + CT is associated with increased likelihood of Drug Toxicity, Muscular Diseases, Rhabdomyolysis and Toxic liver disease when treated with atorvastatin as compared to genotype TT.		[ 171]
Atorvastatin	N.A.	Rhabdomyolysis	Genotypes CC + CT is associated with increased likelihood of Drug Toxicity, Muscular Diseases, Rhabdomyolysis and Toxic liver disease when treated with atorvastatin as compared to genotype TT.		[ 171]
Atorvastatin	N.A.	Toxic Liver Disease	Genotypes CC + CT is associated with increased likelihood of Drug Toxicity, Muscular Diseases, Rhabdomyolysis and Toxic liver disease when treated with atorvastatin as compared to genotype TT.		[ 171]
Pitavastatin	N.A.	Toxic Liver Disease	Genotypes CC + CT are associated with increased concentrations of pitavastatin in healthy individuals as compared to genotype TT.		[ 148]
Rosuvastatin	N.A.	Muscular Diseases	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with rosuvastatin in people with Coronary Artery Disease as compared to genotype TT.		[ 145]
Fluvastatin	N.A.	Overall Survival	Genotypes CC + CT is associated with increased clinical benefit to fluvastatin as compared to genotype TT.		[ 224]
Glucarpidase	N.A.	Nephrotoxicity	Genotypes CC + CT are associated with increased risk of nephrotoxicity requiring treatment with Glucarpidase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 143]
Efavirenz	N.A.	Toxic Liver Disease	Genotypes CC + CT are not associated with concentrations of efavirenz in children with HIV Infections as compared to genotype TT.		[ 226]
Lopinavir	N.A.	Toxic Liver Disease	Genotypes CC + CT are not associated with concentrations of lopinavir in children with HIV Infections as compared to genotype TT.		[ 226]
Ritonavir	N.A.	Toxic Liver Disease	Genotypes CC + CT are not associated with concentrations of ritonavir in children with HIV Infections as compared to genotype TT.		[ 226]
Enalapril	N.A.	Cough	Genotypes CC + CT is not associated with increased likelihood of Cough when treated with enalapril in people with Hypertension as compared to genotype TT.		[ 48]
Edoxaban	N.A.	Leukopenia	Genotypes CC + CT is not associated with exposure to edoxaban in healthy individuals as compared to genotype TT.		[ 228]
Lopinavir	N.A.	Leukopenia	Genotypes CC + CT are associated with increased trough concentration of lopinavir in men with HIV Infections as compared to genotype TT.		[ 6]
Mycophenolic Acid	N.A.	Amenorrhea	Genotypes CC + CT are not associated with exposure to mycophenolic acid in people with Kidney Transplantation as compared to genotype TT.		[ 230]
Rosuvastatin	N.A.	Muscular Diseases	Genotypes CC + CT are not associated with increased risk of Muscular Diseases when treated with rosuvastatin in people with Hyperlipoproteinemia Type II as compared to genotype TT.		[ 40]
Atorvastatin	N.A.	Drug-induced Liver Injury	Genotypes CC + CT are not associated with increased risk of drug-induced liver injury when treated with atorvastatin as compared to genotype TT.		[ 232]
Methotrexate	N.A.	Recurrence	Genotypes CC + CT is associated with decreased likelihood of Recurrence when treated with methotrexate in children with Acute lymphoblastic leukemia as compared to genotype TT.		[ 233]
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with cerivastatin, hmg coa reductase inhibitors, rosuvastatin or simvastatin as compared to genotype TT.		[ 219]
Lopinavir	N.A.	HIV Infectious Disease	Genotypes CC + CT are associated with increased trough concentration of lopinavir in men with HIV Infections as compared to genotype TT.		[ 6]
Lopinavir	N.A.	HIV Infectious Disease	Genotypes CC + CT are not associated with concentrations of lopinavir in children with HIV Infections as compared to genotype TT.		[ 226]
Irinotecan	N.A.	Neoplasms	Genotypes CC + CT are associated with increased risk of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.		[ 61]
Mercaptopurine	N.A.	Acute Lymphoblastic Leukemia	Genotypes CC + CT is associated with decreased dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 144]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes CC + CT is associated with decreased dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 144]
Rosuvastatin	N.A.	Hypercholesterolemia	Genotypes CC + CT are associated with increased concentrations of rosuvastatin as compared to genotype TT.		[ 145]
Rosuvastatin	N.A.	Hypercholesterolemia	Genotypes CC + CT are associated with increased concentrations of rosuvastatin in children with Hypercholesterolemia as compared to genotype TT.		[ 218]
Rosuvastatin	N.A.	Hypercholesterolemia	Genotypes CC + CT are associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.		[ 84]
Rosuvastatin	N.A.	Hypercholesterolemia	Genotypes CC + CT are associated with increased exposure to rosuvastatin in people with Diabetes Mellitus and Hypercholesterolemia as compared to genotype TT.		[ 179]
Simvastatin	N.A.	Hypercholesterolemia	Genotypes CC + CT are associated with increased concentrations of simvastatin acid in children as compared to genotype TT.		[ 214]
Simvastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with simvastatin as compared to genotype TT.		[ 130]
Simvastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with simvastatin in people with Hyperlipidemias as compared to genotype TT.		[ 103]
Rosuvastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with rosuvastatin in people with Coronary Artery Disease as compared to genotype TT.		[ 145]
Rosuvastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT are not associated with increased risk of Muscular Diseases when treated with rosuvastatin in people with Hyperlipoproteinemia Type II as compared to genotype TT.		[ 40]
Rosuvastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with cerivastatin, hmg coa reductase inhibitors, rosuvastatin or simvastatin as compared to genotype TT.		[ 219]
Rosuvastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT is not associated with increased risk of Myalgia unspecified when treated with rosuvastatin as compared to genotype TT.		[ 176]
Atorvastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT are not associated with increased risk of Myalgia unspecified when treated with atorvastatin in people with Hypercholesterolemia as compared to genotype TT.		[ 72]
Atorvastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT are associated with increased risk of dose decrease or switch to another cholesterol-lowering drug in users with a starting dose of more than 20 mg when treated with atorvastatin as compared to genotype TT.		[ 131]
Atorvastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT is associated with increased likelihood of Drug Toxicity, Muscular Diseases, Rhabdomyolysis and Toxic liver disease when treated with atorvastatin as compared to genotype TT.		[ 171]
Lovastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT is associated with increased concentrations of lovastatin acid in healthy individuals as compared to genotype TT.		[ 140]
SN-38	N.A.	Non-small Cell Lung Carcinoma	Genotypes CC + CT are associated with increased dose of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.		[ 61]
Hmg Coa Reductase Inhibitors	N.A.	Cardiovascular Disease	Genotypes CC + CT are not associated with decreased response to hmg coa reductase inhibitors as compared to genotype TT.		[ 149]
Hmg Coa Reductase Inhibitors	N.A.	Hyperlipidemias	Genotypes CC + CT are not associated with decreased response to hmg coa reductase inhibitors as compared to genotype TT.		[ 149]
Hmg Coa Reductase Inhibitors	N.A.	Cardiovascular Disease	Genotypes CC + CT are associated with decreased response to atorvastatin, hmg coa reductase inhibitors, pravastatin or simvastatin in people with Hyperlipidemias as compared to genotype TT.		[ 202]
Hmg Coa Reductase Inhibitors	N.A.	Hyperlipidemias	Genotypes CC + CT are associated with decreased response to atorvastatin, hmg coa reductase inhibitors, pravastatin or simvastatin in people with Hyperlipidemias as compared to genotype TT.		[ 202]
Hmg Coa Reductase Inhibitors	N.A.	Cardiovascular Disease	Genotypes CC + CT is associated with decreased clinical benefit to hmg coa reductase inhibitors in people with HIV Infections as compared to genotype TT.		[ 181]
Hmg Coa Reductase Inhibitors	N.A.	Hyperlipidemias	Genotypes CC + CT is associated with decreased clinical benefit to hmg coa reductase inhibitors in people with HIV Infections as compared to genotype TT.		[ 181]
Atorvastatin	N.A.	Dyslipidaemia	Genotypes CC + CT are not associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotype TT.		[ 55]
Atorvastatin	N.A.	Familial Hypercholesterolemia	Genotypes CC + CT are not associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotype TT.		[ 55]
Atorvastatin	N.A.	Hypercholesterolemia	Genotypes CC + CT are not associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotype TT.		[ 55]
Atorvastatin	N.A.	Hyperlipidemias	Genotypes CC + CT are not associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotype TT.		[ 55]
Atorvastatin	N.A.	Dyslipidaemia	Genotypes CC + CT is not associated with decreased response to atorvastatin in people with Dyslipidaemia as compared to genotype TT.		[ 31]
Atorvastatin	N.A.	Familial Hypercholesterolemia	Genotypes CC + CT is not associated with decreased response to atorvastatin in people with Dyslipidaemia as compared to genotype TT.		[ 31]
Atorvastatin	N.A.	Hypercholesterolemia	Genotypes CC + CT is not associated with decreased response to atorvastatin in people with Dyslipidaemia as compared to genotype TT.		[ 31]
Atorvastatin	N.A.	Hyperlipidemias	Genotypes CC + CT is not associated with decreased response to atorvastatin in people with Dyslipidaemia as compared to genotype TT.		[ 31]
Atorvastatin	N.A.	Dyslipidaemia	Genotypes CC + CT are not associated with decreased response to atorvastatin or simvastatin as compared to genotype TT.		[ 77]
Atorvastatin	N.A.	Familial Hypercholesterolemia	Genotypes CC + CT are not associated with decreased response to atorvastatin or simvastatin as compared to genotype TT.		[ 77]
Atorvastatin	N.A.	Hypercholesterolemia	Genotypes CC + CT are not associated with decreased response to atorvastatin or simvastatin as compared to genotype TT.		[ 77]
Atorvastatin	N.A.	Hyperlipidemias	Genotypes CC + CT are not associated with decreased response to atorvastatin or simvastatin as compared to genotype TT.		[ 77]
Atorvastatin	N.A.	Dyslipidaemia	Genotypes CC + CT is not associated with decreased response to atorvastatin in children with familial hypercholesterolemia as compared to genotype TT.		[ 216]
Atorvastatin	N.A.	Familial Hypercholesterolemia	Genotypes CC + CT is not associated with decreased response to atorvastatin in children with familial hypercholesterolemia as compared to genotype TT.		[ 216]
Atorvastatin	N.A.	Hypercholesterolemia	Genotypes CC + CT is not associated with decreased response to atorvastatin in children with familial hypercholesterolemia as compared to genotype TT.		[ 216]
Atorvastatin	N.A.	Hyperlipidemias	Genotypes CC + CT is not associated with decreased response to atorvastatin in children with familial hypercholesterolemia as compared to genotype TT.		[ 216]
Atorvastatin	N.A.	Dyslipidaemia	Genotypes CC + CT is associated with decreased response to atorvastatin as compared to genotype TT.		[ 87]
Atorvastatin	N.A.	Familial Hypercholesterolemia	Genotypes CC + CT is associated with decreased response to atorvastatin as compared to genotype TT.		[ 87]
Atorvastatin	N.A.	Hypercholesterolemia	Genotypes CC + CT is associated with decreased response to atorvastatin as compared to genotype TT.		[ 87]
Atorvastatin	N.A.	Hyperlipidemias	Genotypes CC + CT is associated with decreased response to atorvastatin as compared to genotype TT.		[ 87]
Atorvastatin	N.A.	Dyslipidaemia	Genotypes CC + CT are associated with decreased response to atorvastatin, hmg coa reductase inhibitors, pravastatin or simvastatin in people with Hyperlipidemias as compared to genotype TT.		[ 202]
Atorvastatin	N.A.	Familial Hypercholesterolemia	Genotypes CC + CT are associated with decreased response to atorvastatin, hmg coa reductase inhibitors, pravastatin or simvastatin in people with Hyperlipidemias as compared to genotype TT.		[ 202]
Atorvastatin	N.A.	Hypercholesterolemia	Genotypes CC + CT are associated with decreased response to atorvastatin, hmg coa reductase inhibitors, pravastatin or simvastatin in people with Hyperlipidemias as compared to genotype TT.		[ 202]
Atorvastatin	N.A.	Hyperlipidemias	Genotypes CC + CT are associated with decreased response to atorvastatin, hmg coa reductase inhibitors, pravastatin or simvastatin in people with Hyperlipidemias as compared to genotype TT.		[ 202]
Atorvastatin	N.A.	Dyslipidaemia	Genotypes CC + CT is not associated with response to atorvastatin in people with Hypercholesterolemia as compared to genotype TT.		[ 73]
Atorvastatin	N.A.	Familial Hypercholesterolemia	Genotypes CC + CT is not associated with response to atorvastatin in people with Hypercholesterolemia as compared to genotype TT.		[ 73]
Atorvastatin	N.A.	Hypercholesterolemia	Genotypes CC + CT is not associated with response to atorvastatin in people with Hypercholesterolemia as compared to genotype TT.		[ 73]
Atorvastatin	N.A.	Hyperlipidemias	Genotypes CC + CT is not associated with response to atorvastatin in people with Hypercholesterolemia as compared to genotype TT.		[ 73]
Enalapril	N.A.	Essential Hypertension	Genotypes CC + CT are associated with increased likelihood of Cough when treated with enalapril in people with Essential hypertension as compared to genotype TT.		[ 86]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes CC + CT are associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 66]
Methotrexate	N.A.	Osteosarcoma	Genotypes CC + CT are associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 66]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes CC + CT is associated with increased concentrations of methotrexate in people with Osteosarcoma as compared to genotype TT.		[ 15]
Methotrexate	N.A.	Osteosarcoma	Genotypes CC + CT is associated with increased concentrations of methotrexate in people with Osteosarcoma as compared to genotype TT.		[ 15]
Simvastatin acid	N.A.	Hypercholesterolemia	Correlated with the increased drug concentrations (compare with Genotype TT)		[ 214]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           9 Drugs in Total
Sorafenib	Drug Info	Thrombocytopenia	Correlated with the increased likelihood of disease in patients (compare with genotype CC)		[ 50]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Irrelevant to the drug concentrations in patients (compare with genotype CC)		[ 9]
Pravastatin	Drug Info	Hypercholesterolemia	Irrelevant to the the drug response in patients (compare with genotype CC)		[ 197]
Methotrexate	N.A.	Statin-related Myopathy	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 9]
Sorafenib	N.A.	Thrombocytopenia	Genotypes CT + TT are associated with increased likelihood of Thrombocytopenia when treated with sorafenib as compared to genotype CC.		[ 50]
Pravastatin	N.A.	Mucositis	Genotypes CT + TT are not associated with the response of total cholesterol, LDL, HDL, triglycerides or CRP to pravastatin when treated with pravastatin in men with as compared to genotype CC.		[ 197]
Methotrexate	N.A.	Mucositis	Genotypes CT + TT is not associated with likelihood of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 9]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 9]
Methotrexate	N.A.	Osteosarcoma	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 9]
Genotype *15/*15	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Rosuvastatin	N.A.	Hypercholesterolemia	SLCO1B1 *15/*15 is associated with increased concentrations of rosuvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.		[ 196]
Rosuvastatin	N.A.	Hypercholesterolemia	SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *37/*15.		[ 197]
Pravastatin	N.A.	Hypercholesterolemia	SLCO1B1 *15/*15 is associated with increased concentrations of pitavastatin or pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.		[ 198]
Pravastatin	N.A.	Hypercholesterolemia	SLCO1B1 *15/*15 is associated with increased pravastatin plasma concentrations (AUC) when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.		[ 152]
Atorvastatin	N.A.	Statin-related Myopathy	SLCO1B1 *15/*15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.		[ 196]
Genotype *15	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Pravastatin	N.A.	Hypercholesterolemia	SLCO1B1 *15 is associated with increased relative bioavailability of pravastatin when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *1.		[ 199]
Pravastatin	N.A.	Hypercholesterolemia	SLCO1B1 *15 is associated with increased concentrations of pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.		[ 200]
Pravastatin	N.A.	Hypercholesterolemia	SLCO1B1 *15 is associated with decreased uptake of atorvastatin, cerivastatin and pravastatin as compared to SLCO1B1 *1/*1.		[ 201]
Atorvastatin	N.A.	Statin-related Myopathy	SLCO1B1 *15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1.		[ 202]
Atorvastatin	N.A.	Statin-related Myopathy	SLCO1B1 *15 is associated with decreased uptake of atorvastatin, cerivastatin and pravastatin as compared to SLCO1B1 *1/*1.		[ 201]
Atorvastatin	N.A.	Statin-related Myopathy	SLCO1B1 *15 is associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1/*1 + *1/*37 + *37/*37.		[ 69]
Genotype *1/*15	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Pravastatin	N.A.	Hypercholesterolemia	SLCO1B1 *1/*15 is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.		[ 152]
Pravastatin	N.A.	Hyperlipidemias	SLCO1B1 *1/*15 is associated with decreased response to pravastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1/*1.		[ 204]
Genotype *5	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Simvastatin	N.A.	Statin-related Myopathy	SLCO1B1 *5 is associated with increased risk of Drug Toxicity when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.		[ 100]
Atorvastatin	N.A.	Statin-related Myopathy	SLCO1B1 *5 is associated with decreased uptake of atorvastatin, cerivastatin and pravastatin as compared to SLCO1B1 *1/*1.		[ 201]
Atorvastatin	N.A.	Statin-related Myopathy	SLCO1B1 *5 is associated with increased risk of Drug Toxicity when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.		[ 100]
Pravastatin	N.A.	Statin-related Myopathy	SLCO1B1 *5 is associated with increased risk of Drug Toxicity when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.		[ 100]
Genotypes *1/*5 + *5/*5	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Atorvastatin	N.A.	Statin-related Myopathy	SLCO1B1 *1/*5 + *5/*5 are associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1.		[ 204]
Atorvastatin	N.A.	Statin-related Myopathy	SLCO1B1 *1/*5 + *5/*5 is associated with increased risk of discontinuation and statin-related myopathy when treated with atorvastatin as compared to SLCO1B1 *1/*1.		[ 205]
Genotypes *5/*15 + *15/*15	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Lovastatin	N.A.	Statin-related Myopathy	SLCO1B1 *5/*15 + *15/*15 are associated with increased exposure to lovastatin acid in healthy individuals as compared to SLCO1B1 *1/*1.		[ 206]
Lovastatin Acid	N.A.	Statin-related Myopathy	SLCO1B1 *5/*15 + *15/*15 are associated with increased exposure to lovastatin acid in healthy individuals as compared to SLCO1B1 *1/*1.		[ 206]
Genotypes *15/*15 + *15/*37	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Pitavastatin	N.A.	Statin-related Myopathy	SLCO1B1 *15/*15 + *15/*37 are associated with increased concentrations of pitavastatin in healthy individuals as compared to SLCO1B1 *37/*37.		[ 207]
Genetic Polymorphism	rs4149081
Site of GPD	chr12:21225087 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.2188/1096 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the drug clearance in patients (compare with allele A); Correlated with the increased gastrointestinal toxicity risk in patients (compare with Allele A)		[ 14]
Methotrexate	N.A.	Mucositis	Allele G is associated with increased risk of GI toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 14]
Methotrexate	N.A.	Infectious Disease	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.		[ 12]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele G is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 14]
Methotrexate	N.A.	Osteosarcoma	Allele G is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 14]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.		[ 12]
Methotrexate	N.A.	Osteosarcoma	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.		[ 12]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:         12 Drugs in Total
Rosuvastatin	Drug Info	Coronary Disease	Correlated with the increased LDL-C reduction in patients (compare with genotypes AG + GG)		[ 23]
Simvastatin	Drug Info	Coronary Disease	Correlated with the increased LDL-C reduction in patients (compare with genotypes AG + GG)		[ 23]
Methotrexate	N.A.	Neutropenia	Genotype AA is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 17]
Simvastatin	N.A.	Toxic Liver Disease	Genotype AA is associated with increased LDL-C reduction when treated with simvastatin in people with Coronary Disease as compared to genotypes AG + GG.		[ 23]
Rosuvastatin	N.A.	Muscular Diseases	Genotype AA is associated with increased LDL-C reduction when treated with rosuvastatin in people with Coronary Disease as compared to genotypes AG + GG.		[ 23]
Rosuvastatin	N.A.	Coronary Disease	Genotype AA is associated with increased LDL-C reduction when treated with rosuvastatin in people with Coronary Disease as compared to genotypes AG + GG.		[ 23]
Simvastatin	N.A.	Coronary Disease	Genotype AA is associated with increased LDL-C reduction when treated with simvastatin in people with Coronary Disease as compared to genotypes AG + GG.		[ 23]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype AA is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 17]
Methotrexate	N.A.	Osteosarcoma	Genotype AA is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 17]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs4140981 AA genotype may have decreased clearance of methotrexate as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149081 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.		[ 7]
Methotrexate	N.A.	Osteosarcoma	Patients with the rs4140981 AA genotype may have decreased clearance of methotrexate as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149081 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.		[ 7]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs4149081 AA genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate may have a decreased, but not absent, risk of GI toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of GI toxicity.		[ 14]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           9 Drugs in Total
Rosuvastatin	Drug Info	Coronary Disease	Correlated with the increased LDL-C reduction in patients (compare with genotype GG)		[ 23]
Simvastatin	Drug Info	Coronary Disease	Correlated with the increased LDL-C reduction in patients (compare with genotype GG)		[ 23]
Rosuvastatin	N.A.	Toxic Liver Disease	Genotype AG is associated with increased LDL-C reduction when treated with rosuvastatin in people with Coronary Disease as compared to genotype GG.		[ 23]
Simvastatin	N.A.	Toxic Liver Disease	Genotype AG is associated with increased LDL-C reduction when treated with simvastatin in people with Coronary Disease as compared to genotype GG.		[ 23]
Rosuvastatin	N.A.	Coronary Disease	Genotype AG is associated with increased LDL-C reduction when treated with rosuvastatin in people with Coronary Disease as compared to genotype GG.		[ 23]
Simvastatin	N.A.	Coronary Disease	Genotype AG is associated with increased LDL-C reduction when treated with simvastatin in people with Coronary Disease as compared to genotype GG.		[ 23]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs4140981 AG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype but decreased clearance of methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149081 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.		[ 7]
Methotrexate	N.A.	Osteosarcoma	Patients with the rs4140981 AG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype but decreased clearance of methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149081 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.		[ 7]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs4149081 AG genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate may have an increased risk of GI toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of GI toxicity.		[ 14]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Methotrexate	N.A.	Toxic Liver Disease	Allele A is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 71]
Methotrexate	N.A.	Discontinuation	Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 7]
Methotrexate	N.A.	Drug Toxicity	Allele A is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele G.		[ 121]
Methotrexate	N.A.	Nausea	Allele A is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele G.		[ 121]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 7]
Methotrexate	N.A.	Osteosarcoma	Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 7]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele A is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 71]
Methotrexate	N.A.	Osteosarcoma	Allele A is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 71]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Rosuvastatin	N.A.	Coronary Disease	Patients with the GG genotype and Coronary Disease may have a decreased response to rosuvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.		[ 23]
Simvastatin	N.A.	Coronary Disease	Patients with the GG genotype and Coronary Disease who are treated with simvastatin may have less LDL-C reduction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin		[ 23]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs4140981 GG genotype may have increased clearance of methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149081 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.		[ 7]
Methotrexate	N.A.	Osteosarcoma	Patients with the rs4140981 GG genotype may have increased clearance of methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149081 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.		[ 7]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs4149081 GG genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate may have an increased risk of GI toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of GI toxicity.		[ 14]
Genetic Polymorphism	rs4363657
Site of GPD	chr12:21215788 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.2149/1076 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Simvastatin	Drug Info	Myocardial Infarction	Correlated with the increased likelihood of muscular diseases in patients (compare with Genotype TT)		[ 130]
Simvastatin	N.A.	Statin-related Myopathy	Genotype CC is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Myocardial Infarction as compared to genotype TT.		[ 130]
Simvastatin	N.A.	Muscular Diseases	Genotype CC is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Myocardial Infarction as compared to genotype TT.		[ 130]
Simvastatin	N.A.	Muscular Diseases	The current evidence base suggests that there is no significant association between the rs4363657 CC genotype and risk of myopathy when treated with simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of myopathy when treated with simvastatin.		[ 209]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Rosuvastatin	Drug Info	Muscular Diseases	Irrelevant to the increased myalgia unspecified risk in patients (compare with Genotype TT)		[ 169]
Rosuvastatin	N.A.	Myalgia	Genotypes CC + CT is not associated with increased risk of Myalgia unspecified when treated with rosuvastatin as compared to genotype TT.		[ 169]
Simvastatin	N.A.	Statin-related Myopathy	Genotypes CC + CT are not associated with response to simvastatin in people with Hypercholesterolemia as compared to genotype TT.		[ 75]
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Genotypes CC + CT are associated with increased likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to genotype TT.		[ 76]
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Genotypes CC + CT are associated with decreased risk of statin-related myopathy when treated with hmg coa reductase inhibitors as compared to genotype TT.		[ 188]
Lovastatin	N.A.	Muscular Diseases	Genotypes CC + CT are associated with increased likelihood of Muscular Diseases when treated with lovastatin or simvastatin in people with Dyslipidaemia as compared to genotype TT.		[ 213]
Simvastatin	N.A.	Muscular Diseases	Genotypes CC + CT are associated with increased likelihood of Muscular Diseases when treated with lovastatin or simvastatin in people with Dyslipidaemia as compared to genotype TT.		[ 213]
Simvastatin	N.A.	Muscular Diseases	Genotypes CC + CT is not associated with increased risk of Myalgia unspecified when treated with rosuvastatin as compared to genotype TT.		[ 169]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Pitavastatin	N.A.	Drug Toxicity	Allele A is associated with increased exposure to pitavastatin and pitavastatin lactone in healthy individuals as compared to allele T.		[ 109]
Pitavastatin Lactone	N.A.	Drug Toxicity	Allele A is associated with increased exposure to pitavastatin and pitavastatin lactone in healthy individuals as compared to allele T.		[ 109]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Atorvastatin	N.A.	Statin-related Myopathy	Allele C is not associated with increased risk of statin-related myopathy when treated with atorvastatin or simvastatin in people with Dyslipidaemia as compared to allele T.		[ 208]
Simvastatin	N.A.	Statin-related Myopathy	Allele C is not associated with increased risk of statin-related myopathy when treated with atorvastatin or simvastatin in people with Dyslipidaemia as compared to allele T.		[ 208]
Hmg Coa Reductase Inhibitors	N.A.	Thrombocytopenia	Allele C is not associated with response to hmg coa reductase inhibitors as compared to allele T.		[ 3]
Simvastatin	N.A.	Muscular Diseases	Allele C is not associated with increased risk of statin-related myopathy when treated with atorvastatin or simvastatin in people with Dyslipidaemia as compared to allele T.		[ 208]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Simvastatin	N.A.	Muscular Diseases	The current evidence base suggests that there is no significant association between the rs4363657 CT genotype and risk of myopathy when treated with simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of myopathy when treated with simvastatin.		[ 208]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Simvastatin	N.A.	Muscular Diseases	The current evidence base suggests that there is no significant association between the rs4363657 TT genotype and risk of myopathy when treated with simvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of myopathy when treated with simvastatin.		[ 208]
Genetic Polymorphism	rs10841753
Site of GPD	chr12:21168436 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.2352/1178 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Irrelevant to the drug response in patients (compare with Allele T)		[ 9]
Methotrexate	N.A.	Myalgia	Allele C is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 9]
Estrone Sulfate	N.A.	Hypercholesterolemia	Allele C is associated with decreased concentrations of estrone sulfate in women with Breast Neoplasms as compared to allele T.		[ 211]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele C is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 9]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug concentrations in patients (compare with genotype CC); Irrelevant to the mucositis risk in patients (compare with genotype CC)		[ 9]
Methotrexate	N.A.	Statin-related Myopathy	Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 9]
Methotrexate	N.A.	Mucositis	Genotypes CT + TT are not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 9]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes CT + TT are not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 9]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with precursor cell lymphoblastic leukemia-lymphoma and the CC genotype may have increased concentrations of methotrexate as compared to patients with the CT and TT genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.		[ 9]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.		[ 9]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.		[ 9]
Genetic Polymorphism	rs2291073
Site of GPD	chr12:21172880 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>G
Minor Allele Frequency	G=0.2925/1465 (Global)
Genotypes GT + TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Lovastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug response (compare with genotype GG)		[ 43]
Lovastatin	N.A.	Fever	Genotypes GT + TT are associated with increased response to lovastatin as compared to genotype GG.		[ 43]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Lovastatin	N.A.	Kidney Transplantation	Patients with the GG genotype may have decreased response to lovastatin as compared to patients with the TT or TG genotypes. Other genetic and clinical factors may influence also a patient's lovastatin response.		[ 43]
Genotype TG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Lovastatin	N.A.	Kidney Transplantation	Patients with the TG genotype may have increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's lovastatin response.		[ 43]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Lovastatin	N.A.	Kidney Transplantation	Patients with the TT genotype may have increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's lovastatin response.		[ 43]
Genetic Polymorphism	rs2291075
Site of GPD	chr12:21178691 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.4155/2081 (Global)
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:         16 Drugs in Total
Etoposide	Drug Info	Acute Myeloid Leukemia	Correlated with the increased event-free survival and overall survival in patients (compare with genotype CC)		[ 211]
Mitoxantrone	Drug Info	Acute Myeloid Leukemia	Correlated with the increased event-free survival and overall survival in patients (compare with genotype CC)		[ 211]
Daunorubicin	Drug Info	Acute Myeloid Leukemia	Correlated with the increased event-free survival and overall survival in patients (compare with genotype CC)		[ 211]
Cytarabine	Drug Info	Acute Myeloid Leukemia	Correlated with the increased event-free survival and overall survival in patients (compare with genotype CC)		[ 211]
Cytarabine	N.A.	Event-free Survival	Genotypes CT + TT are associated with increased event-free survival and overall survival when treated with cytarabine, daunorubicin, etoposide and mitoxantrone in children with Leukemia, Myeloid, Acute as compared to genotype CC.		[ 211]
Cytarabine	N.A.	Overall Survival	Genotypes CT + TT are associated with increased event-free survival and overall survival when treated with cytarabine, daunorubicin, etoposide and mitoxantrone in children with Leukemia, Myeloid, Acute as compared to genotype CC.		[ 211]
Daunorubicin	N.A.	Event-free Survival	Genotypes CT + TT are associated with increased event-free survival and overall survival when treated with cytarabine, daunorubicin, etoposide and mitoxantrone in children with Leukemia, Myeloid, Acute as compared to genotype CC.		[ 211]
Daunorubicin	N.A.	Overall Survival	Genotypes CT + TT are associated with increased event-free survival and overall survival when treated with cytarabine, daunorubicin, etoposide and mitoxantrone in children with Leukemia, Myeloid, Acute as compared to genotype CC.		[ 211]
Etoposide	N.A.	Event-free Survival	Genotypes CT + TT are associated with increased event-free survival and overall survival when treated with cytarabine, daunorubicin, etoposide and mitoxantrone in children with Leukemia, Myeloid, Acute as compared to genotype CC.		[ 211]
Etoposide	N.A.	Overall Survival	Genotypes CT + TT are associated with increased event-free survival and overall survival when treated with cytarabine, daunorubicin, etoposide and mitoxantrone in children with Leukemia, Myeloid, Acute as compared to genotype CC.		[ 211]
Mitoxantrone	N.A.	Event-free Survival	Genotypes CT + TT are associated with increased event-free survival and overall survival when treated with cytarabine, daunorubicin, etoposide and mitoxantrone in children with Leukemia, Myeloid, Acute as compared to genotype CC.		[ 211]
Mitoxantrone	N.A.	Overall Survival	Genotypes CT + TT are associated with increased event-free survival and overall survival when treated with cytarabine, daunorubicin, etoposide and mitoxantrone in children with Leukemia, Myeloid, Acute as compared to genotype CC.		[ 211]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Genotypes CT + TT are associated with increased event-free survival and overall survival when treated with cytarabine, daunorubicin, etoposide and mitoxantrone in children with Leukemia, Myeloid, Acute as compared to genotype CC.		[ 211]
Daunorubicin	N.A.	Leukemia, Myeloid, Acute	Genotypes CT + TT are associated with increased event-free survival and overall survival when treated with cytarabine, daunorubicin, etoposide and mitoxantrone in children with Leukemia, Myeloid, Acute as compared to genotype CC.		[ 211]
Etoposide	N.A.	Leukemia, Myeloid, Acute	Genotypes CT + TT are associated with increased event-free survival and overall survival when treated with cytarabine, daunorubicin, etoposide and mitoxantrone in children with Leukemia, Myeloid, Acute as compared to genotype CC.		[ 211]
Mitoxantrone	N.A.	Leukemia, Myeloid, Acute	Genotypes CT + TT are associated with increased event-free survival and overall survival when treated with cytarabine, daunorubicin, etoposide and mitoxantrone in children with Leukemia, Myeloid, Acute as compared to genotype CC.		[ 211]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Patients with the CC genotype may have less favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.		[ 211]
Daunorubicin	N.A.	Leukemia, Myeloid, Acute	Patients with the CC genotype may have less favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.		[ 211]
Etoposide	N.A.	Leukemia, Myeloid, Acute	Patients with the CC genotype may have less favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.		[ 211]
Mitoxantrone	N.A.	Leukemia, Myeloid, Acute	Patients with the CC genotype may have less favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.		[ 211]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.		[ 211]
Daunorubicin	N.A.	Leukemia, Myeloid, Acute	Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.		[ 211]
Etoposide	N.A.	Leukemia, Myeloid, Acute	Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.		[ 211]
Mitoxantrone	N.A.	Leukemia, Myeloid, Acute	Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.		[ 211]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Patients with the TT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.		[ 211]
Daunorubicin	N.A.	Leukemia, Myeloid, Acute	Patients with the TT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.		[ 211]
Etoposide	N.A.	Leukemia, Myeloid, Acute	Patients with the TT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.		[ 211]
Mitoxantrone	N.A.	Leukemia, Myeloid, Acute	Patients with the TT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.		[ 211]
Genetic Polymorphism	rs4149036
Site of GPD	chr12:21174806 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A
Minor Allele Frequency	A=0.3542/1774 (Global)
Genotypes AC + CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Atorvastatin	Drug Info	Coronary Artery Disease	Correlated with the increased drug response in patients (compare with genotype AA)		[ 43]
Atorvastatin	N.A.	Fever	Genotypes AC + CC are associated with increased response to atorvastatin as compared to genotype AA.		[ 43]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Atorvastatin	N.A.	Acute Lymphoblastic Leukemia	Patients with the AA genotype may have decreased response to atorvastatin as compared to patients with the CC or AC genotypes. Other genetic and clinical factors may influence also a patient's atorvastatin response.		[ 43]
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Atorvastatin	N.A.	Acute Lymphoblastic Leukemia	Patients with the AC genotype may have increased response to atorvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's atorvastatin response.		[ 43]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Atorvastatin	N.A.	Acute Lymphoblastic Leukemia	Patients with the CC genotype may have increased response to atorvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's atorvastatin response.		[ 43]
Genetic Polymorphism	rs1940852753
Site of GPD	chr12:21178680 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Statin-related Myopathy	Allele G is not associated with transport of methotrexate in HEK293 cells as compared to allele A.		[ 212]
Genetic Polymorphism	rs11045854
Site of GPD	chr12:21197100 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.9830/1945 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rosuvastatin	N.A.	Statin-related Myopathy	Allele A is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G.		[ 213]
Genetic Polymorphism	rs11045874
Site of GPD	chr12:21222129 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C / G>T
Minor Allele Frequency	G=0.9010/1783 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rosuvastatin	N.A.	Statin-related Myopathy	Allele C is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G.		[ 213]
Genetic Polymorphism	rs34671512
Site of GPD	chr12:21239042 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C
Minor Allele Frequency	A=0.9550/1889 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rosuvastatin	N.A.	Statin-related Myopathy	Allele C is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele A.		[ 213]
Genetic Polymorphism	rs12305884
Site of GPD	chr12:21200738 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.9620/1903 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rosuvastatin	N.A.	Statin-related Myopathy	Allele A is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G.		[ 213]
Genetic Polymorphism	rs11045873
Site of GPD	chr12:21222127 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A
Minor Allele Frequency	T=0.9190/1818 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rosuvastatin	N.A.	Statin-related Myopathy	Allele A is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele T.		[ 213]
Genetic Polymorphism	rs4149014
Site of GPD	chr12:21130019 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>G
Minor Allele Frequency	T=0.9090/1798 (Global)
Genotypes GG + GT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Drug-induced Liver Injury	Genotypes GG + GT is associated with decreased likelihood of drug-induced liver injury when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to genotype TT.		[ 214]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Isoniazid	N.A.	Drug-induced Liver Injury	Allele G is not associated with risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis as compared to allele T.		[ 215]
Genetic Polymorphism	rs77271279
Site of GPD	chr12:21176898 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>T
Minor Allele Frequency	G=0.9900/1959 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Allele T is associated with increased likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors as compared to allele G.		[ 107]
Genetic Polymorphism	rs59502379
Site of GPD	chr12:21205999 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>C
Minor Allele Frequency	G=0.9880/1955 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Hmg Coa Reductase Inhibitors	N.A.	Statin-related Myopathy	Allele C is associated with increased likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors as compared to allele G.		[ 107]
Genetic Polymorphism	rs999278
Site of GPD	chr12:21180717 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A
Minor Allele Frequency	C=0.6980/1381 (Global)
Genotypes AA + AC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Edoxaban	N.A.	Hemorrhage	Genotypes AA + AC is associated with increased likelihood of Hemorrhage when treated with edoxaban as compared to genotype CC.		[ 63]
Genetic Polymorphism	rs4149057
Site of GPD	chr12:21178665 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.6280/1242 (Global)
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Edoxaban	N.A.	Hemorrhage	Genotypes CC + CT is associated with increased likelihood of Hemorrhage when treated with edoxaban as compared to genotype TT.		[ 63]
Lopinavir	N.A.	Drug Toxicity	Genotypes CC + CT is not associated with concentrations of lopinavir in people with HIV Infections as compared to genotype TT.		[ 68]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Infectious Disease	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 12]
Genetic Polymorphism	rs4149035
Site of GPD	chr12:21165331 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C
Minor Allele Frequency	T=0.2920/577 (Global)
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Atorvastatin	N.A.	Toxic Liver Disease	Genotypes CT + TT is associated with increased likelihood of Toxic liver disease when treated with atorvastatin, fluvastatin, lovastatin, pitavastatin or simvastatin as compared to genotype CC.		[ 216]
Fluvastatin	N.A.	Toxic Liver Disease	Genotypes CT + TT is associated with increased likelihood of Toxic liver disease when treated with atorvastatin, fluvastatin, lovastatin, pitavastatin or simvastatin as compared to genotype CC.		[ 216]
Lovastatin	N.A.	Toxic Liver Disease	Genotypes CT + TT is associated with increased likelihood of Toxic liver disease when treated with atorvastatin, fluvastatin, lovastatin, pitavastatin or simvastatin as compared to genotype CC.		[ 216]
Pitavastatin	N.A.	Toxic Liver Disease	Genotypes CT + TT is associated with increased likelihood of Toxic liver disease when treated with atorvastatin, fluvastatin, lovastatin, pitavastatin or simvastatin as compared to genotype CC.		[ 216]
Simvastatin	N.A.	Toxic Liver Disease	Genotypes CT + TT is associated with increased likelihood of Toxic liver disease when treated with atorvastatin, fluvastatin, lovastatin, pitavastatin or simvastatin as compared to genotype CC.		[ 216]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Infectious Disease	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 12]
Genetic Polymorphism	rs11045818
Site of GPD	chr12:21176827 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.9470/1874 (Global)
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Atorvastatin	N.A.	Toxic Liver Disease	Genotypes AA + AG is associated with increased likelihood of Toxic liver disease when treated with atorvastatin, fluvastatin, lovastatin, pitavastatin or simvastatin as compared to genotype GG.		[ 216]
Fluvastatin	N.A.	Toxic Liver Disease	Genotypes AA + AG is associated with increased likelihood of Toxic liver disease when treated with atorvastatin, fluvastatin, lovastatin, pitavastatin or simvastatin as compared to genotype GG.		[ 216]
Lovastatin	N.A.	Toxic Liver Disease	Genotypes AA + AG is associated with increased likelihood of Toxic liver disease when treated with atorvastatin, fluvastatin, lovastatin, pitavastatin or simvastatin as compared to genotype GG.		[ 216]
Pitavastatin	N.A.	Toxic Liver Disease	Genotypes AA + AG is associated with increased likelihood of Toxic liver disease when treated with atorvastatin, fluvastatin, lovastatin, pitavastatin or simvastatin as compared to genotype GG.		[ 216]
Simvastatin	N.A.	Toxic Liver Disease	Genotypes AA + AG is associated with increased likelihood of Toxic liver disease when treated with atorvastatin, fluvastatin, lovastatin, pitavastatin or simvastatin as compared to genotype GG.		[ 216]
Genetic Polymorphism	rs374113543
Site of GPD	chr12:21179006 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=1.0000/1979 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Atorvastatin	N.A.	Hypercholesterolemia	Allele A is associated with increased severity of Hypercholesterolemia when treated with atorvastatin or simvastatin as compared to allele G.		[ 217]
Simvastatin	N.A.	Hypercholesterolemia	Allele A is associated with increased severity of Hypercholesterolemia when treated with atorvastatin or simvastatin as compared to allele G.		[ 217]
Genetic Polymorphism	rs373327528
Site of GPD	chr12:21172776 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Allele A	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Atorvastatin	N.A.	Hypercholesterolemia	Allele A is associated with increased severity of Hypercholesterolemia when treated with atorvastatin or simvastatin as compared to allele G.		[ 217]
Simvastatin	N.A.	Hypercholesterolemia	Allele A is associated with increased severity of Hypercholesterolemia when treated with atorvastatin or simvastatin as compared to allele G.		[ 217]
Genetic Polymorphism	rs4149044
Site of GPD	chr12:21177062 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>T
Minor Allele Frequency	A=0.6440/1274 (Global)
Genotypes AA + AT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Lopinavir	N.A.	Drug Toxicity	Genotypes AA + AT is not associated with concentrations of lopinavir in people with HIV Infections as compared to genotype TT.		[ 68]
Genetic Polymorphism	rs4149045
Site of GPD	chr12:21177086 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.6440/1274 (Global)
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Lopinavir	N.A.	Drug Toxicity	Genotypes AG + GG is not associated with concentrations of lopinavir in people with HIV Infections as compared to genotype AA.		[ 68]
Genetic Polymorphism	rs34234515
Site of GPD	chr12:21150197 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	C=0.9630/1905 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Atezolizumab	N.A.	Drug-induced Liver Injury	Allele A is associated with increased likelihood of Drug-induced liver injury when treated with atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab or pembrolizumab as compared to allele C.		[ 218]
Avelumab	N.A.	Drug-induced Liver Injury	Allele A is associated with increased likelihood of Drug-induced liver injury when treated with atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab or pembrolizumab as compared to allele C.		[ 218]
Durvalumab	N.A.	Drug-induced Liver Injury	Allele A is associated with increased likelihood of Drug-induced liver injury when treated with atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab or pembrolizumab as compared to allele C.		[ 218]
Ipilimumab	N.A.	Drug-induced Liver Injury	Allele A is associated with increased likelihood of Drug-induced liver injury when treated with atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab or pembrolizumab as compared to allele C.		[ 218]
Nivolumab	N.A.	Drug-induced Liver Injury	Allele A is associated with increased likelihood of Drug-induced liver injury when treated with atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab or pembrolizumab as compared to allele C.		[ 218]
Pembrolizumab	N.A.	Drug-induced Liver Injury	Allele A is associated with increased likelihood of Drug-induced liver injury when treated with atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab or pembrolizumab as compared to allele C.		[ 218]
Genetic Polymorphism	rs1910167
Site of GPD	chr12:21053900 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.9520/1884 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Bilirubin	N.A.	Discontinuation	Allele C is associated with increased concentrations of bilirubin in children as compared to allele T.		[ 219]
Genetic Polymorphism	rs4149087
Site of GPD	chr12:21239628 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C / T>G
Minor Allele Frequency	T=0.5590/1106 (Global)
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Misoprostol	N.A.	Fever	Genotype GG is associated with increased likelihood of Fever when treated with misoprostol in women with Postpartum hemorrhage NOS as compared to genotypes GT + TT.		[ 220]
Genetic Polymorphism	rs11045872
Site of GPD	chr12:21219410 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G / A>T
Minor Allele Frequency	A=0.9190/1818 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Methotrexate	N.A.	Discontinuation	Allele G is associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 7]
Methotrexate	N.A.	Infectious Disease	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.		[ 12]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele G is associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 7]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Pediatric patients with ALL and the AA genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.		[ 7]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Pediatric patients with ALL and the AG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.		[ 7]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Pediatric patients with ALL and the GG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.		[ 7]
Genetic Polymorphism	rs2417955
Site of GPD	chr12:21143541 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A
Minor Allele Frequency	T=0.5490/1086 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Infectious Disease	Allele A is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.		[ 12]
Genetic Polymorphism	rs10444413
Site of GPD	chr12:21164734 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C / T>G
Minor Allele Frequency	T=0.9440/1868 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Infectious Disease	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.		[ 12]
Genetic Polymorphism	rs1463565
Site of GPD	chr12:21182447 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>C / G>T
Minor Allele Frequency	G=0.6700/1325 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Infectious Disease	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele G.		[ 12]
Genetic Polymorphism	rs4149026
Site of GPD	chr12:21162481 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G
Minor Allele Frequency	A=0.7450/1474 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Infectious Disease	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.		[ 12]
Genetic Polymorphism	rs4149034
Site of GPD	chr12:21164988 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.4970/983 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Infectious Disease	Allele A is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele G.		[ 12]
Genetic Polymorphism	rs2900476
Site of GPD	chr12:21183129 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G / C>T
Minor Allele Frequency	C=0.3300/653 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Infectious Disease	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.		[ 12]
Genetic Polymorphism	rs4149086
Site of GPD	chr12:21239517 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.9980/1975 (Global)
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Gemcitabine	N.A.	Overall Survival	Genotypes AG + GG is associated with decreased overall survival when treated with gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.		[ 221]
Genetic Polymorphism	rs3829306
Site of GPD	chr12:21139346 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	C=0.9490/1878 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Cyclophosphamide	N.A.	Peripheral Nervous System Diseases	Allele T is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele C.		[ 222]
Epirubicin	N.A.	Peripheral Nervous System Diseases	Allele T is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele C.		[ 222]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Allele T is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele C.		[ 222]
Genetic Polymorphism	rs58310495
Site of GPD	chr12:21204777 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>G / C>T
Minor Allele Frequency	C=0.8000/1583 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Fluvastatin	N.A.	Statin-related Myopathy	Allele T is associated with increased concentrations of fluvastatin in healthy individuals as compared to allele C.		[ 124]
References
1	Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance. Pharmacotherapy. 2014 Mar;34(3):265-71.
2	Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics. 2008 Sep;9(9):1217-27.
3	Associations between four polymorphisms of the SLCO1B1 and effectiveness of the statins: a meta-analysis. Pharmacogenet Genomics. 2023 Jun 01;33(4):65-78.
4	The pharmacogenetics of OATP1B1 variants and their impact on the pharmacokinetics and efficacy of elbasvir/grazoprevir. Pharmacogenomics. 2019 Jun;20(9):631-641.
5	Influence of SLCO1B1 polymorphisms on lopinavir C. Br J Clin Pharmacol. 2020 Jul;86(7):1289-1295.
6	The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br J Clin Pharmacol. 2010 Jan;69(1):95-8.
7	Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 2013 Feb 7;121(6):898-904.
8	Polymorphisms of MTHFR Associated with Higher Relapse/Death Ratio and Delayed Weekly MTX Administration in Pediatric Lymphoid Malignancies. Leuk Res Treatment. 2013;2013:238528.
9	Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia. Oncotarget. 2017 Jun 6;8(23):37761-37772.
10	Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis. Pharmacogenomics J. 2017 Oct;17(5):412-418.
11	Association of MTHFR and ABCB1 polymorphisms with MTX-induced mucositis in Chinese paediatric patients with acute lymphoblastic leukaemia, lymphoma or osteosarcoma-A retrospective cohort study. J Clin Pharm Ther. 2021 Dec;46(6):1557-1563.
12	A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial. J Clin Pharmacol. 2018 Dec;58(12):1541-1549.
13	PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet. 2012 Nov 1;21(21):4793-804.
14	Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009 Dec 10;27(35):5972-8.
15	Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma. Pharmacogenet Genomics. 2014 Oct;24(10):514-21.
16	Effects of SLCO1B1 on elimination and toxicities of high-dose methotrexate in pediatric acute lymphoblastic leukemia. Pharmacogenomics. 2022 Oct;23(15):821-834.
17	Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011 Oct;57(4):612-9.
18	Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J. 2015 Aug 1;36(29):1901-12.
19	No Effect of SLCO1B1 and CYP3A4/5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Male Subjects. Biol Pharm Bull. 2017;40(1):88-96.
20	Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study. J Antimicrob Chemother. 2014 Dec;69(12):3320-8.
21	SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization. Pharmacogenomics. 2015;16(5):449-58.
22	Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients. Pharmacogenomics. 2018 Feb;19(3):175-184.
23	Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia. Pharmacogenet Genomics. 2012 Nov;22(11):803-6.
24	CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 polymorphisms in patients with bosentan-induced liver toxicity. Clin Pharmacol Ther. 2014 Jun;95(6):583-5.
25	SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol. 2017 Nov;73(11):1409-1416.
26	SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics. 2010 Dec;11(12):1703-13.
27	Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther. 2011 Feb;89(2):210-6.
28	Impact of SLCO1B3 polymorphisms on clinical outcomes in lung allograft recipients receiving mycophenolic acid. Pharmacogenomics J. 2020 Feb;20(1):69-79.
29	Effects of SCT genetic polymorphisms on methotrexate concentrations and toxicities in Chinese children with acute lymphoblastic leukemia. Leuk Lymphoma. 2025 Jun;66(6):1068-1078.
30	Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies. J Clin Pharmacol. 2019 Sep;59(9):1236-1243.
31	Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort. Pharmacogenet Genomics. 2015 Jan;25(1):8-18.
32	Mixed effects of OATP1B1, BCRP and NTCP polymorphisms on the population pharmacokinetics of pravastatin in healthy volunteers. Xenobiotica. 2016 Sep;46(9):841-9.
33	Novel and replicated clinical and genetic risk factors for toxicity from high-dose methotrexate in pediatric acute lymphoblastic leukemia. Pharmacotherapy. 2023 Mar;43(3):205-214.
34	Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther. 2004 May;75(5):415-21.
35	Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients. Pharmacogenet Genomics. 2012 Jun;22(6):399-407.
36	Association of polymorphisms in pharmacogenetic candidate genes (OPRD1, GAL, ABCB1, OPRM1) with opioid dependence in European population: a case-control study. PLoS One. 2013 Sep 25;8(9):e75359.
37	Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol. 2015 Mar;71(3):329-40.
38	CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Ther Drug Monit. 2011 Aug;33(4):417-24.
39	Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet. 2013 Aug;6(4):400-8.
40	Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis. 2010 Jul;211(1):28-9.
41	Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation. Int J Mol Sci. 2015 Aug 25;16(9):20168-82.
42	Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population. J Clin Pharm Ther. 2016 Jun;41(3):329-33.
43	An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 2005;5(6):352-8.
44	Role of SLCO1B1, ABCB1, and CHRNA1 gene polymorphisms on the efficacy of rocuronium in Chinese patients. J Clin Pharmacol. 2015 Mar;55(3):261-8.
45	SLCO1B1 and ABCB1 variants synergistically influencethe atorvastatin treatment response in South Indian coronary artery disease patients. Pharmacogenomics. 2022 Aug;23(12):683-694.
46	Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics. 2013 Aug;14(11):1283-94.
47	The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis. Pharmacogenet Genomics. 2018 Dec;28(12):261-267.
48	Pharmacogenetic predictors of development of secondary to enalapril dry cough in hypertensive patients. Drug Metab Pers Ther. 2023 Sep 01;38(3):247-254.
49	Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. Eur J Clin Pharmacol. 2014 May;70(5):539-47.
50	Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity. Pharmacogenomics. 2016 Sep;17(14):1483-90.
51	OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. J Clin Pharm Ther. 2010 Feb;35(1):99-104.
52	SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer. PLoS One. 2013 Oct 15;8(10):e77223.
53	Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenet Genomics. 2008 Nov;18(11):937-42.
54	Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients. Eur J Clin Pharmacol. 2014 Oct;70(10):1211-9.
55	Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects. Pharmazie. 2017 May 01;72(5):288-295.
56	Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia. Clin Appl Thromb Hemost. 2018 Dec;24(9_suppl):240S-247S.
57	UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol. 2009 Apr;14(2):136-42.
58	Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenomics J. 2016 Feb;16(1):54-9.
59	Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. Eur J Clin Pharmacol. 2013 Jun;69(6):1269-74.
60	Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int J Mol Sci. 2011;12(9):5815-27.
61	Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer. 2009 Jan;63(1):115-20.
62	Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005 Oct;78(4):330-41.
63	Association between SLCO1B1 genetic polymorphisms and bleeding risk in patients treated with edoxaban. Sci Rep. 2023 Sep 25;13(1):15967.
64	Associations Between the Polymorphisms in the Coding Sequence of SLCO1B1 and Blood Lipid Levels Before and After Treatment by Atorvastatin in the Chinese Han Adults with Dyslipidemia. Pharmgenomics Pers Med. 2024;17:551-561.
65	Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). J Antimicrob Chemother. 2016 Jun;71(6):1609-18.
66	Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood. 2013 Jun 27;121(26):5145-53.
67	Effect of CYP4F2 Polymorphisms on Ticagrelor Pharmacokinetics in Healthy Chinese Volunteers. Front Pharmacol. 2021;12:797278.
68	Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans. Pharmacogenomics. 2016 May;17(7):679-90.
69	Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients. Drug Metab Pharmacokinet. 2019 Dec;34(6):387-395.
70	Influence of Calcineurin Inhibitors and Genetic Polymorphism of Transporters on Enterohepatic Circulation and Exposure of Mycophenolic Acid in Chinese Adult Renal Allograft Recipients. J Clin Pharmacol. 2023 Apr;63(4):410-420.
71	Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021 May;68(5):e28858.
72	SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol. 2012 Mar;68(3):273-9.
73	SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals. Int J Mol Sci. 2015 Aug 31;16(9):20609-19.
74	Impacts of Pharmacokinetic Gene Polymorphisms on Steady-State Plasma Concentrations of Simvastatin in Thai Population. Clin Transl Sci. 2025 May;18(5):e70225.
75	Lack of association between SLCO1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients. J Clin Pharm Ther. 2018 Oct;43(5):647-655.
76	A comprehensive review and meta-analysis of risk factors for statin-induced myopathy. Eur J Clin Pharmacol. 2018 Sep;74(9):1099-1109.
77	No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population. Mol Biol Rep. 2014 Jul;41(7):4631-8.
78	Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients. Acta Pharmacol Sin. 2010 Mar;31(3):382-6.
79	Relationship between SLCO1B1 polymorphisms and methotrexate intolerance in Mexican children with juvenile idiopathic arthritis. Clin Rheumatol. 2024 Dec;43(12):3849-3853.
80	Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers. Pharmazie. 2015 Jul;70(7):480-8.
81	Endogenous Metabolites-Mediated Communication Between OAT1/OAT3 and OATP1B1 May Explain the Association Between SLCO1B1 SNPs and Methotrexate Toxicity. Clin Pharmacol Ther. 2018 Oct;104(4):687-698.
82	Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy. Med Sci Monit. 2015 Feb 21;21:563-9.
83	Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly. Atherosclerosis. 2012 Feb;220(2):413-7.
84	Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers. J Cardiovasc Pharmacol. 2016 Nov;68(5):383-390.
85	A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy. Pharmacogenomics J. 2021 Jun;21(3):296-307.
86	SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril)-Induced Cough: a Pharmacogenetic Study. Sci Rep. 2015 Nov 26;5:17253.
87	Association of SLCO1B1 Polymorphisms and Atorvastatin Safety and Efficacy: A Meta-analysis. Curr Pharm Des. 2018;24(34):4044-4050.
88	Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. Cancer Biol Ther. 2011 Nov 01;12(9):780-7.
89	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014 Oct 28;5:5068.
90	Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet Genomics. 2005 May;15(5):303-9.
91	High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 2004 Jul;14(7):429-40.
92	Pharmacogenetics and Pharmacokinetics of Moxifloxacin in MDR-TB Patients in Indonesia: Analysis for. Antibiotics (Basel). 2025 Feb 16;14(2).
93	Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br J Clin Pharmacol. 2006 Jun;61(6):706-15.
94	The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother. 2011 Sep;55(9):4122-7.
95	Impact of pharmacogenetics on pharmacokinetics of first-line anti-tuberculosis drugs in the HIRIF trial. J Infect Dis. 2025 Apr 17.
96	The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study. Clin Pharmacol Ther. 2019 Aug;106(2):450-457.
97	SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther. 2013 Dec;94(6):695-701.
98	Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther. 2006 May;79(5):419-26.
99	Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003 Jun;73(6):554-65.
100	The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009 Oct 20;54(17):1609-16.
101	Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. Pharmacogenomics J. 2013 Aug;13(4):335-41.
102	Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol. 2008 Mar;48(3):311-21.
103	Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 2012 Jun;12(3):233-7.
104	CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes. Diabetes Care. 2016 Nov;39(11):1902-1908.
105	Simvastatin intolerance genetic determinants: some features in ethnic Uzbek patients with coronary artery disease. Arch Med Sci Atheroscler Dis. 2017;2:e68-e75.
106	A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients. Drug Metab Pharmacokinet. 2016 Dec;31(6):467-470.
107	SLCO1B1 Functional Variants, Bilirubin, Statin-Induced Myotoxicity, and Recent Sub-Saharan African Ancestry: A Precision Medicine Health Equity Study. Clin Pharmacol Ther. 2025 Jun;117(6):1696-1705.
108	A Genome-wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites. Clin Pharmacol Ther. 2020 Aug;108(2):287-297.
109	Identification of Genetic Variants Associated with Pravastatin and Pitavastatin Pharmacokinetics. Clin Pharmacol Ther. 2025 Jun;117(6):1763-1774.
110	Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
111	Association of ABCC2 with levels and toxicity of methotrexate in Malaysian Childhood Acute Lymphoblastic Leukemia (ALL). Pediatr Hematol Oncol. 2020 Apr;37(3):185-197.
112	Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid. Pharmacogenet Genomics. 2015 Dec;25(12):595-608.
113	Candidate-Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol-Lowering Response to Simvastatin. Clin Transl Sci. 2017 May;10(3):172-177.
114	Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations. J Cardiovasc Pharmacol. 2015 Jul;66(1):80-5.
115	Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. Pharmazie. 2013 Feb;68(2):124-8.
116	Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing. PLoS One. 2019;14(6):e0218115.
117	Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms. Pharmacogenet Genomics. 2020 Dec;30(9):208-211.
118	OATP1B1 polymorphism as a determinant of erythromycin disposition. Clin Pharmacol Ther. 2012 Nov;92(5):642-50.
119	Genome-Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP. Clin Pharmacol Ther. 2024 Jun;115(6):1428-1440.
120	Discordant associations between SLCO1B1 521TC and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146. Ther Drug Monit. 2013 Apr;35(2):209-16.
121	Single nucleotide polymorphisms associated with methotrexate-induced nausea in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2021 Apr 01;19(1):51.
122	Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2018 Apr;18(2):275-280.
123	SLCO1B1 Genetic Variation Influence on Atorvastatin Systemic Exposure in Pediatric Hypercholesterolemia. Genes (Basel). 2024 Jan 15;15(1).
124	Enantiospecific Pharmacogenomics of Fluvastatin. Clin Pharmacol Ther. 2019 Sep;106(3):668-680.
125	Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia. Am Heart J. 2016 Sep;179:1-9.
126	Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007 Dec;82(6):726-33.
127	SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther. 2006 Oct;80(4):356-66.
128	HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics. 2010 Feb;20(2):112-20.
129	SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006 Dec;16(12):873-9.
130	SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789-99.
131	The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics. 2014 Jan;24(1):43-51.
132	Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
133	Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin. Clin Pharmacol Ther. 2021 Sep;110(3):733-740.
134	Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics. 2008 Oct;18(10):921-6.
135	Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants. Pharmacogenet Genomics. 2023 Sep 01;33(7):153-160.
136	Candidate Genes for Prediction of Efficacy and Safety of Statin Therapy in the Kazakh Population. Twin Res Hum Genet. 2023 Jul 25:1-7.
137	Association between rs4149056 variant in. Pharmacogenomics. 2020 Feb;21(3):163-172.
138	Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol. 2012 May;68(5):645-55.
139	Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach. Pharm Res. 2015 Jun;32(6):1864-83.
140	Effect of polymorphisms in CYP3A4, PPARA, NR1I2, NFKB1, ABCG2 and SLCO1B1 on the pharmacokinetics of lovastatin in healthy Chinese volunteers. Pharmacogenomics. 2017 Jan;18(1):65-75.
141	Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circ Cardiovasc Genet. 2010 Jun;3(3):276-85.
142	SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study. BMC Cancer. 2016 May 27;16:337.
143	Novel risk factors for glucarpidase use in pediatric acute lymphoblastic leukemia: Hispanic ethnicity, age, and the ABCC4 gene. Pediatr Blood Cancer. 2021 Aug;68(8):e29036.
144	SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy. J Pediatr Hematol Oncol. 2018 Jul;40(5):e289-e294.
145	Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites. Acta Pharmacol Sin. 2019 Apr;40(4):492-499.
146	Impact of Genetic Variation on Pravastatin Systemic Exposure in Pediatric Hypercholesterolemia. Clin Pharmacol Ther. 2019 Jun;105(6):1501-1512.
147	Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. Indian Heart J. 2018 Dec;70 Suppl 3(Suppl 3):S120-S125.
148	CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics. Pharmazie. 2013 Mar;68(3):187-94.
149	Meta-Analysis of the SLCO1B1 c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins. Ann Lab Med. 2015 May;35(3):329-35.
150	Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach. Clin Pharmacol Ther. 2014 Jul;96(1):90-100.
151	SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br J Clin Pharmacol. 2007 Sep;64(3):346-52.
152	Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics. 2007 Aug;17(8):647-56.
153	Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population. Eur J Clin Pharmacol. 2018 Aug;74(8):1021-1028.
154	Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? Eur J Clin Pharmacol. 2015 Mar;71(3):341-55.
155	Pharmacogenetic Testing in a 70-Year-Old Woman with Polypharmacy and Multiple Comorbidities: A Case Report. Am J Case Rep. 2023 Feb 21;24:e938850.
156	SLCO1B1 genetic variation and hormone therapy in menopausal women. Menopause. 2018 Aug;25(8):877-882.
157	The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition. Pharmacogenomics. 2017 Apr;18(5):459-469.
158	Atorvastatin Metabolite Pattern in Skeletal Muscle and Blood from Patients with Coronary Heart Disease and Statin-Associated Muscle Symptoms. Clin Pharmacol Ther. 2023 Apr;113(4):887-895.
159	Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians. Br J Clin Pharmacol. 2016 Jun;81(6):1078-90.
160	Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. Pharmacogenomics. 2017 Jun;18(9):865-880.
161	Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia. Br J Haematol. 2014 Aug;166(3):410-20.
162	A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses. 2012 Oct;28(10):1227-34.
163	Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). J Antimicrob Chemother. 2015 Nov;70(11):3096-9.
164	Effects of genetic polymorphisms on methotrexate levels and toxicity in Chinese patients with acute lymphoblastic leukemia. Blood Sci. 2023 Jan;5(1):32-38.
165	Predictive Value of. Genes (Basel). 2023 Feb 10;14(2).
166	Pharmacogenetic aspects of efficacy and safety of methotrexate treatment in pediatric acute lymphoblastic leukemia. Drug Metab Pers Ther. 2023 Dec 01;38(4):349-357.
167	Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. Clin Pharmacol Ther. 2013 Mar;93(3):275-82.
168	ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study. Pharmacogenomics. 2015 Jul;16(8):803-15.
169	Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am Heart J. 2013 Jun;165(6):1008-14.
170	Pharmacogenomic insights into atorvastatin and rosuvastatin adverse effects: a prospective observational study in the UAE's multiethnic population. Hum Genomics. 2025 Apr 25;19(1):44.
171	Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin. Eur J Clin Pharmacol. 2020 Jul;76(7):939-946.
172	SLCO1B1 rs4149056 genetic polymorphism predicting methotrexate toxicity in Chinese patients with non-Hodgkin lymphoma. Pharmacogenomics. 2017 Nov;18(17):1557-1562.
173	Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor-containing regimen. Br J Clin Pharmacol. 2023 Sep;89(9):2739-2746.
174	Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects. Sci Rep. 2019 Dec 19;9(1):19410.
175	The effect of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Chinese people. Pharmazie. 2017 Jun 01;72(6):365-368.
176	Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study. Clin Pharmacol Ther. 2018 Jul;104(1):178-187.
177	Influence of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients. Pharmacogenomics. 2019 May;20(7):517-527.
178	Characterization of statin dose response in electronic medical records. Clin Pharmacol Ther. 2014 Mar;95(3):331-8.
179	Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet. 2004 Oct;19(5):375-80.
180	Effects of two functionally important SLCO1B1 gene polymorphisms on pharmacokinetics of atorvastatin. Pak J Pharm Sci. 2017 Jul;30(4):1363-1370.
181	Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. J Antimicrob Chemother. 2014 Nov;69(11):3061-6.
182	Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers. Eur J Clin Pharmacol. 2013 Mar;69(3):407-13.
183	Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. J Clin Pharmacol. 2018 Jun;58(6):823-833.
184	POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia. Pharmacogenomics. 2014 Dec;15(16):1963-72.
185	Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia. Clin Transl Sci. 2020 May;13(3):628-637.
186	Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J. 2018 Dec;18(6):721-729.
187	Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet. 2012 Apr 1;5(2):257-64.
188	Correlation between single-nucleotide polymorphisms and statin-induced myopathy: a mixed-effects model meta-analysis. Eur J Clin Pharmacol. 2021 Apr;77(4):569-581.
189	Associations between. Pharmacogenomics. 2023 Jun;24(8):475-484.
190	Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus. Pharmacotherapy. 2017 Sep;37(9):1073-1080.
191	An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure. Pharmacogenomics J. 2018 Jan;18(1):153-159.
192	The reduced function allele SLCO1B1 c.521T>C is of no practical relevance for the renal graft function over the first post-transplant year in patients treated with mycophenolic acid. Pharmacogenet Genomics. 2024 Sep 01;34(7):226-235.
193	ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population. BMC Genet. 2016 Jun 13;17(1):79.
194	The Role of Candidate Polymorphisms in Drug Transporter Genes on High-Dose Methotrexate in the Consolidation Phase of the AIEOP-BFM ALL 2009 Protocol. Clin Transl Sci. 2025 Feb;18(2):e70136.
195	The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin. Br J Clin Pharmacol. 2012 Feb;73(2):303-6.
196	Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Drug Metab Pharmacokinet. 2019 Feb;34(1):78-86.
197	Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin Pharmacol Ther. 2008 Feb;83(2):251-7.
198	The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
199	Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic Information on SLCO1B1 and ABCC2 polymorphisms. J Clin Pharmacol. 2009 Nov;49(11):1309-17.
200	Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics. 2006 Nov;16(11):801-8.
201	Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22.
202	Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. Drug Des Devel Ther. 2017;11:1135-1146.
203	Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J Hum Genet. 2006;51(9):822-826.
204	SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability. J Pers Med. 2021 Mar 13;11(3).
205	SLCO1B1*5 Allele Is Associated With Atorvastatin Discontinuation and Adverse Muscle Symptoms in the Context of Routine Care. Clin Pharmacol Ther. 2022 May;111(5):1075-1083.
206	SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid. Pharmacogenet Genomics. 2015 Aug;25(8):382-7.
207	SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther. 2007 Nov;82(5):541-7.
208	SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Med Sci Monit. 2015 May 20;21:1454-9.
209	A pilot study on the association between. Biomarkers. 2019 Nov;24(7):659-665.
210	Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole. Pharmacogenomics. 2019 Jun;20(8):571-580.
211	Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clin Pharmacol Ther. 2016 Jun;99(6):651-60.
212	Functional consequences of genetic variations in the human organic anion transporting polypeptide 1B3 (OATP1B3) in the Korean population. J Pharm Sci. 2012 Mar;101(3):1302-13.
213	An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>C. Pharmacogenomics J. 2019 Jun;19(3):240-248.
214	SLCO1B1 variants and the risk of antituberculosis drug-induced hepatotoxicity: a systematic review and meta-analysis. Pharmacogenomics. 2023 Dec;24(18):931-942.
215	Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. PLoS One. 2017 Oct 16;12(10):e0186200.
216	Transporter Genes and statin-induced Hepatotoxicity. Cardiovasc Drugs Ther. 2024 May 29.
217	SLCO1B1 Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients. Int J Mol Sci. 2024 Apr 17;25(8).
218	Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors. Hepatol Commun. 2024 Sep 01;8(9).
219	Genetic determinants of serum bilirubin using inferred native American gene variants in Chilean adolescents. Front Genet. 2024;15:1382103.
220	Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry. Pharmacogenomics. 2015;16(9):919-28.
221	SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1. Pancreas. 2018;47(5):637-642.
222	Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin Cancer Res. 2014 May 01;20(9):2466-75.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.